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Abstract
The abnormal misfolding and aggregation of intrinsically disordered proteins into ordered
fibrillar amyloid aggregates is recognized as a common pathological event in
neurodegenerative disorders (ND) such as Alzheimer’s and Parkinson’s diseases. The key role
of fibrillar and pre-fibrillar aggregates in ND makes them ideal biomarkers to better understand
disease progression but also for early disease detection and therapeutic intervention. The work
described herein was conducted to gain a better understanding of amyloid interaction to lipid
membrane and its role in peptide toxicity. This research was also focused on evaluating the
fluorescent probe, oligomeric p-phenylene ethynylene (OPE), as an amyloid sensor detecting
disease-relevant pre-fibrillar and fibrillar aggregates both in vitro and in biological samples.
Finally, OPE’s capability to selectively photo-oxidize amyloid fibrils to ensure their
disassembly and clearance was investigated. Taken together, this study revealed the potential
of OPE as a theranostic agent for neurodegenerative disorders.
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1

Chapter 1: Introduction

1.1 Neurodegenerative Disorders
Neurodegenerative disorders are a group of diseases characterized by a progressive
deterioration of the central nervous system causing memory loss and cognitive impairments,
such as Alzheimer’s and Parkinson’s diseases1. In 2015, 46.8 million people were affected by
these disorders worldwide, and this number is expected to double over the next 20 years due
to the rise of life expectancy2. These diseases are currently diagnosed through clinical
symptoms analysis and are confirmed postmortem based on neuropathological biomarkers3.
To this day, these disorders cannot be cured, and the predicated cost of patients care in the
United States is one of the highest ($259 billion for dementia care vs $157 billion for cancer
care)4, 5. The cause of neurodegeneration is still unclear, but a common pathological hallmark
has been reported among these different disorders: accumulation of amyloid aggregates6-8.
Amyloid aggregates can be made of a large array of proteins such as amyloid β (Aβ) and tau
proteins that form amyloid plaques and neurofibrillary tangles in Alzheimer’s disease, or αsynuclein proteins composing the Lewy bodies in Parkinson’s diseases9. Despite the high
polymorphism of these aggregates, they all share a common secondary structure rich in βsheet.

1.2 Amyloid Aggregation Mechanism
Amyloid aggregation is a complex process which takes place through a nucleation-dependent
polymerization mechanism10. Two pathways have been described: primary and secondary
nucleation. During the primary nucleation, the native protein misfolds in an intermediate prone
to aggregation which will form oligomers and protofibrils, also called pre-fibrillar aggregates
1

(Figure 1-1A). These pre-fibrillar aggregates act as seeds that grow into stable fibrillar
aggregates rich in β-sheet6-8,

10, 11

. The secondary nucleation consists in the formation of

aggregates through fibril fragmentation or “surface catalyzed nucleation” where fibrils are used
as scaffold by monomeric proteins to produce aggregates (Figure 1-1B). 11, 12

Figure 1-1: Nucleation dependent aggregation (A) primary nucleation10 (B) secondary
nucleation mechanism11.

Protein aggregation is believed to start decades before the onset of clinical symptoms8,
13, 14

. Additionally, there is evidence that pre-fibrillar aggregates are more labile and neurotoxic

than amyloid plaques7,

15-20

. It is believed that they exert their toxicity through several

mechanisms such as cell membrane disruption leading to cellular homeostasis disruption and
cell apoptosis9, 21, 22, or by inducing local inflammation upon binding to membrane or by
2

interacting with specific membrane-receptors23, 24. Despite their lowest toxicity, amyloid fibrils
also play a role in neurodegeneration through several mechanisms such as impairing axonal
transport25, 26. The key role of the amyloid aggregates in neurodegenerative disorders make
these fibrillar and pre-fibrillar aggregates ideal biomarkers for early disease detection and
therapeutic intervention.

1.3 Membrane-Mediated Toxicity, Fibrillation and Transmissibility of
Amyloid Proteins
The neurotoxicity of amyloid aggregates is still poorly understood; however, many have shown
that amyloid proteins capability to interact with the neuronal cell membrane, more particularly
with anionic lipids, might play a central role27, 28. This interaction is believed to play a key role
in protein toxicity,27, 28 protein fibrillation29-33 and disease spatial progression34.
Many studies have shown that upon interaction to cell membrane, amyloid proteins
destabilize the lipid packing through three main mechanisms: (1) “carpeting-effect
mechanism”, (2) “pore-formation mechanism” and (3) “detergent-like mechanism” 35 (Figure
1-2). Through the “carpeting-effect mechanism” the amyloid protein blankets the lipid
membrane causing membrane thinning. The carpeting effect also results in an asymmetric
pressure between the two lipid layers and causes the generation of membrane curvature. “Pore
formation mechanism” consists in the permeation of the membrane by the formation of ionchannel-like structures by the amyloid proteins. Membrane disruption can also be caused by a
“detergent-like mechanism” where the proteins form a micelle-like structure with the lipid
membrane. Overall, this membrane destabilization causes a loss of membrane integrity leading
to cell apoptosis.
3

Figure 1-2: Schematic of the membrane disruption mechanism associated with amyloid
protein interaction to lipid membrane: carpeting-effect, pore-formation and detergent-effect.
Modified from Williams and Serpell, 201135.

There is evidence that upon interaction to the lipid membrane, amyloid proteins such
as Tau

29, 30

, Aβ

31, 36

and α-synuclein

32, 33

also undergo fast fibrillation. This membrane-

mediated fibrillation might be caused by (1) partial folding of the protein upon interaction to
the hydrophobic lipid membrane, (2) change in the orientation of the protein and (3) increase
in the local protein concentration37. Membrane-mediated fibrillation seems to be affected by
many parameters such as the surface chemistry, the surface roughness or membrane curvature
36, 38

.
Membrane interaction is also believed to play a role in the cell-to-cell transmissibility

of amyloid proteins, which is responsible for the predictable spatial progression of various
neurodegenerative disorders39. In fact, cell internalization of tau aggregates is believe to be
involved in transcellular propagation of the disease by inducing fibrillization of intracellular
tau34. These observations involved the presence of cellular pathways mediating the release and
uptake of protein aggregates from the neuronal cells that are still poorly understood.
Overall, the molecular changes associated with protein-lipids membrane interaction
implicated in membrane destabilization, protein fibrillation and cell-to-cell transmissibility are
still elusive. A better comprehension of these mechanism could guide the development of novel
therapeutic strategies.
4

1.4 Amyloid Aggregates as Biomarkers
The deposition of amyloid aggregates in the brain has been correlated with cognitive
impairments in patient suffering of neurodegenerative disorders, which make them ideal
biomarkers for both early diagnosis and therapeutic intervention. Recently, physicians have
also reported a correlation between neurodegeneration and increase in amyloid oligomers in
cerebrospinal fluid (CSF) that reach up to 1 pg/mL in AD patients40, 41.
The scientific community is currently developing and evaluating new probes for the
selective detection and imaging of amyloid aggregates composed of a large array of proteins.
Histological stains such as thioflavin T (ThT) and congo red (CR) are being used to detect a
wide range of protein amyloids42, 43. Both dyes are believed to arrange themselves along the
long axis of the fibrils and intercalate perpendicularly to the β-strands in the β-sheets (Figure
1-3). Once bonded to fibrils, ThT displays a fluorescence red shift accompanied by a large
fluorescence enhancement while CR shows a change in light polarization leading to applegreen birefringence43-45. Both dyes present several limitations. CR lacks sensitivity and has
been shown to interact non-selectively with native proteins with various secondary structures,
which could lead to false-positive results43, 46. ThT is more specific than CR for the detection
of amyloid fibrils. However, ThT binding is affected by fibrils morphology such as the flatness
of the β-sheet,47 which explains ThT lack of detection of heavily twisted β-sheet-rich fibrils
made of several proteins such as chymotrypsin or bovine IgG43, 48, 49. Overall, the influence of
fibrils morphology on ThT sensing properties makes this probe ineffective for the detection of
a wide range of amyloid proteins with high polymorphism.
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Figure 1-3: The common structure of fibrils and a structural rationale for fibril–ThT
interactions (Modified from Biancalana and Koide, 201047). A. Amyloid fibrils are made of
cross-β structure that forms layers of laminated β-sheets. B. ThT interaction to amyloid fibrils
is proposed to follow a “channel” model where ThT binds along the surface side-chain grooves
running parallel to the long axis of the β-sheet. ThT is represented by the brown arrow.

Radiopharmaceutical probes are used to image protein amyloids in vivo through different
tomographic imaging techniques such as Positron Emission Tomography (PET)50. The main
PET probes currently used for the detection of amyloid plaques are the non-FDA approved
11

C-Pittsburgh Compound-B50, 51 used in clinical research and three FDA-approved probes

used in clinical trials:

F-flutemetamol (Vizamyl™),

18

18

F-florbetapir (Amyvid™) and

18

F-

florbetaben (NeuraCeqTM)52, 53. Despite the high selectivity and specificity of these probes
toward amyloid plaques found in AD, development of efficient probes to detect α-synuclein
accumulating in Lewy bodies in PD54, 55, or tau proteins accumulating in neurofibrillary tangles
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in AD56, 57, are still in its infancy. Additionally, these PET probes are inadequate at detecting
oligomers and protofibrils, the putative toxic species56. These limitations call for the need to
develop new sensors to detect early aggregates and mature fibrils made of different amyloid
proteins such as Aβ, tau and α-synuclein that are involved in neurodegenerative diseases. These
new probes should display high selectivity toward the amyloid conformation, low limit of
detection and low interference by other biomolecules such as albumin or collagen present in
biological fluids or in the brain. These new probes would assure a better understanding of the
disease, guarantee a more reliable diagnosis, and be a valuable tool for evaluating new
treatments.

1.5 Therapeutic Interventions
The anticipated increase of patients with neurodegenerative disorders in the next 15 years and
the cost associated to patient care give rise to the urgent need to develop an efficient therapy.
Protein aggregation plays a key role in neurodegenerative disorders and is an ideal target for
therapeutic intervention58-60. The main therapeutic strategies targeting amyloid proteins can be
organized in three groups61:
1. Inhibition of amyloid aggregation and fibrillization62. Several compounds have already
been studied for their capability to inhibit the nucleation-dependent aggregation such
as flavonoids (epigallocatechin gallate63), surfactants64, small peptides65,

66

or

switchable photo-oxygenizers67-69. This last class of compounds has recently been
described for their capability to reduce fibril production and lower aggregate
neurotoxicity by oxidizing amyloid proteins.
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2. Amyloid remodeling into non-toxic oligomers. Small molecules such as curcumin70 or
keampferol-3-O-rhamnoside71 have been shown to modify the amyloid aggregates into
non-toxic aggregates without inhibiting fibrils production.
3. Amyloid degradation and clearance which consists in destabilizing and/or
disassembling pre-fibrillar and fibrillar aggregates. Several strategies have been
investigated to induce amyloid degradation such as the use of proteases60,

72, 73

or

amyloid photo-oxidizers such as methylene blue (MB)67-69.
The evaluation of new compounds targeting the amyloid cascade would assure a better
understanding of the amyloid hypothesis and could initiate the development of new strategies
to treat neurodegenerative diseases.

1.6 Amyloid Degradation and Clearance by Photodynamic Therapy
Photodynamic therapy (PTD) is commonly used in dermatology and oncology for the
treatment of various tumors and nonmalignant diseases74-76. This strategy consists in the
administration of a photosensitizer (PS) followed by its illumination at a specific wavelength.
Upon irradiation, the PS reaches an excited singlet state (Sn) which will decay back to the
ground state through quenching or by emitting fluorescence (Figure 1-4). The PS can also
undergo electron spinning leading to the generation of a triplet excited state (T1). From the
triplet state, the PS will form free radicals through electron transfer or will generate singlet
oxygen species through the type I and II reactions, respectively (Figure 1-4)76, 77. An efficient
PS should accumulate in the targeted area, it should be light-controllable, it should have high
quantum yields for the generation of singlet oxygen and also present low off-target reaction74.
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Figure 1-4: Modified Jablonski Diagram Describing the Photosensitization Type I and Type
II Mechanisms. After absorption of a photon, the photosensitizer is activated from its ground
singlet electronic state (So) to an excited singlet state (Sn). Through internal conversion and
vibrational relaxation, the singlet state S1 is reached and can return to So through
quenching/non-radiative relaxation or fluorescence. S1 energy can also be converted in an
exited triplet state through intersystem crossing. T1 can return to ground state through
phosphorescence or can transfer its energy to a biological molecule (R) to form free radicals
(Type I reaction) or to a triplet oxygen (3O2) to form singlet oxygen 1O2 (type II reaction) which
will cause oxidative damage.

PDT has recently been investigated to photo-oxidize amyloid proteins implicated in
neurodegenerative disorders. Several PS such as riboflavin67, rose bengal78, water-soluble
porphyrin molecules79, flavin-based catalysts67, 68 or methylene blue (MB)69, were evaluated.
They were shown to either photo-oxidize Aβ monomers and inhibit their aggregation67, 78, 79,
or to photo-oxidize amyloid fibrils causing their disassembly into shorter structures
characterized by lower cell toxicity68. PS currently evaluated for the oxidation of amyloid
proteins such as MB, present one main drawback: low selectivity toward the toxic amyloid
conformation. As a consequence, the native protein playing important physiological functions
might be oxidized as well as other biomolecules such as protein, lipid and nucleic acids80 which
could cause neuronal death. The off-target oxidation of current PS highlights the need to
develop new photosensitizers highly selective toward the toxic amyloid aggregates.
9

1.7 Oligomeric p-Phenylene Ethynylenes – Amyloid Aggregates Detection
Oligomeric p-phenylene ethynylenes (OPEs) is a novel class of water-soluble fluorescent
sensors which are highly versatile in terms of size (1, 2 or 3 repeat units) and charge (positively
or negatively charged) (Figure 1-5)81, 82.

Figure 1-5: OPEs structure81

OPEs are characterized by minimal background fluorescence due to ethyl ester termini
quenching by water molecules83. Upon binding to hydrophobic scaffolds, OPEs display a large
fluorescence enhancement caused by (1) backbone planarized, (2) hydrophobic unquenching
and (3) formation of super-luminescent complexes mainly made of J-dimers81, 82, 84. J-dimers
spectral signatures are summarized in Figure 1-685. A large library containing 18 different
phenylene ethynylenes-based oligomers were screened for the selective detection of the
fibrillar conformation of two model proteins oppositely charged at neutral pH, the positively
charged hen egg white lysozyme (HEWL) and negatively charged bovine insulin (BINS)81, 82.
The anionic OPE12- made of one repeat unit and two side chains terminated by a sulfonate
group (OPE1- on Figure 1-5), was found to selectively detect both BINS and HEWL fibrils
over their monomeric counterparts. The cationic OPE24+ made of two repeat units and four side
chains terminated by a quaternary amine group (OPE2+ on Figure 1-5), displayed stronger
fluorescence enhancement in the presence of HELW fibrils, but did not detect selectively BINS
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fibrils likely due to electrostatic interactions between the positively charged OPE and the
negatively charged monomeric protein.
The selective binding of OPE with the fibrillar conformation of two model proteins
makes this sensor highly promising for the detection of fibrillar and pre-fibrillar aggregates
composed of disease-relevant proteins.

Figure 1-6: Schematic representation of H and J-aggregates and the associated changes in the
absorption (blue) and emission (red) spectra from cyanine dye monomers85. H aggregates are
produced from dye parallel stacking. They are characterized by a hypsochromic shift (a shift
in the absorption to a shorter wavelength) and usually present low to no fluorescence. Jaggregates are made of scattered dye aggregates. They are characterized by a bathochromic
shift (a shift in the absorption to a longer wavelength), a sharper emission peak, and a small
Stokes shift (the difference in wavelength between positions of the peak of absorption and
emission spectra)86.

1.8 Oligomeric p-Phenylene Ethynylenes – Photosensitizing Activity
The photosensitizing activity of OPE12- was recently evaluated in the presence of a positively
charged detergent cetyltrimethylammonium bromide (CTAB)87. Upon binding to CTAB, OPE
was shown to display fluorescence turn-on which can be used for optical detection and to
sensitize local singlet oxygen species through the generation of triplet state (Figure 1-7). This
11

photosensitization activity was found to be switchable with light illumination and through
selective binding to a scaffold.

Figure 1-7: Schematic of detergent-induced self-assembly (DISA) model of OPE for optical
detection and selective sensitization of singlet oxygen species87

OPEs switchable photosensitization of singlet oxygen could be used to selectively photooxidize hydrophobic scaffolds such as amyloid aggregates. Taken together, the selective turnon fluorescence of OPE upon binding to the amyloid conformation of model proteins and its
photosensitizing activity make OPE highly promising as a theranostic agent for early detection
of amyloid aggregates and treatment of neurodegenerative diseases.
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Chapter 2: Specific Aims and Overview

The key role of amyloid aggregates in neurodegenerative disorders make them ideal target to
better understand disease progression but also for early disease detection and therapeutic
intervention. The lack of information on amyloid toxicity mechanism and the lack of sensing
probes guided the research described in this dissertation which present two main focuses:
1. First, characterizing the molecular-level changes associated with amyloid protein
insertion into lipid membrane which is believed to play a key role in amyloid toxicity
and fibrillation.
2. Secondly, evaluating OPE for the selective sensing and oxidation of toxic pre-fibrillar
and fibrillar aggregates made of disease-relevant proteins which will illustrate the
potential of this fluorescence sensor as a theranostic agent.
This research was organized in five specific aims:
1. Characterize the membrane mediated toxicity and fibrillization of Tau PHF6. PHF6 is
the hexapeptide

306

VQIVYK311 located in the microtubule binding domain of Tau

protein. PHF6 is believed to form the main core of Tau paired helical filament (PHF)
and to play a key role in the interaction of tau protein with lipid membrane. To gain a
better understanding of the membrane-mediated fibrillation of Tau protein, we
characterized the molecular-level changes associated with the insertion of PHF6 into a
negatively charged lipid membrane. In this study, two PHF6 isoforms were evaluated:
the non-acetylated NH3+-PHF6 which present a positive net charge at pH 6 and the Nacetylated PHF6 (Ac-PHF6) which is neutrally charged at pH 6. By using these
isoforms, we investigated the influence of the charge on peptide fibrillation potency
and membrane interaction. First, peptide neurotoxicity and membrane permeation
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activity were analyzed by MTS and Live/Dead assays, respectively. Then, PHF6
insertion into lipid membrane and the associated structural changes were characterized
by in situ synchrotron X-ray reflectivity (XR) and grazing incidence X-ray diffraction
(GIXD) on a lipid monolayer membrane at the air/water interface. Finally, PHF6
membrane-mediated fibrillation was examined in the presence of large unilamellar
vesicle by using a combination of characterization methods including circular
dichroism (CD) spectroscopy, dynamic light scattering (DLS) and transmission
electron microscopy (TEM) imaging. Thanks to this study, we gained a better
understanding

of

tau’s

membrane-mediated

fibrillation

and

its

role

in

neurodegenerative disorders.
2. Evaluate OPEs selectivity and sensitivity for detecting fibrillar and pre-fibrillar
aggregates made of disease-relevant proteins. Previous studies have shown that OPEs
interact selectively with the amyloid conformation of model proteins81, 82, 84. In this
study, we further evaluated OPE amyloid sensing properties through the detection of
fibrillar and pre-fibrillar aggregates made of three different disease-related proteins,
Aβ40, Aβ42 and α-synuclein. The binding efficiency of OPE12- and OPE24+ were
characterized though fluorescence measurement and by calculating the amyloid
detection factor (ADF), the limit of detection, and the dissociation constant. We also
compared OPE sensing properties to a well-known sensor, thioflavin T (ThT). This
study contributed to a better understanding of OPE as an amyloid probe and more
importantly we showed the potential of OPE for the detection of the most toxic species,
pre-fibrillar aggregates. This research was published in 2019 in ACS Chemical
Neuroscience titled “High Selectivity and Sensitivity of Oligomeric p-Phenylene
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Ethynylenes for Detecting Fibrillar and Pre-Fibrillar Amyloid Protein Aggregates”
(DOI - 10.1021/acschemneuro.8b00719). In addition to the work presented herein, our
group is putting more effort to evaluate OPE as an amyloid probe both ex vivo and in
vivo. I have contributed to the investigation of OPE for the sensing of neurofibrillary
tangles in brain sections prepared from both human and mouse tauopathy model
(rTg4510). We found that OPE12- was a superior ex vivo sensor as it co-localized with
the phosphorylated-tau at pThr231 (reactive to AT180 antibody) and detected
neurofibrillary tangles at a lower concentration compared to ThT (1.5 mM for ThT vs
5 µM for OPE). This research is still on-going and will be completed by the graduate
student Florencia Monge.
3. Characterize OPE as an amyloid dye in terms of background fluorescence, effect on
amyloid aggregation and cell toxicity. To further characterize OPE as an amyloid dye,
we first determined the optimal OPE12- concentration for amyloid sensing by analyzing
OPE background fluorescence at various concentration. We also evaluated the effect
of OPE on amyloid aggregation when co-incubated with Aβ40 at different molar ratio
OPE to protein (1:2, 1:5 and 1:10). Finally, we investigated OPE neurotoxicity. This
study revealed that OPE does not alter the amyloid aggregation during co-incubation
with the amyloid peptide and more importantly that OPE maintains its sensing
properties. These results combined with the selective sensing of early pre-fibrillar
aggregates, open the door to future applications such as the characterization of amyloid
aggregation kinetic through real-time fluorescence microscopy.
4. Evaluation of oligomeric p-phenylene ethynylenes sensing properties in a complex
biological sample, cerebrospinal fluid (CSF). Increase in amyloid oligomer
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concentration in CSF has been correlated with cognitive impairment in AD88, 89. A
probe selectively detecting amyloid aggregates in CSF could be used to ensure early
disease diagnosis. Such probe needs to be highly selective toward the aggregated
conformation of the protein and its sensing properties should not be altered by the
presence of other biological molecules such as glucose, salt and non-amylogenic
proteins. To evaluate OPE sensing of amyloid aggregates in CSF, we first evaluated
OPE12- and OPE24+ background fluorescence in this complex environment. Then, OPEs
sensing properties were investigated in healthy CSF spiked with amyloid aggregates at
21 µg/mL. We also investigated OPE detection of amyloid aggregates in CSF isolated
from patients with dementia through the protein misfolding cyclic amplification
(PMCA) assay. This assay consisted in using the seeding potency of the amyloid
aggregates present in dementia CSF. For this assay, CSF samples were spiked with
monomeric Aβ40 which is expected to form fibrils in the presence of seed oligomers.
Overall, this study contributed to a better understanding of OPEs sensing properties in
a complex, disease-relevant biological sample and helped us investigate OPE as a
diagnostic tool through the detection of amyloid aggregates in CSF.
5. Evaluate the photosensitizing activity of OPE on amyloid fibrils. Photo-oxidation of
amyloid aggregates is a novel strategy currently investigated to inhibit protein
aggregation and to assure fibrils disassembly67-69. The challenge of such strategy is to
develop a controllable photo-oxidizer selectively targeting amyloid aggregates. The
selective binding of OPE and its photosensitizing activity were combined to develop a
new switchable photo-oxygenation system. In this project, we evaluated OPE as an
amyloid photo-oxidizer by monitoring Aβ fibrils oxidation by dot blot and mass
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spectrometry. The consequences of fibrils photo-oxidation in terms of fibrils
disassembly and fibrils toxicity were also characterized by TEM imaging and cell
proliferation assay, respectively. The characterization of OPE as a controllable and
selective amyloid photo-oxidation could contribute to the development of a novel
generation of theranostic (‘therapeutic’+’diagnostic’) molecules for the detection and
treatment of neurodegenerative diseases.
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3.1 Abstract
The aggregation of the tau protein into neurofibrillary tangles is believed to correlate with cognitive
decline in several neurodegenerative disorders including Alzheimer’s disease. Recent studies suggest
that tau interaction with the cell membrane could serve as a toxicity pathway and also enhance
fibrillation into paired helical filaments (PHFs). Conformational changes associated with taumembranes interactions are poorly understood and their characterization could lead to a better
understanding of tau pathogenicity. In this study, we investigated the molecular level structural changes
associated with the six amino acid PHF6 peptide interaction with lipid membranes and characterized
their effects on membrane stability and peptide fibrillation. Two forms of PHF6 were used, the
aggregation prone PHF6 with N-terminal acetylation (Ac-PHF6) and the non-aggregation prone PHF6
with a standard N-terminus (NH3+-PHF6). Both PHF6 peptides were found to be neurotoxic and
exhibited similar membrane-mediated changes which consist of (1) favorable interaction with anionic
membranes, (2) membrane destabilization through lipid extraction and (3) membrane-mediated
fibrillation. The rate at which these changes occurred is the main difference observed between the two
peptides. NH3+-PHF6 shows slow membrane-mediated fibrillation after six days of incubation, while
Ac-PHF6 adopted a β-sheet conformation at the surface of the membrane within hours. Ac-PHF6
interactions with the membrane were also accompanied by membrane invagination and rapid membrane
destabilization. Overall, our results show that membrane interactions could play a critical role in tau
toxicity and fibrillation and its characterization is important for significant advancement in the
development of novel therapeutic strategies.
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3.2 Introduction
The misfolding and aggregation of the microtubule-associated protein tau into
neurofibrillary tangles (NFTs) is implicated in the development of Alzheimer’s disease (AD)
and other tauopathies such as Down’s syndrome and frontotemporal dementia90. The tau
protein is composed of a projection domain made of acidic and proline-rich regions and a
microtubule binding (MTB) domain containing up to four repeat units made of tubulin binding
motifs (Figure 3-1)91, 92. The physiological function of tau is to stabilize microtubules93, 94 in
order to ensure cytoskeletal organization and cellular trafficking95. Tau’s function is modulated
by post-translational modifications such as phosphorylation, which controls its affinity to the
microtubules96,

97

. In AD, tau is hyperphosphorylated which leads to the abnormal

accumulation of unattached tau and promotes its self-aggregation into insoluble paired helical
filaments (PHFs)95. The deposition of NFTs was found to correlate with cognitive decline and
neurodegeneration98, and is involved in the rapid transcellular propagation of the disease34.
MTB domains play major roles in both tau’s physiological function and aggregation.
Indeed, two hexapeptide segments, 275VQIINK280 (PHF6*) and 306VQIVYK311 (PHF6) located
in the second and third repeat units of the MTB domain, respectively, form the core of tau
fibrils99-101. Both hexapeptides form stable parallel-β-sheet twisted filaments similar to the βsheet structures found in tau-oligomers and NFTs102, 103, which make them relevant models to
investigate tau aggregation and toxicity pathways104.
Tau’s toxicity mechanism is not well understood. However, recent studies indicate that
tau binding to the lipid membrane disrupts cell membrane homeostasis and cause cell
apoptosis27, 28. There are several hypothesized mechanisms by which amyloid proteins interact
with and destabilize lipid membranes. Amyloid-β (Aβ), α-synuclein and amylin proteins have
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been described to form “ion-channel-like structures” on the cell membrane105, which permeates
the membrane and allows calcium flux106. Aβ and α-synuclein have also been shown to
remodel lipid membranes through a “carpeting-effect mechanism”35, where the amyloid
proteins blanket the lipid membrane causing membrane thinning107 or generating membrane
curvature108, 109. Membrane disruption can also be caused by a “detergent-like mechanism” as
observed with Aβ35, where the peptide removes lipids from the membrane by forming micellelike structures with the lipids. Tau protein was also shown to extract lipids through a similar
mechanism leading to the formation of stable protein/lipid complexes27. Molecular-level
details of lipid membrane destabilization caused by tau protein, however, remain poorly
understood.
Tau interaction with the cell membrane is also suspected to nucleate fibrillation.
Previous studies have shown that upon interaction with anionic lipid membrane, tau29, 30, Aβ31
and α-synuclein32, 33 are more prone to fibril formation. Possible explanations for accelerated
fibril nucleation include membrane-induced changes to protein structure, partial folding of the
intrinsically disordered proteins via membrane association or penetration, and increased
protein concentration at the membrane37. In tau protein, three segments located in the MTB
domain (253-261, 315-323, and 346-355) have been found to bind to lipid membranes and
adopt a helical structure which promotes protein aggregation by enhancing protein-protein
interactions28, 110.
In this study, we investigated the molecular level structural changes associated with the
insertion of two PHF6 isoforms into lipid membranes and explored the effects on membrane
stability and peptide fibrillation. After characterizing fibrillation of both peptides, their
neuronal cell toxicity was evaluated. Angstrom level structural changes associated with PHF6
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insertion into a lipid monolayer membrane at the air/water interface were investigated by in
situ synchrotron X-ray reflectivity (XR) and grazing incidence X-ray diffraction (GIXD). The
membrane-mediated conformational changes and fibrillation of PHF6 were also characterized
in the presence of large unilamellar vesicles (LUVs). We found that both peptides
preferentially inserted into the negatively charged lipid membrane which led to different
conformational changes; NH3+-PHF6 inserted into the lipid membrane while Ac-PHF6 formed
a layer at the surface. Despite different macroscale events, both PHF6s disrupted membrane
stability and underwent membrane-mediated fibrillation.

3.3

Results

PHF6 is an amphiphilic hexapeptide(32) located in the third repeat unit of the tau MTB (Figure
3-1A). This hexapeptide has been shown to drive tau fibrillation by forming the core of β-sheet
rich tau aggregates(11-13). In this study, we characterized the structural changes associated
with PHF6 upon interaction with lipid membranes and investigated its role in cell toxicity and
peptide fibrillation. Two PHF6 isoforms were evaluated, non-acetylated PHF6 (NH3+-PHF6)
and N-terminal acetylated PHF6 (Ac-PHF6) (Figure 3-1B and 1C), to investigate the influence
of peptide charge on fibrillation and membrane interaction.
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Figure 3-1: Structures of hTau40 protein and PHF6 peptides. (A): hTau40, made of 411 amino
acids, is the longest isoform found in the brain. It is composed of a projection domain (green)
and microtubule binding domain (blue). PHF6 is a hexapeptide found in the third repeat unit
of the microtubule binding domain (R3) and is amphiphilic. (B) and (C): Structures of NH3+PHF6 and Ac-PHF6 peptides. The acetyl group, the positive and negative charges are indicated
in black, blue, and red, respectively.

N-acetylation of PHF6 promotes fibrillation
PHF6 has been previously described to form fibrillar aggregates rich in parallel βsheets101, 102. In this study we evaluated the capability of NH3+-PHF6 (net charge at pH 6: +1)
and Ac-PHF6 (net charge at pH 6: 0) to form fibrils by incubating the peptides in MilliQ water
at 3 mg/mL at 70˚C for 3 days.
As shown by TEM images in Figure 3-2A and C, unincubated NH3+-PHF6 and AcPHF6 showed very few features indicating that both peptides are soluble and likely
monomeric. After 3 days of incubation at 70˚C, only Ac-PHF6 formed characteristic amyloid
fibrils (Figure 3-2D) while NH3+-PHF6 remained unaggregated (Figure 3-2B). These results
are consistent with previous findings101 and indicate that Ac-PHF6 is more prone to fibrillation
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than NH3+-PHF6, which could be due to electrostatic repulsions between positively charged
NH3+-PHF6 peptides.

Figure 3-2: TEM images of NH3+-PHF6 and Ac-PHF6 before and after 3 days of incubation
at 70 ˚C at 3 mg/mL under quiescent condition. Both PHF6 peptides appear monomeric when
unincubated and only Ac-PHF6 formed mature fibrils after 3 days of incubation.

PHF6 peptides are cytotoxic
We next evaluated neuronal toxicity of unincubated NH3+-PHF6, unincubated Ac-PHF6, and
pre-formed Ac-PHF6 fibrils on cultured neuroblastoma SH-SY5Y cells by MTS assay.
Normalized viability results are reported in Figure 3-3. Compared to untreated cells (control),
cells treated with unincubated and fibrillar PHF6 displayed lower levels of cell viability (p ≤
0.01), with final viabilities lower than the 70% threshold generally considered for
cytotoxicity111. No significant difference in cell viability was observed between cells treated
with unincubated NH3+-PHF6 and Ac-PHF6. Additionally, the pre-formed Ac-PHF6 fibrils
exhibited highest toxicity with a viability value close to 40%.
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Figure 3-3: SHSY-5Y cell viability after 48 hours of treatment with 20 µM of unincubated
NH3+-PHF6, unincubated Ac-PHF6, or preformed Ac-PHF6 fibrils. Cell viability was
normalized to the control, untreated cells. Error bars represent standard deviations of quintuplet
experiments. Red line represents 70% cell viability used as a threshold for cytotoxicity.
Asterisks indicate significant differences between two conditions (t-test with a p-value ≤ 0.01).

To complement the MTS-based cell toxicity assay, a live/dead stain assay was
performed. Two stains were used, calcein-AM and ethidium homodimer-1 (EthD1). Live cells
were stained green by the conversion of the cell-permeant calcein-AM to green fluorescent
calcein dye (excitation at 494 nm, emission at 517 nm). Membrane compromised cells were
stained red from binding of the non-cell-permeant EthD1 to DNA that induces fluorescence
turn-on (excitation at 528 nm, emission at 617 nm). After incubating the neuroblastoma cells
with 10 µM unincubated NH3+-PHF6, unincubated Ac-PHF6, or fibrillar Ac-PHF6 for 24
hours, fluorescence images were taken (Figure 3-4A) and the number of dead cells was
quantified (Figure 3-4B). Compared to the untreated control, all PHF6 samples caused
significant increases in dead counts (cells/mm2) (p ≤ 0.01), indicating that PHF6 caused
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membrane permeation which could contribute to the peptide’s toxicity. Comparable results
were obtained for both unincubated NH3+-PHF6 and Ac-PHF6, indicating no significant
difference in their membrane permeation activity. Additionally, the β-sheet rich fibrils caused
higher dead cell counts (Figure 3-2) than the unincubated peptides. Taken together, our results
show that both NH3+-PHF6 and Ac-PHF6 are cytotoxic and the fibrillar state is more toxic and
membrane disruptive compared to the unaggregated state.

Figure 3-4: Live/dead staining assay results of SHSY-5Y cells incubated with 10 µM
unincubated NH3+-PHF6, unincubated Ac-PHF6, or preformed Ac-PHF6 fibrils. (A):
Fluorescence images of SHSY-5Y cells exposed to PHF6. Green and red cells correspond to
live cells (calcein-AM staining) and dead cells (EthD1 staining), respectively. The red arrows
indicate the dead cells. (B): Quantitative results of live/dead assay images, where dead cells
were counted from 4 fluorescence images taken for each treatment condition. Asterisks
represent significant differences between two conditions (t-test with a p-value ≤ 0.01).

PHF6 inserts into and destabilizes lipid membranes
One hypothesized mechanism of amyloid protein toxicity is the disruption of cell
membrane structure and function via direct protein-membrane interactions. Indeed, the
live/dead staining assay results show a correlation between PHF6 peptide toxicity and
membrane permeabilization. To characterize PHF6 interactions with the cell membrane, we
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used lipid monolayers formed at the air/water interface in a Langmuir trough as a model
membrane system. Two lipids were used, zwitterionic DMPC and anionic DMPG. The
insertion of NH3+-PHF6 or Ac-PHF6 into monolayers was measured while the monolayer
surface area was held constant (Figure 3-5). As such, favorable interactions that cause tau to
insert into the lipid monolayer led to increases in surface pressure.
Both PHF6 peptides readily inserted into anionic DMPG monolayers, causing initial
fast increases in surface pressure after injecting the peptides into the subphase (Figure 3-5).
Consistent with previously published findings with hTau4029, the truncated Ac-PHF6 did not
insert into zwitterionic DMPC monolayer (data not shown), indicating that the peptide
preferentially interacts with anionic lipid membranes. The insertion of NH3+-PHF6 resulted in
higher surface pressure increases than Ac-PHF6 (Figure 3-5A). As both peptides exhibited
similar adsorption to a clean air/water interface (Supplementary Figure S1), the difference in
membrane insertion was likely due to differences in their specific interactions with the lipid
membrane rather than their intrinsic surface activities. After NH3+-PHF6 rapidly inserted into
the membrane, a slow but persistent decrease in surface pressure was observed over time,
indicating that some material was being removed from the surface (lipids and/or peptides).
Note that this pressure loss is not due to instability of the lipid film, as lipid monolayers held
at 25 mN/m did not show appreciable pressure loss over time (data not shown). Interestingly,
Ac-PHF6 displayed two unique phases of surface pressure loss after the initial rapid increase:
a sharp decrease in surface pressure, followed by a slower loss of about 2 mN/m per hour. This
two-phase surface pressure loss might be caused by different mechanisms of membrane
destabilization.
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To monitor lipid monolayer morphology, fluorescence microscopy (FM) was used to
image the monolayer before and after peptide insertion (Figure 3-5B and Figure 3-5C); 0.5
mol% headgroup labeled lipid dye Texas-Red DHPE (TR-DHPE) was included in the
monolayer for FM imaging. A DMPG monolayer compressed to 25 mN/m has undergone
phase transition where ordered liquid-condensed domains (LC) domains formed in the
disordered liquid-expanded (LE) phase. As the bulky fluorescent dye was excluded from the
LC phase, it appeared as dark patches while LE phase appeared bright.
The insertion of NH3+-PHF6 caused negligible changes to the monolayer morphology
as FM images appeared similar before and at different time points of peptide insertion (Figure
3-5B). In contrast, insertion of Ac-PHF6 resulted in drastic changes to monolayer morphology,
where at least three fluorescence intensity levels were observed in FM images (Figure 3-5C).
In addition to the bright LE and dark LC phases, a third even brighter phase was formed in the
LE portion of the film at earlier time points (Figure 3-5C, 15-45 min). These brighter features
could be membrane invagination112 caused by the insertion of Ac-PHF6. After 1 hour of
incubation, the third bright phase disappeared and the dark LC domains became progressively
reduced, which could be due to the disruption of these domains by the peptide or reduction of
the monolayer surface pressure observed with time.
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Figure 3-5: Isotherms (A) and fluorescence microscopy (FM) images (B and C) of NH3+PHF6 and Ac-PHF6 insertion into DMPG monolayer at the air/water interface under constant
area conditions. 0.5 mol% fluorescent dye Texas Red-DHPE was included in the DMPG
monolayer. Contrast in the FM images arises from the dye being excluded from liquidcondensed (LC) domains (shown as dark patches), making the liquid-expanded (LE) fluid lipid
phase bright. Interesting, three different levels of brightness were observed in FM images of
Ac-PHF6 insertion, where the LC (dark) and LE (gray) are in coexistence with a brighter phase
during earlier time points (15-45min) of Ac-PHF6 insertion.

One cause for the higher level of insertion of NH3+-PHF6 compared to Ac-PHF6 could
be the different overall peptide charges due to acetylation. At pH 6.0 (approximate water pH),
NH3+-PHF6 had a net positive charge that promoted its insertion into the negatively charged
lipid membrane. In contrast, Ac-PHF6 had a neutral charge and therefore had less attraction to
the anionic DMPG lipid headgroups. Overall, both peptides favorably interacted with the
anionic membrane and extracted material (lipids, peptides, or both) from the membrane.
Additionally, our results show that although Ac-PHF6 inserted less into the membrane than
NH3+-PHF6, it caused faster and more disruptions to the membrane stability and morphology.

NH3+-PHF6 inserts into the membrane while Ac-PHF6 accumulates at the
membrane surface
It is clear that both PHF6 peptides destabilized the cell membrane and caused toxicity.
The peptides favorably interact with anionic lipid monolayers and some differences are seen
on their effects on membrane morphology. To gain further insights into the molecular level
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structural changes of the peptides and the lipid monolayer accompanying PHF6 insertion, we
used in situ synchrotron X-ray scattering techniques to determine the angstrom-level structure
and organization of lipids and tau peptides at the air/water interface.
X-ray reflectivity (XR) was employed to determine the electron density distribution of
lipid-peptide films at the air/water interface in the direction perpendicular to the film surface
(z-direction) with sub-angstrom resolution. Using this method one can distinguish between
regions of materials with different electron densities such as, in our case, phospholipid tails,
lipid headgroups, peptides, or mixtures of these components. This information can be used to
reconstruct a model depicting the structure of the phospholipid/peptide film in the z-direction
(averaged over the coherent volume of the X-ray beam) and determine the location of peptide
in the membrane as previously described31. A DMPG monolayer at 25 mN/m was modeled as
two “slabs” of different electron densities (Figure 3-6A1 and Figure 3-6A2 and
Supplementary Table S3) – a 15.9 ± 0.2 Å thick slab of phospholipid tails at a normalized
electron density (ρ/ρwater) value of 0.98 ± 0.03 and a 9.1 ± 0.3 Å thick slab of more electron
dense phospholipid heads with a ρ/ρwater value of 1.58 ± 0.02. The insertion of NH3+-PHF6 into
the lipid monolayer induced subtle structural changes to the DMPG monolayer (Figure 3-6).
At 2.5 hours after injection, ρ/ρwater of the DMPG lipid head groups decreased from 1.58 ± 0.02
(Figure 3-6A2) to 1.49 ± 0.03 (DMPG + NH3+-PHF6) (Figure 3-6B2). This change could be
caused by the insertion of NH3+-PHF6 into the lipid headgroups, thus decreasing the ρ/ρwater
value of this layer. The ρ/ρwater values of proteins, including Aβ40 and hTau40, adsorbed to an
air/water interface have been previously reported to be around 1.2629, 31. Thus, the intermediate
ρ/ρwater value of 1.49 ± 0.03 (Figure 3-6B2) is likely a mix of peptides and lipid headgroups.
Concurrently, ρ/ρwater of the lipid tails increased slightly from 0.98 ± 0.03 to 1.02 ± 0.004,

30

suggesting some peptide insertion into the tails. A third slab was modeled beneath the lipid
head groups of electron density that was subtly distinguishable from the water subphase
(ρ/ρwater value of 1.041± 0.005). This indicated a sparsely populated layer of NH3+-PHF6
adsorbed to the lipid head groups. A similar observation was made at 4.5 and 6.5 hours – a
small change in electron density indicated NH3+-PHF6 insertion into the membrane and a
sparse layer of adsorbed peptide.

Figure 3-6: X-ray reflectivity (XR) results of NH3+-PHF6 interacting with a DMPG
monolayer. (A1-D1): Normalized Fresnel reflectivity (R/RF) profiles of a DMPG monolayer
before (A1) and 2.5 (B1), 4.5 (C1), and 6.5 (D1) hours after injecting NH3+-PHF6 into the
subphase. Experimental data are plotted as points with errors, and the fitted model is overlaid
as solid lines. (A2-D2): Electron density profiles normalized to that of water (ρ/ρwater) for a
DMPG monolayer before (A2) and 2.5 (B2), 4.5 (C2), and 6.5 (D2) hours after injecting NH3+PHF6 into the subphase. The depth, or distance in the z-direction, is plotted with zero marking
the air/lipid tails interface; negative values are in the air and positive values extend into the
water subphase. Solid lines represent slab model fits and the dashed lines represent smoothed
slab model fits where the slabs were fit with roughness at interfaces. Lipids and NH3+-PHF6
(green) schematics are included to help visualize the molecular layers that gave rise to the fitted
ρ/ρwater profiles. Larger-scale schematics of the membrane structure without (A2) or with
NH3+-PHF6 inserted into the membrane (B2-D2) are shown in the upper left hand corner of
the electron density profiles.
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In contrast, insertion of Ac-PHF6 induced drastic changes to the lipid monolayer
structure (Figure 3-7 and Supplemental Table S4). After 2.5 hours of Ac-PHF6 incubation
with the monolayer, the membrane had clearly lost many features of its original structure.
Three slabs were needed to fit the XR reflectivity data (Figure 3-7B2). The two slabs
representing the lipid monolayer had decreased electron densities with increased roughness
values indicating less distinct layers. Combined with the drastic decreases in surface pressure
observed after the addition of Ac-PHF6 (Figure 3-5), the decrease in electron density was
likely due to loss of lipids at the surface. A third layer, extending 24.1 ± 0.07 Å into the water
subphase at a ρ/ρwater value of 1.21 ± 0.0014 is likely a peptide layer forming underneath the
membrane (Figure 3-7B2). This highly perturbed monolayer structure could be the result of
large-scale membrane deformations, such as invagination, which were also observed by FM
imaging (Figure 3-5C). At 4.5 hours, the membrane-peptide film resembled a typical lipid
monolayer with a less prominent peptide layer underneath the lipid headgroups (16.3 ± 0.3 Å
thick with a ρ/ρwater value of 1.06 ± 0.0018). The electron density of the lipid membrane layers
decreased by about 10% compared to that at 25 mN/m, reflecting the loss of material at the
surface. Finally, at 6.5 hours the lipid/peptide film structure was similar to that at 2.5 hours –
a highly perturbed lipid monolayer covered with a thick layer of bound peptides.
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Figure 3-7: X-ray reflectivity (XR) results of Ac-PHF6 interacting with a DMPG monolayer.
(A1-D1): R/RF profiles for a DMPG monolayer before (A1) and 2.5 (B1), 4.5 (C1), and 6.5
(D1) hours after injecting Ac-PHF6 into the subphase. Data are plotted as points with
experiment error, and the fitted model is overlaid as solid lines. (A2-D2): ρ/ρwater profiles of a
DMPG monolayer before (A2) and 2.5 (B2), 4.5 (C2), and 6.5 (D2) hours after injecting AcPHF6 into the subphase. The depth is plotted with zero marking the air/lipid tails interface;
negative values are in the air and positive values extend into the water subphase. The solid
lines represent slab model fits and the dashed lines represent smoothed slab model fits where
the slabs were fit with roughness at interfaces. Lipids and Ac-PHF6 (red) schematics are
included to help visualize the molecular layers that gave rise to the fitted ρ/ρwater profiles.
Larger-scale schematics of membrane structures unperturbed (A2) and flat (C2) membranes,
or those containing invaginations and major deformations (B2 and D2) are inlaid for each
electron density profile.

PHF6 forms β-sheet rich structures and disrupts lipid packing
While analysis of XR data provides electron density distributions averaged over both
in-plane ordered and disordered parts of the monolayer, grazing incidence X-ray diffraction
(GIXD) detects only ordered diffracting species present at the air/water interface. As the
expected ordered structures included condensed phospholipid tails and repeating peptide
structures such as β-sheet-rich fibrillar structures, GIXD was used to monitor assembly of
PHF6 peptides and its impacts on lipid packing. Fitting of integrated diffraction peaks gave
rise to the lattice spacing (d-spacing), coherence length (Lc), and relative amounts of diffracting
material in the plane of the lipid/peptide film31. Lc is calculated from the full width at half
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maximum peak intensity (FWHM) and Lc value represents the average size of diffracting
crystallites. GIXD diffraction images and a summary of the peak fitting parameters are
reported in Supplementary Material Figure S2, Tables S1 and S2.
DMPG monolayer at 25 mN/m showed a single diffraction peak indicating
hexagonally packed lipid tails in the LC phase with a distance between acyl tails of 4.87 ± 0.02
Å (Table 3-1) and a Lc value of 513 ± 15 Å (Table 3-1 and Figure 3-8A). One hour after
NH3+-PHF6 injection, the ordered lipid tails adopted a distorted hexagonal packing as two
diffraction peaks were observed. At 3.5 hours, lipid tails again became hexagonally packed.
However, the total amount of diffracting lipids decreased by ~60% based on peak intensity
decrease. The in-plane lipid packing remained largely the same for the rest of the experiment
and no other ordered structures were observed.
In contrast, the interaction of Ac-PHF6 with DMPG was more dynamic (Figure 3-8B,
and Table 3-1 and Table 3-2). At one hour after Ac-PHF6 injection, the lipid diffraction peak
shifted slightly to indicate larger d-spacing between lipid tails. The phospholipid diffraction
peak also broadened significantly, corresponding to a more than 5-fold reduction of Lc from
ca. 500 to 73 ± 11 Å. Concurrently, a second, non-lipid diffraction peak appeared at a qxy value
of 1.33 Å-1 that corresponds to a d-spacing of 4.74 ± 0.02 Å (Table 3-2). As this d-spacing
exactly matches the distance between β-strands of amyloid fibers measured by X-ray
diffraction113, the appearance of this peak indicates the formation of semi-crystalline β-strand
lattice structures of Ac-PHF6 stabilized by hydrogen bonds. The Lc calculated from the peptide
diffraction peak was 125 ± 19 Å, indicating that ca. 26 peptides are in positional registry in the
crystallites. At 3.5 hours, two lipid diffraction peaks were observed, indicating distorted
hexagonal packing with tail-tail intermolecular distances of 4.841 ± 0.016 and 4.966 ± 0.018
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Å with corresponding Lc values of 340 ± 50 and 95 ± 14 Å, respectively. Interestingly, at 3.5
hours, the peptide diffraction peak diminished significantly before returning to a high intensity
peak at 5 hours. At 5 hours the lipid diffraction indicated a return to hexagonal packing with
small ordered lipid domains (Lc of 76 ± 11 Å), and at 7 hours both the lipid and peptide
diffraction peaks were diminished significantly.
We additionally extracted Bragg rod data by integrating X-ray diffraction images over
qxy to determine the length of the coherently scattering molecular entity along the z-dimension
(Lm). Analysis of the Ac-PHF6 diffraction peak at 1.33 Å-1 at 5 hours after peptide injection
yielded a Lm value of 20.2 ± 0.6 Å (Supplementary Figure S4). Thus, of the 24.12 ± 0.07 Å
thick peptide layer accumulated underneath the lipid headgroups as detected by XR, 20.2 Å of
it was participating in diffraction.
Taken together, GIXD resolved three distinct stages of the Ac-PHF6-membrane film
after peptide addition. The first is low intensity diffraction from hexagonal lipid packing with
strong peptide diffraction observed 1.0 hour post injection. At this stage, Ac-PHF6 is bound to
the DMPG monolayer, and the binding disrupted lipid packing and induced the peptide to
assemble in β-sheet rich crystalline aggregates. This stage is followed by a second distinct
stage of high intensity distorted hexagonal lipid packing with little peptide diffraction at 3.5
hours. The interpretation of this drastic change in the peptide-lipid film is that as the β-sheet
rich Ac-PHF6 aggregates grew, they detached from the lipid monolayer and resulted in a
diminished peptide diffraction peak at the air/water interface. This loss of peptides from the
interface is corroborated by observed loss of surface pressure and changes in membrane
morphology (Figure 3-5). At this stage, another cycle of Ac-PHF6 insertion and assembly
occurred (5.0-6.5 hours), leading to detachment and loss of material at the interface at 7.0 hours
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post injection where significant surface pressure loss and only a weak lipid diffraction peak
were observed.

Figure 3-8: Grazing incidence X-ray diffraction (GIXD) results of Ac-PHF6 and NH3+-PHF6
interacting with DMPG lipid monolayers. Background-subtracted integrated diffraction values
(points) are overlaid with the Voigt model fit to the data (solid lines). Error bars are shown in
gray. (A): Bragg peaks from time-dependent NH3+-PHF6 interactions with a DMPG lipid
monolayer. Only lipid diffraction peaks around 1.48 Å-1 from condensed lipid tail packing
were observed. (B): Bragg peaks obtained from Ac-PHF6 interactions with a DMPG
monolayer over time. The new peaks around 1.32 Å-1 are attributed to peptide diffraction from
in-registry β-sheets. (C): GIXD peaks from Ac-PHF6 interactions with DMPG 5 hours after
peptide injection. No other samples showed peaks in this region.
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Table 3-1: GIXD fitting parameters obtained from DMPG lipid diffraction peaks after
injection of NH3+-PHF6 or Ac-PHF6.
Surface
Tail-Tail
Integrate Coherence
Sample
Pressure Intermolecula
d Peak
Length
(mN/m)
NH3+-PHF6 Lipid Diffraction Peaks

r Distance

Area

Lc (Å)*

DMPG

25.2

668 ± 12

510 ± 80

DMPG + NH3+-PHF6 – 1.0 h

30.0

4.87 ± 0.02
(Å)
4.96 ± 0.02

820 ±50

120 ± 20

4.84 ± 0.02

690 ± 20

630 ± 100

DMPG + NH3+-PHF6 – 3.5 h

31.7

4.85 ± 0.02

277 ± 9

580 ± 90

DMPG + NH3+-PHF6 – 5.0 h

30.8

4.84 ± 0.02

246 ± 8

600 ± 90

DMPG + NH3+-PHF6 – 7.0 h

28.6

4.84 ± 0.02

310 ± 8

580 ± 90

DMPG

28.9

4.870 ± 0.015

890 ± 40

480 ± 80

DMPG + Ac-PHF6 – 1.0 h

37.3

4.912 ± 0.017

1200 ±100

73 ± 11

DMPG + Ac-PHF6 – 3.5 h

33.3

4.966 ± 0.018

1210 ± 60

95 ± 14

4.841 ± 0.016

370 ± 30

340 ± 50

Ac-PHF6 Lipid Diffraction Peaks

DMPG + Ac-PHF6 – 5.0 h

30.1

4.897 ± 0.017

860 ± 60

76 ± 11

DMPG + Ac-PHF6 – 7.0 h

26.3

4.91 ± 0.02

150 ± 50

90 ± 14

*A conservative 15% error is assumed for Lc values

From the GIXD data, we additionally deduced tertiary structural information about the
Ac-PHF6 β-sheet rich aggregates (or protofibrils). In GIXD the X-rays travel in the plane of
the lipid monolayer and they only diffract from ordered species with their unit cell
perpendicular to that plane. Thus, the β-strand unit cell must be oriented perpendicular to the
lipid monolayers, which suggests that the fibril growth axis was parallel to the lipid membrane
(Figure 3-9F). At 5.0 hours, two additional diffraction peaks were observed at qxy values below
0.5 Å-1 (Figure 3-8C), with d-spacings of 9.0 ± 0.06 and 11.5 ± 0.13 Å. Although the exact
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structures that gave rise to these peaks are unknown, we posit that at least one of the peaks
arose from inter-β-sheet packing of the protofibril as amyloid fibrils have been reported to have
an approximate spacing of 10 Å between β-sheets113. Thus, these diffraction peaks may have
arisen from two types of inter-sheet packing arrangements. Alternatively, the diffraction could
be from ordered phospholipid headgroups templated by electrostatic interactions with the
protofibril. Although lipid headgroups diffraction is typically not observed by liquid surface
X-ray scattering experiments, this study may be a unique case driven by the high degree of
ordering in the bound protein protofibrils and their strong interaction with the negatively
charged head groups via positively charged lysine moieties. These observations, along with
the XR data, corroborate dynamic Ac-PHF6-membrane interactions and structural
reorganization as described previously.

Table 3-2: GIXD fit parameters of Ac-PHF6 diffraction peaks after injecting the peptide
underneath a DMPG monolayer.

Sample

d-Spacing (Å)

Integrate
d Peak
Area

Coherence
Length
Lc (Å)*

DMPG + Ac-PHF6 – 1.0

4.74 ± 0.02

770 ± 40

125 ± 19

DMPG + Ac-PHF6 – 3.5
h
DMPG
+ Ac-PHF6 – 5.0
h

4.73 ± 0.03

150 ± 30

86 ± 13

4.73 ± 0.03

770 ± 40

210 ± 30

h

11.5 ± 0.3

43 ± 11

69 ± 10

9.01 ± 0.14

130 ± 20

37 ± 6

4.74 ± 0.02

280 ± 30

125 ± 19

DMPG + Ac-PHF6 – 7.0

h conservative 15% error is assumed for Lc values.
*A

With the findings from GIXD and XR, we constructed a detailed structural model for
PHF6 peptide interaction with the anionic lipid membrane (Figure 3-9). Favorable
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electrostatic interactions cause NH3+-PHF6 to fully insert into the phospholipid monolayer, as
evidenced by modulated electron density of the headgroups and tails. A sparsely populated
peptide layer was observed outside of the DMPG monolayer. As a result of peptide interaction,
packing of lipid tails became distorted (Figure 3-9A and Figure 3-9C). Ac-PHF6 first
interacted with DMPG to form a 16 Å thick layer of peptides underneath the lipid headgroups
and induced distorted hexagonal packing of the lipid tails (Figure 3-9D). This layer was
possibly formed by burying the C-terminal cationic lysine in the anionic headgroups, leaving
16 Å of peptide to protrude below the lipid monolayer (Figure 3-9B and Figure 3-9D). AcPHF6 quickly formed β-sheet rich protofibrillar structures after inserting into the DMPG
membrane as evidenced by a β-strands d-spacing of 4.7 Å (Figure 3-9F). These protofibrils
are oriented with the growth axis parallel to the membrane, and likely had one terminal lysine
inserted into the lipid headgroups. In addition to the β-strands d-spacing of 4.7 Å, two
additional d-spacings of 9.0 and 11.5 Å were also observed between the β-sheets (Figure 3-9F
The 24 Å thickness of the peptide layer under the monolayer was consistent with the PHF6
fibril structure114 with one terminal lysine excluded from the measurement (Figure 3-9 E/F
and Supplementary Figure S3). This model was further corroborated by Bragg rod analysis
of the 5.0 hours Ac-PHF6 1.328 Å-1 diffraction peak (Supplementary Figure S4). The result
was that 20.2 ± 0.6 Å of the peptide layer were contributing to the diffraction peak out of the
24 Å protein layer measured by XR studies.
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Figure 3-9: Model for PHF6 interactions with DMPG monolayer based on XR and GIXD data.
(A): NH3+-PHF6 structure extracted from a previously published structure of a paired helical
filament114. Positive charges on the peptide are circled in blue. (B): Ac-PHF6 structure with
the positive charge circled in blue (blue). The length of the peptide (red) excluding the Cterminal lysine is estimated. (C): Model for non-fibrillar (unincubated) NH3+-PHF6 interacting
with a DMPG monolayer. Electrostatic interactions drive the insertion of the positively charge
peptide into the anionic DMPG monolayer. Lipid tails are in a distorted hexagonal packing
structure (D): Model for unincubated Ac-PHF6 interactions with DMPG. Peptide inserts with
the cationic lysine (blue) into the anionic DMPG headgroup. A 16 Å layer of peptide is
observed below the lipid monolayer, and lipids are in a distorted hexagonal structure. (E):
Model of an Ac-PHF6 fibril derived from a previously published fibril structure
(Supplemental Figure S3) 114. 2 peptides are shown here. Measured distance (red) excludes
one terminal lysine, assuming that the lysine is embedded in the DMPG head groups. Positive
charges are circled in blue. (F): Model for inserted and assembled Ac-PHF6 protofibril
interacting with DMPG monolayer. Lipid packing is disrupted due to peptide interactions, and
one terminal lysine is assumed to insert into the anionic phospholipid head group. The fibril
forms a 24 Å layer of peptide beneath the lipids. The fibril growth axis is parallel to the plane
of the lipids, and there is a lattice spacing of 4.7 Å between β-strands, and 9.0 or 11.5 Å spacing
between β-sheets.

PHF6 interaction with LUVs promotes fibrillation
NH3+-PHF6 and Ac-PHF6 displayed selective favorable interactions with anionic
DMPG membrane and Ac-PHF6 was also shown to assemble into β-sheet rich protofibrils
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upon interaction. In order to investigate the effect of this interaction on peptide fibrillation,
both hexapeptides were incubated in water with 100 nm large unilamellar vesicles (LUVs)
composed of 70 mol% POPC and 30 mol% POPG. Peptide secondary structures, vesicle size
distribution, and formation of fibrils were evaluated using circular dichroism (CD)
spectroscopy, dynamic light scattering (DLS), and TEM imaging, respectively. We did not use
the popular fluorescence probe Thioflavin T to track fibril formation because of its poor
binding to PHF6 fibrils.
Freshly solubilized NH3+-PHF6 and Ac-PHF6 were rich in random coils as shown by
the negative peak at around 195 nm in CD spectra (Figure 3-10). After 1-hour incubation with
vesicles (168 µg/mL peptide with 688 µM lipids) at room temperature, drastic changes in
secondary structure were observed for both peptides; positive and negative peaks at around
200 nm and 218 nm, respectively, appeared, indicating the formation of β-sheet rich structures.
A stronger CD signal was observed in the case of Ac-PHF6 showing a higher β-sheet content
compared to NH3+-PHF6. The formation of β-sheets by Ac-PHF6 corroborates our finding
from GIXD measurements (Figure 3-8). However, GIXD did not detect β-sheet assembly of
NH3+-PHF6 at the pure DMPG membrane surface. CD is a bulk solution technique, thus, the
measured β -sheet content in NH3+-PHF6 incubated with LUVs could be from the peptide
adopting a β-sheet conformation in solution, and not at the surface of the membrane. As NH3+PHF6 was shown to destabilize the lipid monolayer (Figure 3-5), it is likely that the peptide
could adopt a β-sheet conformation when complexed with dissolved lipids. Alternatively, the
membrane curvature found in LUVs may induce β-sheet structures more than what is observed
in the flat lipid monolayer system36, 38.
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Figure 3-10: CD spectra of 168 µg/mL NH3+-PHF6 and Ac-PHF6 peptides alone (168 µg/mL)
(solid line) and in the presence LUVs (688 µM lipids, 70 mol% POPC and 30 mol% POPG)
after 1 hour incubation at room temperature (dashed line). LUVs caused the largely random
coil peptides to adopt β-sheet rich structures.

LUV size distribution was monitored by DLS during incubation with both peptides (50
µg/mL PHF6 in the presence of 20 µM lipids) (Figure 3-11). LUVs were stable for over 7
days at room temperature where hydrodynamic radius (Rh) remained unchanged at ~50 nm
(Figure S5). The addition of NH3+-PHF6 to the LUVs did not induce any changes to the vesicle
size distribution during the first 24 hours, but the size distribution became broader and Rh
increased after 6 days (Figure 3-11A). By day 8, the vesicles likely became unstable and
agglomerated. In contrast, after mixing with Ac-PHF6, an immediate broadening of LUV size
distribution and increase of Rh were observed (Figure 3-11B). By day 6, size distribution
shifted towards larger sizes and became very broad. These changes are likely caused by
immediate peptide binding and vesicle agglomeration, followed by peptide fibrillation at
longer incubation times.

42

Figure 3-11: Size distribution of LUVs (20 µM lipids, 70 mol% POPC and 30 mol% POPG)
incubated at room temperature in the presence of 50 µg/mL NH3+-PHF6 (A) or Ac-PHF6 (B)
over time as detected by DLS. LUVs size distribution was unchanged after 1 day of incubation
with NH3+-PHF6 and became larger after 6 days of incubation. In contrast, Ac-PHF6 induced
rapid increase of Rh and broader LUV size distribution immediately upon addition.

To further understand the increase of the LUV size induced by NH3+-PHF6 and AcPHF6 and the changes in secondary structures, the samples were imaged by TEM (Figure 3-12
The sample containing NH3+-PHF6 incubated with LUVs for 1 hour showed round, 100-200
nm-sized features (Figure 3-12A). These are likely peptide-coated LUVs as bare lipid vesicles
are completely disrupted during the drying step in sample preparation for TEM31. After 6 days
of incubation, long fibrils were visible, which supports DLS measurements that showed the
presence of larger structures in the sample. When incubated alone, NH3+-PHF6 did not form
fibrils in the same incubation period, indicating that the interaction with the lipid membrane
promoted NH3+-PHF6 fibrillation, possibly by reducing the repulsive electrostatic interactions
between positively charge ammonium groups of NH3+-PHF6. Also, by binding to the lipid
membrane, the increased local concentration of NH3+-PHF6 is also expected to promote
peptide fibrillation.
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In the presence of LUVs, Ac-PHF6 produced long fibrils after only a few hours of
incubation (Figure 3-12B), which is consistent with the high β-sheet content measured by CD
spectroscopy (Figure 3-10) and by GIXD (Figure 3-8). Fibrils produced in the presence of
LUVs formed large clusters connected to small dark agglomerates, which appear to be AcPHF6-coated-LUVs. In contrast, when the same peptide was incubated alone, significantly
slower fibrillation was observed; short protofibrils were observed after 1 hour and long fibrils
were only observed after 6 days of incubation. Taken together, our results show that anionic
vesicles accelerated fibrillation of both NH3+-PHF6 and Ac-PHF6.

Figure 3-12: TEM images of NH3+-PHF6 (A) and Ac-PHF6 (B) incubated alone (100 µg/mL)
and in the presence of LUVs (40 µM) over 6 days at room temperature under quiescent
condition.
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3.4 Discussion
The interaction of the tau protein with the lipid membrane is believed to play a key role
in peptide toxicity and fibrillation. In this study, we investigated the lipid membrane interaction
of PHF6, a hexapeptide located in the third repeat unit of the MTB domain forming the core
of tau PHFs and revealed its effect on membrane structure and peptide fibrillation. We used
two PHF6 peptides, one fibrillation prone (Ac-PHF6) and another not fibrillation prone (NH3+PHF6), to study the effect of these peptides on cell toxicity, membrane interaction, and
membrane-mediated fibrillation.
We found that both unincubated PHF6s are neurotoxic and pre-formed Ac-PHF6 fibrils
exert higher toxicity (Figure 3-3). Membrane disruption via direct peptide interactions has
been proposed as a mode of toxicity for amyloidogenic proteins, and is the central hypothesis
tested in this work. Membrane destabilization caused by PHF6 is supported by Langmuir
trough isotherm experiments where both Ac-PHF6 and NH3+-PHF6 favorably interact with
anionic, but not zwitterionic, lipid monolayers at the air/water interface (Figure 3-5). This
interaction leads to lipid extraction from the interface into the aqueous subphase as observed
by a decrease in the membrane surface pressure after the insertion of PHF6. This model agrees
with a previously published study showing that full length tau inserts into negatively charged
lipid membranes and extracts lipids from the membrane27. Furthermore, the interaction of
PHF6 with lipid membranes also enhances fibrillation kinetics of both peptides. Strikingly, in
the presence of anionic LUVs, Ac-PHF6 formed fibrils within one hour of incubation,
compared to 6 days required for complete fibrillation in the absence of vesicles. Likewise, the
non-aggregating NH3+-PHF6 was able to form fibrils after 6 days of incubation with LUVs.
Based on these results, we propose a 3-step model for PHF6 membrane-mediated toxicity: (1)
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peptide insertion into the lipid membrane, (2) membrane destabilization through lipid
extraction and (3) membrane-mediated fibrillation.
Despite a similar membrane-mediated toxicity mechanism, NH3+-PHF6 and Ac-PHF6
undergo different molecular-level changes when interacting with the lipid membrane, which
are summarized in Figure 3-13. XR data (Figure 3-6) indicate that the cationic NH3+-PHF6
fully and rapidly inserts into the negatively charged DMPG monolayer and does not
immediately form β-sheets at the membrane surface but forms fibrils within six days (Figure
3-11 and Figure 3-12). Binding of the positively charged peptides to the anionic membrane
reduces the electrostatic repulsion between the peptides and increases its local concentration,
both of which promote the peptide’s assembly into fibrils. In contrast, Ac-PHF6 associated
with the membrane, likely via lysine-mediated electrostatic interactions, but does not fully
insert into the lipid headgroups (Figure 3-9). The peptide quickly destabilizes the membrane
(Figure 3-5) and assembles into β-sheet enriched protofibrils on the surface of the lipid
membrane. These aggregates promote extensive membrane destabilization through both
membrane invagination and fast peptide fibrillation.
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Figure 3-13: Model for NH3+-PHF6 (A) and Ac-PHF6 (B) lipid membrane disruption and
membrane-induced peptide fibrillation. Non-aggregation prone NH3+-PHF6 quickly inserts
into lipid membrane and slightly destabilizes the membrane while promoting a slow
fibrillation. In contrast, the aggregation prone Ac-PHF6 rapidly inserts into lipid membrane
and quickly assemble into β-sheet rich protofibrils. Membrane destabilization and invagination
occur concurrently.

It is important to note the difference in kinetics observed between experiments
performed with a lipid monolayer made of pure DMPG lipids and LUVs made of 7:3
POPC:POPG lipids. In the LUV system, Ac-PHF6 reached complete fibrillation and disruption
of the vesicles within one hour, but in the lipid monolayer system large changes were observed
up to 7 hours. The differences in lipid compositions, membrane fluidity, membrane curvature,
and peptide concentration are likely to influence both peptide interaction with lipid membranes
and membrane destabilization kinetics, as observed in the case of α-synuclein38. However, both
of our experimental systems show the same trends for membrane interaction and fibrillation,
while acknowledging a difference in peptide interaction kinetics.
Overall, the aggregation prone Ac-PHF6 exhibits fast membrane-mediated fibrillation
and rapid membrane disruption, while the non-aggregation prone NH3+-PHF6 displays both
slower membrane disruption and membrane-mediated fibrillation. Additionally, the preformed Ac-PHF6 fibrils displayed higher neurotoxicity than unincubated Ac-PHF6 and NH3+PHF6 (Figure 3-3), indicating that the peptide’s assembly state and secondary structures are
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involved in lipid membrane destabilization and toxicity. Also, it is important to note that the
lipid models used in this study were mainly composed of negatively charged lipids that do not
capture the full complexity of the cell membrane. This may account for some discrepancy
between the in vitro experiments and the in vivo cell toxicity assays. The cell membrane is
asymmetric with zwitterionic extracellular leaflet and anionic cytosolic leaflet115, 116. While the
tau protein originates inside the cell, future investigations must also consider the extracellular
lipid environment as it likely plays an important role in transmission of tau toxicity throughout
the brain.
In this study, we have gained molecular-level insights about PHF6-membrane
interactions and effects of these interactions on tau aggregation and membrane structure. This
knowledge enhances our understand of membrane-mediated tau neurotoxicity and fibrillation.
Our results, together with a previously published study27, support a lipid extraction mechanism
of tau induced membrane destabilization, which results in the formation of stable peptide-lipid
complexes. These complexes are also likely involved in the fast peptide fibrillation observed
in the presence of vesicles. The production of such complexes could be linked to transcellular
propagation as cell internalization of tau aggregates is believed to induce fibrillation of
intracellular tau34. Further study of tau-lipid complexes can shed light on the role of tau in
neurodegenerative diseases. With this study we also introduced two PHF6 models, one
fibrillation prone (Ac-PHF6) and one non-aggregation prone (NH3+-PHF6). These models are
useful tools to study the two toxicity events associated with amyloid proteins: membrane
disruption and protein fibrillation. These PHF6 models could be used to better understand the
mechanism of action of therapeutic molecules and could help elucidate the toxicity
mechanisms associated with amyloid aggregates.
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3.5 Experimental Procedures
Materials
SH-SY5Y neuroblastoma cells, Dulbecco’s Modified Eagle’s Medium (DMEM) F12 media,
and fetal bovine serum (FBS) were purchased from Sigma-Aldrich (St. Louis, MO). Penicillinstreptomycin (PS) at 10,000 U/mL was purchased from Thermo Fisher Scientific (Waltham,
MA). The CellTiter 96® AQueous One Solution Cell Proliferation Assay, a tetrazolium
compound

[3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-

tetrazolium (MTS)-based metabolic assay, was purchased form Promega (Madison, WI).
Ethidium homodimer-1 (EthD-1) and calcein-AM were purchased from Invitrogen (Thermo
Fisher Scientific, Waltham, MA). Lipids [1,2-Dimyristoyl-sn-glycero-3-phosphorylglycerol
(DMPG), 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG)] were obtained from Avanti Polar
Lipids (Alabaster, AL). Texas Red 1,2-dihexadecanoyl-sn-glycero-3-Phosphoethanoloamine
triethylammonium salt (TR-DHPE) was purchased from Molecular Probes Inc. Chloroform
and methanol were purchased from Millipore Sigma. A MilliQ purification system (Millipore
Synergy UV) was used to purify all water used. Copper grids, 400 mesh, covered by a
Formvar/Carbon film (5-10 nm) were purchased from Ted Pella (Redding, CA) and 2%
aqueous uranyl acetate was purchased from Electron Microscopy Sciences (Hatfield, PA).
Peptide synthesis, purification and incubation
N-acetyl VQIVYK (Ac-PHF6) and non-acetylated VQIVYK (NH3+-PHF6) were synthesized
by a solid-phase method as previously described101. Peptides were purified by reverse phase
HPLC (RP-HPLC) using an acetonitrile-water gradient containing 0.1% TFA. Purified PHF6
were lyophilized and stored at -70 ˚C until use. Peptide molecular weights were confirmed by
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electrospray ionization mass spectrometry and peptide purity was determined by RP-HPLC.
Stock solutions were prepared by solubilizing the peptides in MilliQ water at 4 mg/mL and
filtering with a 0.02 µm filter. PHF6 concentration was determined by absorbance
measurement using a Nanodrop (Thermo Fisher Scientific, Waltham, MA) (ɛ280nm = 1195.9
cm-1M-1,117 MWAc-PHF6 = 790 g/mol, MWNH3+-PHF6 = 748 g/mol). PHF6 peptides were
incubated at 70 ˚C for 3 days at 3 mg/mL or at room temperature for up to 6 days at 100 µg/mL.
MTS-based cell viability assay
SH-SY5Y neuroblastoma cells at passage 20 were cultivated at 37 ˚C and 5 % CO2 in DMEM
F12 media containing 10 % FBS and 1% PS. 96-well plates were seeded with 20,000 cells/well.
Cells were incubated for 16 h to allow cell attachment prior to serum deprivation over 24 h
ensuring cell synchronization to a quiescent state. Cells were then treated with 20 µM PHF6
for 48 h. After treatment, cell viability was determined by the MTS reduction assay. The assay
was performed by adding 20 µL of CellTiter 96® AQueous One Solution Cell Proliferation
Assay to each well. The conversion of MTS into formazan by metabolically active cells was
monitored through absorbance at 490 nm after 3 h of incubation at 37 ˚C and 5 % CO2. The
optical density (OD) of formazan was measured using a Spectra Max M2 plate reader
(Molecular Devices, Sunnyvale, CA). The % cell viability was calculated using Equation 1.
% 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =

𝑂𝐷𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑂𝐷𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑂𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑂𝐷𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑

× 100

(1)

The control and background samples consisted of untreated cells and unseeded wells,
respectively. Each condition was tested in quadruplicates and data were statistically analyzed
using JMP Pro 13 software (SAS Institute, Inc., Cary, NJ). The effect of the PHF6 on cell
viability was analyzed using t-test with a p-value ≤ 0.01 and 70% cell viability was used as a
threshold to define cytotoxicity.
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Live/dead staining assay
SH-SY5Y cells were grown in a 6-well plate at 150,000 cells/well. After 24 h incubation at 37
˚C and 5 % CO2, cells were treated with 10 µM PHF6 peptide diluted in DMEM F12 media
containing 10% FBS and 1 % PS. After another 24 h, cells were incubated with 1 µM EthD-1
and 0.2 µM calcein-AM in DMEM F12 media over 30 min at 37 ˚C and 5 % CO2. Cells were
rinsed with media and imaged using a Nikon Eclipse TS100 fluorescence microscope (Nikon
Instruments, Inc., Melville, NY). Two filters blocks were used. A TRITC (G2E/C) filter cube
was used to detect EthD-1 (red fluorescence) and a FITC (B2E/C) filter cube was used to detect
calcein (green fluorescence). Images were then merged using Image J (National Institutes of
Health, Bethesda, MD, USA)118. Finally, dead cell density (number of dead cells/mm2) was
determined and the results were statistically analyzed using JMP Pro 13 software (SAS
Institute, Inc., Cary, NJ) based on the average of four images taken for each condition with
both filters. The effect of PHF6 on the number of dead cells/mm2 was analyzed using t-test
with a p-value ≤ 0.01.
Lipid monolayer insertion assays
A Langmuir trough (KSV Instruments Ltd., Finland) Micromini model with Delrin barriers
was used to measure insertion of NH3+-PHF6 and Ac-PHF6 into a lipid monolayer composed
of 100% DMPG. Water (50 mL) was used as the subphase, and experiments were performed
at 30 ± 0.5 ˚C (temperature was controlled via a circulating water bath). DMPG was initially
dissolved at 3.0 mg/mL in 7:3 v/v chloroform to methanol solution and sonicated. TR-DHPE
was dissolved in 9:1 chloroform to methanol at 0.5 mg/mL. The final spreading solution for
the trough was composed of 0.2 mg/mL DMPG with 0.5 mol% TR-DHPE in 9:1 v/v
chloroform to methanol. After spreading the lipids on the air/water interface, solvent was
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allowed to evaporate for 10 minutes before compressing the lipids with symmetric barriers at
3.0 mm/sec to a surface pressure of 25 mN/m. For constant area experiments, the barrier
position was fixed so that peptide insertion resulted in pressure increase. NH3+-PHF6 and AcPHF6 were dissolved in water at 800 μM, vortexed, and the supernatant was collected after 10
minutes of centrifugation at 14,000 rpm to remove insoluble peptides. Peptides were injected
into the subphase to reach a final concentration of 5 μM in the trough subphase. Fluorescence
microscopy images were taken with an IX51 model inverted fluorescent microscope
(Olympus) with an Exi Aqua Bio-Imaging Camera (QImaging).
X-ray scattering experiments
X-ray scattering experiments were performed at the Advanced Photon Source at Argonne
National Labs, Sector 15 NSF’s ChemMatCARS. Experiments were carried out in a 6.5x6.5
cm2 (20 mL subphase volume) Langmuir trough equipped with a Wilhelmy plate balance.
Water subphase was degassed and maintained at room temperature (~23˚C) and DMPG was
deposited at the air/water interface to form a monolayer at 25 mN/m. An aliquot of NH3+-PHF6
or Ac-PHF6 was then injected into the subphase to a final peptide concentration of 5 μM in the
trough. To prevent background scattering and oxidative beam damage to the monolayer, the
trough was in a sealed canister and purged with helium gas to reduce the gaseous oxygen
content to < 2%. The wavelength of the X-ray beam was 1.24 Å, and X-rays were detected
with a Dectris PILATUS 100K detector. Data was integrated using Python software built by
beamline support scientists (https://github.com/weibu/Liquid_Surface_ChemMatCARS). A
typical set of XR and GIXD scans required approximately 45-60 min to obtain. As an
additional precaution against beam damage, the trough was systematically translated during
data collection. The dimensions of the incoming X-ray beam footprint on the liquid surface
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were ~1 mm by 3-10 mm for XR, and ~1 mm by 29 mm for GIXD. X -ray reflectivity (XR)
and GIXD measurements were collected and analyzed as described in the Supplemental
Material.
Preparation of large unilamellar vesicles (LUVs)
LUVs composed of 70 mol% POPC and 30 mol% POPG were prepared as previously
described31. A 4 mM lipid solution was prepared in chloroform and dried overnight under
vacuum. Dried lipid film was rehydrated with MilliQ water to 2 mM concentration. Lipid
solution was vortexed and incubated for 30 minutes at room temperature before being exposed
to five freeze/thaw cycles. Finally, rehydrated lipids were extruded 19 times using an extruder
with 100 nm pore size polycarbonate membranes (Avanti Polar Lipids, Alabaster, AL).
Circular dichroism spectroscopy
PHF6 secondary structures were analyzed immediately after solubilization in water at 168
µg/mL and after 1 hour incubation in the presence of 688 µM LUVs by circular dichroism
(CD) spectroscopy using an AVIV 410 CD spectrometer (Aviv Biomedical Inc., Lakewood,
NJ). A 0.1 cm path length quartz cell (Starna Cells, Atascaders, CA) was used and CD spectra
were obtained in triplicates between 180-260 nm with an averaging time of 15 s. The average
CD signal in millidegree was then converted to molar ellipticity (θ)119.
Dynamic light scattering (DLS)
LUVs were analyzed by DLS to determine their size distribution when incubated alone at 20
µM or in the presence of 50 µg/mL NH3+-PHF6 or Ac-PHF6. Samples were analyzed using a
DAWN HELEOS II light scattering instrument (Wyatt Technology Corporation, Santa
Barbara, CA) in a quartz microcuvette. Scattering intensity at 90˚ was recorded over 10 min
and analyzed using the regularization tool on ASTRA 5.3.4.20 software.
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Transmission electron microscopy (TEM) imaging
PHF6 peptides were imaged by TEM to visualize fibrillation. Peptides were diluted to 50
µg/mL with water and 4 µL of the diluted sample was loaded onto a glow discharge (30 s)
copper grid. Excess sample was wicked away and the grid was stained with 2 % uranyl acetate
4 times, 4 µL of stain for 5 min followed by 3 more stains of 1 min each. Between each staining
step, the excess of stained was wicked away. After staining, the grid was air dried and was
imaged using HITACHI HT7700 transmission electron microscope (Hitachi High
Technologies Corp., Tokyo, Japan).
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3.9 Supplementary Information
Supplemental Experimental Procedure: X-ray scattering data analysis
X -ray reflectivity (XR) was used to measure the electron density of materials deposited at the
air/water interface on a Langmuir trough. X-ray scattering theory and the liquid diffractometer
used here have been fully described previously120-122 so they are only briefly summarized here.
By measuring the intensity of reflected X-rays, one can deduce detailed information on the
electron density distribution normal to the interface, (z), laterally averaged over both the
ordered and disordered parts of the film. The reflectivity is defined as the ratio of reflected to
incident beam intensities, in a specular geometry, as a function of the vertical momentum
transfer vector qz = (4π/) sin, where  is the incident angle of the X-ray on the surface.
Finally, the reflectivity curve can be analyzed to obtain the in-plane averaged electron density
distribution normal to the interface.
The data was collected by tilting a germanium monochromator crystal to deflect the
beam and change the angle of incidence on the sample. Intensities were collected over the
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range 0.01< qz < 0.8 Å-1, background subtracted, and normalized to incident beam flux. Data
presented are divided by the Fresnel reflectivity (scattering from infinitely sharp air-water
interface) (RF) with error bars representing one standard deviation error for each data point.
Division by the Fresnel reflectivity provided better visualization of the XR data. In fitting
reflectivity data, a ‘slab’ model was used to obtain the electron density profile normal to the
interface31. The studied system was divided into layers, or slabs, of certain thickness, constant

 and interconnected by interfacial roughness approximated by error functions. The parameters
of such model were adjusted using Motofit program123 to obtain lowest 2 values and
reasonable values of the parameters.
In GIXD experiments, an evanescent wave was generated by an incident beam striking
the water surface at an angle corresponding to a value of momentum transfer vector in the z
direction, qz = 0.85qc where qc = 0.02176 Å-1 is the critical momentum transfer vector for total
external reflection from the water subphase. Diffracted intensities were recorded as a function
of both qz= 2πsinαf/λ where αf is the out-of-plane angle of the diffracted beam, and qxy≈
4πsin(θxy/2)/λ where θxy is the angle between the incident and diffracted beam projected onto
the horizontal plane. The GIXD intensity resulting from a powder of 2-D, azimuthally
disoriented, crystallites can be represented as Bragg peaks (resolved in the qxy direction but
integrated over the qz) or Bragg rods (resolved in the qz direction but integrated over the qxy).
The scattered signal was recorded using a 2-D Pilatus 100K PSD and slits to define a pinhole
focusing geometry to yield a qz vs. qxy intensity distribution with a horizontal resolution of qxy
= 0.006 Å-1. GIXD data were background subtracted and the Bragg peaks were fit with the
Multi Peak Fit 2 function for Igor with Gaussian, Lorentzian, or Voigt profiles depending on
the goodness of fit. A conservative 15 % error is assumed for the full width half maximum
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(FWHM) values from Voigt profile fits. The qxy resolution of the ChemMatCARS liquid
surface instrument of qxy = 0.006 Å-1 was taken into consideration to calculate the FHHM
values. The angular positions of the Bragg peaks determine the d-spacings, d = 2/qxymax
(where the qxymax is the position of the maximum of the Bragg peak) for the 2D lattice. For
hexagonally packed phospholipid acyl tails, intermolecular distance does not correspond
directly to d-spacing, but is calculated from the d-spacing by the trigonometric relationship
intermolecular distance = d-spacing / sin(60). From the FWHM of the peaks, coherence length
Lc of the 2D crystallites, the average distance in the direction of the reciprocal lattice vector
qxy over which ordering extends, can be determined using Equation 2.
𝐿𝑐 =

0.9 𝑥 2𝜋
√𝐹𝑊𝐻𝑀2 −0.0062

(2)

For analysis, the areas of the Bragg peaks indicate the amounts of diffracting material present
at the air/water interface. The intensity distribution along the Bragg rod reflects the molecular
structure factor and could be analyzed to determine the length of the coherently scattering
moiety, Lm, magnitude of its tilt vis-à-vis the surface normal, and the magnitude of molecular
motion. The FWHM in the Bragg rod intensity distribution relates to the length of the
diffracting molecular entity. The Bragg rods measured in this work were fitted with Equation
2 to calculate Lm values. Since the Bragg rods were very broad and the instrumental resolution
along qz is small (limited only by the size of the detector’s pixel), Equation 2 was used without
calculating intrinsic FWHM. Detailed analysis methods and theory have been previously
described121, 122, 124.
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Supplementary Figures and Tables:

Figure S1: Surface activity measurements of NH3+-PHF6 and Ac-PHF6. Adsorption of 3 μM
PHF6 to a clean air/water interface at 30 C.

Table S1: Complete GIXD Fit Parameters for NH3+-PHF6

Sample

q xy Position
(Å-1)

d Spacing
(Å)

FWHM

InterMolecule
Distance
(Å)

Integrated
Peak Area

Coherence
Length
Lc (Å)

Surface
Pressure
(mN/m)

Lipid Diffraction Peaks
DMPG

1.491 ± 0.007

0.0124 ± 0.0004

4.213 ± 0.017

4.87 ± 0.02

668 ± 12

513 ± 15

25.2

NH3+-PHF6 – 1.0 h

1.462 ± 0.007

0.0492 ± 0.003

4.30 ± 0.02

4.96 ± 0.02

820 ±50

115 ± 6

30.0

1.498 ± 0.007

0.0107 ± 0.0003

4.194 ± 0.017

4.84 ± 0.02

690 ± 20

628 ± 18

NH3+-PHF6 – 3.5 h

1.497 ± 0.007

0.0114 ± 0.0004

4.196 ± 0.018

4.85 ± 0.02

277 ± 9

580 ± 20

31.7

NH3+-PHF6 – 5.0 h

1.499 ± 0.007

0.0111 ± 0.0004

4.191 ± 0.018

4.84 ± 0.02

246 ± 8

600 ± 20

30.8

NH3 -PHF6 – 7.0 h

1.498 ± 0.007

0.0113 ± 0.0003

4.194 ± 0.017

4.84 ± 0.02

310 ± 8

582 ± 18

28.6

+
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Table S2: Complete GIXD Fit Parameters for Ac-PHF6. Inter-molecule distance refers to the
distance between alkyl tails in case of diffraction from DMPG lipids.
Sample

q xy Position
(Å-1 )

FWHM

d Spacing Unit Cell a, b
(Å)

Inter-Molecule
Distance (Å)

Integrated
Peak Area

Coherence
Length
Lc (Å)

Surface
Pressure
(mN/m)

Lipid Diffraction Peaks
DMPG

1.490 ± 0.007

0.012 ± 0.002

4.218 ± 0.018

4.870 ± 0.015

890 ± 40

480 ± 80

28.9

Ac-PHF6 – 1.0 h

1.477 ± 0.007

0.077 ± 0.011

4.25 ± 0.02

4.912 ± 0.017

1200 ±100

73 ± 11

37.3

Ac-PHF6 – 3.5 h

1.461 ± 0.007

0.059 ± 0.009

4.30 ± 0.02

4.966 ± 0.018

1210 ± 60

95 ± 14

33.3

1.499 ± 0.007

0.018 ± 0.003

4.192 ± 0.018

4.841 ± 0.016

370 ± 30

340 ± 50

Ac-PHF6 – 5.0 h

1.481 ± 0.007

0.074 ± 0.011

4.24 ± 0.02

4.897 ± 0.017

860 ± 60

76 ± 11

30.1

Ac-PHF6 – 7.0 h

1.478 ± 0.009

0.062 ± 0.009

4.25 ± 0.03

4.910 ± 0.02

150 ± 50

90 ± 14

26.3

Ac-PHF6 β-Sheet Diffraction Peaks
Ac-PHF6 – 1.0 h

1.327 ± 0.007

0.045 ± 0.007

4.74 ± 0.02

/

770 ± 40

125 ± 19

37.3

Ac-PHF6 – 3.5 h

1.329 ± 0.009

0.065 ± 0.010

4.73 ± 0.03

/

150 ± 30

86 ± 13

33.3

Ac-PHF6 – 5.0 h

1.328 ± 0.007

0.027 ± 0.004

4.73 ± 0.02

/

770 ± 40

210 ± 30

30.1

Ac-PHF6 – 7.0 h

1.326 ± 0.007

0.045 ± 0.007

4.74 ± 0.02

/

280 ± 30

125 ± 19

26.3

30.1

Ac-PHF6 low q xy Protein Diffraction Peaks
Ac-PHF6 – 5.0 h

0.545 ± 0.012

0.081 ± 0.012

11.5 ± 0.3

/

43 ± 11

69 ± 10

0.697 ± 0.011

0.15 ± 0.02

9.01 ± 0.14

/

130 ± 20

37 ± 6

*A conservative 15% error is assumed for FWHM and Lc values.
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Figure S2: 2D grazing incidence X-ray diffraction plots. Raw data used for grazing incidence
X-ray diffraction. Color bar on the right indicates the scale of the images, with once scale used
for the top DMPG sample, another scale used for all Ac-PHF6 samples, and a third scale used
for all images on the bottom (second DMPG sample and all NH3+-PHF6). Data collection
artifacts besides the diffraction peaks are observed for Ac-PHF6 7 hours and NH3+-PHF6 3.5
hours. In the first case the constant line of scattering at qxy=1.1 Å-1 was caused by an accidental
vibration of the liquid surface. We believe that the scattering along Scherrer-ring observed in
case of NH3+-PHF6 at 3.5 hours was caused by a contaminating aggregate at the surface which
came into the footprint of the X-ray beam – the Langmuir trough was moved occasionally
perpendicular to the x-ray beam during the scans to avoid excessive beam damage. Returning
to the same position in the trough at 9 hours produced the same Scherrer-ring, thus the signal
is a position-dependent contaminant and not a time-dependent scattering feature.

Table S3: NH3+-PHF6 XR Fit Parameters
Slab 1 (Tails)

Slab 2 (Heads)

Slab 3 (outside layer)

Subphase

ρ / ρwater

Roughness

Thickness

ρ / ρwater

Roughness

Thickness

ρ / ρwater

DMPG 15.9 ± 0.2

0.98 ± 0.03

3.3 ± 0.3

9.1 ± 0.3

1.58 ± 0.02

3.4 ± 0.2

/

/

/

2.8 ± 0.4

7.8

PHF6 16.5 ± 0.3
2.5 h

1.019 ± 0.004

3.52 ± 0.03

8.9 ± 0.5

1.49 ± 0.03

3.2 ± 0.2

14.3 ± 1.0

1.041 ± 0.005

2.4 ± 0.2

5.0 ± 0.9

3.4

PHF6 16.2 ± 0.4
4.5 h

1.009 ± 0.005

3.52 ± 0.04

9.0 ± 0.7

1.5 ± 0.05

3.4 ± 0.3

12.9 ± 1.1

1.037 ± 0.005

2.4 ± 0.3

3.9 ± 0.8

3.4

PHF6 16.0 ± 0.3
6.5 h

1.017 ± 0.007

3.29 ± 0.06

9.3 ± 0.5

1.52 ± 0.03

3.4 ± 0.3

12.5 ± 0.7

1.052 ± 0.005

2.2 ± 0.2

3.9 ± 0.5

4.1

Thickness
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Roughness Roughness

χ2

Table S4: Ac-PHF6 XR Fit Parameters
Slab 1 (Tails)

Slab 2 (Heads)

Slab 3 (outside layer)

ρ / ρwater

Roughness

Thickness

ρ / ρwater

Roughness

Thickness

ρ / ρwater

DMPG 15.7 ± 0.4

0.931 ± 0.007

3.59 ± 0.05

8.1 ± 0.6

1.55 ± 0.05

3.5 ± 0.3

/

/

PHF6
2.5 h

7.2 ± 0.2

0.607 ± 0.005

12*

PHF6 15.0 ± 0.1
4.5 h

0.805 ± 0.003

2.3 *

PHF6
6.5 h

0.746 ± 0.005

13.1 *

Thickness

4.7 ± 0.2

13.77 ± 0.03 0.883 ± 0.003
10.3 ± 0.3

4.6 *

1.204 ± 0.005

2.3 *

13.54 ± 0.04 0.952 ± 0.003

4.0 *

Subphase

Roughness Roughness

χ2

/

2.8 ± 0.2

8.2

4.5 *

5.8 *

12.1

1.061± 0.002

2.3 *

2.3 *

14.2

23.60 ± 0.06 1.239 ± 0.001

4.2 *

5.6 *

11.0

24.12 ± 0.07 1.206 ± 0.001
16.3 ± 0.3

*Fixed to reduce number of parameters during fitting

Figure S3: Model for PHF6 fibril structure deduced from published cryo-EM structures of Tau
filaments114. (A) Structure of 306-VQIVYK-311 (blue) and interacting partner 373-THKLTF378 (green) are extracted from the complete structure of a paired helical filament isolated from
an Alzheimer’s disease brain (PDB 5O31)114. VQIVYK forms parallel β-sheets with crosssheet interactions with sidechains of THKLTF. (B) Atomistic structure of 306-VQIVYK-311
(blue) interactions with 373-THKLTF-378 (green). The two peptides form a hydrophobic core
of amino acid side chains to stabilize interactions cross β-sheet interactions. (C) Predicted
structure for PHF6 fibrils assuming a similar cross β-sheet packing motif as the natural paired
helical filament isolated from Alzheimer’s disease brain. The original VQIVYK (blue) remains
in position, while a second copy of VQIVYK (pink) was rotated and translated from the
original coordinates to optimize the hydrophobic core of the structure.
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Figure S4: Bragg rod analysis of the protein diffraction peak centered at 1.328 Å-1 measured
for Ac-PHF6 interactions with DMPG 5 hours after protein injection. Bragg rod data was
extracted by integrating X-ray diffraction images along qz for the span of the diffraction peak.
Data was fit with a Lorentzian model centered around 0.08 Å-1 with an amplitude of 497 ± 7.
The resulting FWHM from the fit was 0.277 ± 0.008 Å-1, corresponding to a calculated Lm
value of 20.2 ± 0.6 Å. The position of the maximum of the Bragg rod at 0.08 Å-1 above the
horizon (defined as qz=0 Å-1) testifies that the coherently scattering molecular entity is slightly
tilted from the interface normal. The sharp intensity spike at qz~0 Å-1 is the Vineyard-Yoneda
peak resulting from interference of the incident and refracted beams.

Figure S5: Size distribution of LUVs (20 µM lipids, 70%mol POPC, 30%mol POPG)
incubated at room temperature over time. LUV are characterized by an overall size of 50 nm.
Over 7 days of incubation at room temperature, the LUV overall size distribution was
unchanged indicating high stability.
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4.1 Abstract
Misfolding and aggregation of amyloid proteins into fibrillar aggregates is a central pathogenic
event in neurodegenerative disorders such as Alzheimer’s (AD) and Parkinson’s diseases (PD).
Currently, there is a lack of reliable sensors for detecting the range of protein aggregates
involved in disease etiology, particularly the pre-fibrillar aggregate conformations that are
more neurotoxic. In this study, the fluorescent sensing of two novel oligomeric p-phenylene
ethynylenes (OPEs), anionic OPE1- and cationic OPE2+, for detecting pre-fibrillar and
fibrillar aggregates of AD-associated amyloid-β (Aβ40 and Aβ42) and PD-associated αsynuclein proteins (wildtype, and single mutants A30P, E35K, and A53T) over their
monomeric counterparts, were tested. Furthermore, the performance of OPEs was evaluated
and compared to thioflavin T (ThT), the most widely used fibril dye. Our results show that
OPE1- and OPE2+ exhibited aggregate-specific binding inducing large fluorescence turn-on
and spectral shifts based on a combination of backbone planarization, hydrophobic
unquenching, and super-luminescent OPE complex formation sensing modes. OPEs exhibited
higher selectivity, higher binding affinity, and comparable limits of detection for Aβ40 fibrils
compared to ThT. OPE2+ exhibited the largest fluorescence turn-on and highest sensitivity.
Significantly, OPEs detected pre-fibrillar aggregates of Aβ42 and α-synuclein that ThT failed
to detect. The superior sensing performance, the non-protein specific detection, and the ability
to selectively detect fibrillar and pre-fibrillar amyloid protein aggregates point to the potential
of OPEs to overcome the limitations of existing probes and promise significant advancement
in the detection of the myriad of protein aggregates involved in the early stages of AD and PD.
Keywords: Alzheimer’s and Parkinson’s diseases, oligomers, amyloid fibrils, protein
aggregate detection, fluorescent optical probes, oligomeric p-phenylene ethynylenes
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4.2 Introduction
Neurodegenerative disorders such as Alzheimer’s (AD) and Parkinson’s diseases (PD) are one
of the biggest global health crises of the 21st century, with about 50 million people affected
worldwide and at a cost that is projected to rise to $2 trillion per year by 2030 in the United
States 2. AD and PD are complex and multifactorial 125-128. While many factors may contribute
to disease etiology

129, 130

, including inflammation

131-134

and microbial infection

135-137

, the

misfolding and aggregation of largely intrinsically disordered proteins into highly ordered
fibrillar amyloid aggregates is still recognized as a central pathogenic event and one that is
believed to occur decades before the onset of neurodegeneration and cognitive impairment 128,
138-140

. Monitoring the course of amyloid formation at the biochemical, cellular, and tissue

levels is thus vital to understanding and combating these diseases 141.
Amyloid formation is complex and heterogeneous, and proceeds through the formation
of a range of oligomeric intermediates that have been shown to be the primary toxic species
that lead to neuronal loss and synaptic dysfunction 129, 142-149. Thus, useful probes for tracking
the disease process need to exhibit sufficient sensitivity to detect an array of aggregate
conformations, including oligomers as well as fibrils. In addition, comorbidities among the
diseases 127, for example, 80% of PD patients develop dementia 150, caused by the co-deposition
of multiple pathological proteins necessitates that useful probes simultaneously detect
aggregates formed by different proteins. For instance, Alzheimer’s disease is characterized by
the accumulation of both amyloid plaques composed of the amyloid-β (Aβ) peptide and
neurofibrillary tangles made of the tau protein151. In the case of Parkinson’s disease, the
deposition of Lewy bodies composed of the α-synuclein protein are observed as well as the
accumulation of tau aggregates 152, 153. Probes that can detect aggregates made of a variety of
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proteins are therefore potentially clinically useful. Unfortunately, no such probes are currently
available.
Many studies have sought to develop probes for protein aggregates, including
conformation- and sequence-specific antibodies154. However, the myriad of challenges
associated with antibody-based detection and failures of immunotherapy clinical trials

155, 156

have spurred renewed efforts in developing small-molecule probes for detecting and localizing
amyloids. Fluorescent dyes157, radiolabeled positron-emission tomography (PET), single
photon emission computed tomography (SPECT) ligands158-161, and metal-ligated magnetic
resonance imaging (MRI) contrast agents 162 have been developed but their diagnostic value is
thus far limited. For example, Pittsburgh Compound B

158

and

18

F-AV-45

159

only detect

amyloid- (A) fibrillar deposits in the AD brain. They are of limited use because they fail to
detect neurotoxic pre-fibrillar aggregates that better correlate with clinical symptoms. They
also do not detect tau aggregates, further undermining their diagnostic value as AD is
characterized by complex regional localization of both A and tau deposits. Additionally, no
clinically tested probes are available for imaging PD-related α-synuclein aggregates163.
Compounds that bind specifically to amyloids tend to share a common “rigid
conjugated rod” motif, where the linear shape and aromaticity favors binding to hydrophobic
sites on the amyloid fibril 164, 165. Probes that have been investigated include molecules derived
from Congo red, curcumin 166-168, thioflavin T (ThT) 169-171, and oligo-thiophenes 172-177. These
ligands, when used for fluorescent imaging, primarily function on a “molecular rotor” basis,
in which fluorescence enhancement and red shift arise from backbone planarization (restriction
to rotation) of the conjugated region within the fluorophore when bound to a planar site on the
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amyloid fibril. This single sensing mode gives rise to the probes’ ability to detect primarily the
fibrillar conformation of amyloid proteins.
Recently, we tested a novel class of fluorescent sensors, oligomeric p-phenylene
ethynylenes (OPEs) for the selective detection of fibrillar aggregates of model proteins over
their monomeric counterparts 81, 82. The phenylene ethynylenes (PE) backbone of the OPEs has
a delocalized electronic structure, which gives rise to strong absorption and emission

178-180

.

Importantly, the rapid transport of the electronic excited state along the backbone contributes
to increased sensitivity, leading to signal amplification when interacting with analytes

178-180

.

Water soluble PE-compounds suitable for biological applications such as OPEs have shown
greater than 106-fold amplification sensitivity to quenching, that is, the probes are quenched in
water through partial proton transfer from an interfacial water molecule to the OPE terminal
oxygen causing rapid deactivation of the excited singlet state, and exhibit fluorescence “turnon” in response to release of interfacial water, changes in their conformation, and/or ligand
interactions

83, 178, 181, 182

. In addition to backbone planarization induced fluorescence

increase181, bathochromic shift, hydrophobic unquenching (e.g., from binding to a hydrophobic
site) and formation of super-luminescent OPE-complexes offer additional fluorescence “turnon” sensing mechanisms 81, 82, 87
OPEs have been shown to selectively bind to β-sheet enriched fibrillar aggregates made
of the model amyloid protein hen egg white lysozyme (HEWL)

81

. Upon binding, OPEs

exhibited fluorescence turn-on and red shifted spectra; complexation of the OPEs to form Jdimers was also observed 81, 82, 181. A library of 18 PE-based oligomers and polymers that vary
in size, charge, water solubility, and the types and geometries of functional groups, was
screened for their capability to selectively detect the amyloid conformation of two model
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proteins that are oppositely charged at physiological pH, bovine insulin and HEWL. We found
that characteristics contributing toward fibril-selective, but not protein-specific detection
included moderate size, negative charge, and high environmental sensitivity of the ethyl ester
termini to fluorescence quenching in water 82. One compound in particular, the anionic OPE1(Table 4-1), was found to show high binding selectivity toward both insulin and HEWL, and
the cationic OPE2+ (Table 4-1), although displayed stronger fluorescence enhancement in the
presence of HELW fibrils, did not detect insulin fibrils 82.
To evaluate the efficacy of the OPEs for detecting disease-relevant protein aggregates,
we evaluated in this study the capability of OPE1- and OPE2+ to selectively detect fibrillar
and pre-fibrillar aggregates of AD associated Aβ40 and Aβ42 peptides and four variants of PD
associated α-synuclein proteins over their monomeric counterparts. First, fibrillar and prefibrillar aggregates of the proteins were prepared and characterized. Next, selectivity and
specificity of OPE1- and OPE2+ to detect the aggregated conformation of the proteins were
quantified and compared to ThT.

4.3 Results and Discussion
In this study, we tested the sensing capability of two ethyl ester-terminated OPEs, the
negatively charged OPE1- characterized by one repeat unit and two side chains each terminated
with a sulfonate group and the positively charged OPE2+ with two repeat units and two side
chains each terminated with a quaternary amine group (Table 4-1). OPE sensing of Aβ40 and
Aβ42 fibrils associated with AD as well as protofibrils and fibrils made of four different αsynuclein proteins involved in PD was evaluated. Additionally, performance of the OPE
sensors was compared to the most commonly used amyloid dye ThT (Table 4-1).
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Table 4-1: Structures of thioflavin T, OPE1- and OPE2+

Formation and characterization of Aβ40 fibrils
Aβ40 fibrils are known to display high polymorphism at the molecular level where the
morphology and structure of the fibrils are highly sensitive to incubation conditions 183, 184. A
useful sensor needs to robustly detect the common fibrillar conformation even if their
structures differ at the molecular scale. In this study, we tested OPE1- and OPE2+ detection of
Aβ40 fibrils produced in two different conditions: Tris buffer at pH 8.0 (protein net charge: 4.4) 65, 185, and phosphate buffer (PB) at pH 7.4 (protein net charge: -2.9) 186. The morphology
and secondary structures of Aβ40 fibrils formed after 21 days of incubation at 37 ˚C and 100
µM were analyzed by TEM imaging and circular dichroism (CD) spectroscopy, respectively.
Kinetics of Aβ40 fibril formation was also monitored using the standard ThT fluorescence
assay.
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TEM images of unincubated Aβ40 samples (Figure 4-2 A and C) show very few
features; the dark spots are likely artifacts of the TEM grid or sample preparation. Sizeexclusion higher performance liquid chromatogram (SEC) of the unincubated sample shows a
single well-defined protein peak (see Figure S1 in Supplemental Information) corresponding
to a low molecular weight species. Thus, Aβ in the unincubated sample was soluble and likely
monomeric. TEM images of Aβ40 fibrils produced in pH 8.0 Tris (Figure 4-2 B) and in pH 7.4
PB (Figure 4-2 D) show twisted fibrils with similar widths (Tris: 11.5 ± 2.8 nm; PB: 13.3 ±
1.5 nm). However, the fibrils produced in Tris buffer appear to be longer (766 ± 250 nm) than
those produced in PB buffer (261 ± 150 nm). Fibril samples were also centrifuged to remove
insoluble aggregates and the supernatant was analyzed by SEC. Results show that 8% and 21%
of monomers were left after 21 days of incubation in Tris and PB, respectively, and no
oligomeric aggregates were present (Figure S1).

Figure 4-2: TEM images of unincubated Aβ40 (A and C) and after 21 days of incubation at
37 ˚C and 100 µM (B and D) in pH 8.0 Tris (A and B) or in pH 7.4 PB (C and D). Scale bars
represent 200 nm.
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The secondary structures of unincubated Aβ40 and fibrils were analyzed using CD
(Figure 4-3 and Figure S2 in Supplemental Information). CD spectra show a well-defined
peak at 200 nm for unincubated Aβ40, which is characteristic of random coils (Figure S2).
Fibrils produced in both Tris and PB showed structures rich in β-sheets as evidenced by the
presence of the peak at 218 nm (Figure 4-3).

Figure 4-3: Molar ellipticity of Aβ40 after 21 days of incubation in Tris pH 8.0 and PB pH
7.4 at 37 ˚C. The peak at 218 nm arises from β-sheet structures.

Fibril formation was additionally confirmed and tracked by the standard ThT
fluorescence assay 47, 187 (Figure 4-4). Aβ40 samples incubated at different times were mixed
with ThT at final concentrations of 5 µM Aβ and 20 µM ThT and the emission spectra of ThT
were recorded at an excitation wavelength of 440 nm. Integrated emission intensities were
normalized to that of mature fibrils (Figure 4-4). ThT fluorescence profiles of Aβ incubated in
the two buffers were remarkably similar and showed characteristic features of nucleationcontrolled aggregation kinetics, where a lag phase of about 7 days was followed by a rapid
fibril growth phase and finally a plateau phase during which most of the monomeric proteins
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had been converted to fibrils. Taken together, Aβ40 fibrils rich in β-sheets were successfully
prepared by incubating the peptide in two different solution conditions. The fibrils were
morphologically similar but appear to differ in lengths. Molecular-level structural differences,
for example, parallel vs. anti-parallel β-sheet architectures 188-190, may exist between the fibrils.
However, they were not characterized further using high-resolution methods in this study.

Figure 4-4: Fluorescence profiles of ThT (20 µM) and OPE (1 µM) mixed with Aβ40 (5 µM)
incubated in Tris pH 8.0 (A) or PB pH 7.4 (B) for different days. Integrated fluorescence
intensities were background subtracted and normalized to signal obtained from samples
incubated for 21 days. Errors bars are standard deviations from triplicate samples.
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Fluorescence of OPE binding to Aβ40 fibrils and monomers
To assess OPE binding to Aβ40 fibrils, fluorescence of each OPE mixed with Aβ samples
incubated for different times was measured (Figure 4-4) at a low concentration of 1 µM OPE.
As shown in Figure 4-4, normalized fluorescence intensities of the two OPEs yielded similar
profiles compared to those obtained from ThT, indicating that the OPEs selectively detected
Aβ40 fibrils as well as ThT at a higher concentration of 20 µM.
To further investigate the photophysical properties of OPE sensing, emission and
excitation spectra of ThT, OPE1- and OPE2+ in the presence of unincubated and fibrillar Aβ40
at 5 µM protein and 1 µM sensor were analyzed (Figure 4-5). The integrated emission
intensities were also calculated and statistically analyzed (Figure S4). Absorbance spectra
were additionally recorded and shown in Figure S3.
Both OPEs are highly quenched in buffers showing low fluorescence intensities (black
spectra in Figure 4-5). No significant fluorescence increases were observed in the presence of
Aβ40 monomers over the OPE background, except for OPE2+ with Aβ monomers (blue
spectra in Figure 4-5A3 and B3). These small increases in OPE2+ fluorescence could be due
to weak electrostatic interactions between the negatively charged peptide and the positively
charged OPE. In contrast, large fluorescence enhancements were observed when OPEs were
mixed with Aβ40 fibrils produced in both Tris and PB. Additionally, red shifts in the excitation
spectra were observed for OPE1- and OPE2+ (Table 4-2); blue shifts, albeit smaller, were also
observed in emission spectra (Table 4-2 and Figure 4-5). Bathochromic red shifts can arise
from OPE J-dimer formation driven by stacking interactions in the presence of two side chains
located on opposite sides of the central phenyl ring

191

, and/or planarization during complex

formation, and/or desolvation of the terminal ethyl ester groups

73

192

. This result is consistent

with the binding patterns of OPE1- and OPE2+ to HEWL and insulin fibrils previously
reported 81, 82. In contrast, ThT at 1 µM exhibited small increases in fluorescence intensity in
the presence of both fibrils (10 to 30-fold lower by comparison with OPEs fluorescence).

Figure 4-5: Excitation (dashed lines) and emission spectra (solid lines) of ThT (A1 and B1),
OPE1- (A2 and B2), or OPE2+ (A3 and B3) alone (black) in the presence of Aβ40 monomers
(blue) or Aβ40 fibrils (red) incubated in Tris pH 8.0 (A) and PB pH 7.4 (B). Fluorescence was
recorded in the presence of 5 µM protein and 1 µM sensor.

Table 4-2: Maximum excitation and emission wavelengths of 1 µM ThT, OPE1- or OPE2+
sensors in the presence of 5 µM Aβ40 monomers or fibrils
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Quantitative evaluation of sensor performance
Effective sensors of amyloid protein aggregates need to have high selectivity that detects the
aggregated conformations but not their non-aggregated conformers, high sensitivity, high
signal to background ratio, and high affinity. Sensors additionally need to be non-protein
specific, that is, selective for the aggregate conformations of a range of protein protomers.
Our results show that OPE1- and OPE2+ bind specifically and selectively to Aβ40
fibrils over Aβ40 monomers at a concentration significantly lower than that usually used for
ThT and induce 10 to 30-folds higher fluorescence intensity than ThT (Figure 4-5 A1 and B1).
To quantitatively assess sensor performance, selectivity of OPEs toward Aβ40 fibrils at a 5 to
1 protein to sensor molar ratio was analyzed. The amyloid detection factor (ADF) was
calculated using Equation 1

82

, where F(dye

in buffer),

F(dye+fibrils) and F(dye+monomers) are the

integrated emission intensities for sensor alone, sensor in the presence of fibrils, and sensor in
the presence of monomers, respectively.
𝑨𝑫𝑭 =

𝑭(𝒅𝒚𝒆+𝒇𝒊𝒃𝒓𝒊𝒍𝒔) − 𝑭(𝒅𝒚𝒆+𝒎𝒐𝒏𝒐𝒎𝒆𝒓𝒔)
𝑭(𝒅𝒚𝒆 𝒊𝒏 𝒃𝒖𝒇𝒇𝒆𝒓)

(1)

Positive ADF values indicate selective sensing of fibrils over monomers, while negative ADF
values indicate selective sensing of the monomers. ADF values close to zero indicate no
selective sensing, which for the ethyl ester terminated OPEs could be due to a lack of binding
to either the monomeric or the fibrillar conformation of the protein. As shown in Table 3, all
three sensors yielded positive ADF values for Aβ40 sensing, indicating that they are all
selective sensors of Aβ40 fibrils over Aβ40 monomers. ThT was the least selective with an
ADF value of 0.53  0.1 that is closest to 0. The cationic OPE2+ was the most selective with
the highest ADF values; an ADF value of 11  1 was obtained for longer fibrils prepared in
Tris buffer and an ADF value of 7.4  0.5 was obtained for shorter fibrils prepared in PB buffer
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(Table 4-3). Selectivity of OPE1- (ADF values of around 2.5) was intermediate between ThT
and OPE2+.

Table 4-3: Amyloid detection factor (ADF), limit of detection (LOD) and dissociation constant
(Kd) for ThT, OPE1- and OPE2+ sensing of Aβ40 fibrils produced in pH 8.0 Tris and in pH
7.4 PB.

Errors reported are standard errors.

Sensitivity is another important performance metric of sensors. For amyloid sensors,
sensitivity depends on binding affinity and the magnitude of induced fluorescence. To compare
sensitivity of the three compounds for detecting Aβ fibrils, their limits of detection (LOD) were
determined (Equation 2) 193, 194, which indicates the lowest protein concentration that can be
detected by each sensor with a high degree of certainty. Fluorescence of the sensors at various
protein concentrations were determined and the protein concentration corresponding to LOD
was calculated by using the slope of the signal vs. concentration correlation (Equation 2).
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝐿𝑂𝐷 =

3𝜎
𝑆

(2)

where σ is the standard deviation of the dye alone (blank) and S is the slope of the signal vs.
concentration correlation (Figure S5). As shown in Table 4-3, LOD values are in the submicromolar range for all three sensors. LOD values of ThT are consistent with previously
reported values 195. OPEs and ThT display similar LOD values for both Aβ40 fibrils and both
OPEs display lower LOD values compared to that of ThT.
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Finally, the affinity of ThT, OPE1- and OPE2+ binding to Aβ40 fibrils was evaluated
through the determination of the dissociation constant (kd) (Table 4-3). Binding curves were
obtained for the dyes in the presence of Aβ40 fibrils produced in Tris and PB buffers (Figure
S6). OPEs can bind as single molecules or as complexes, particularly to planar binding sites
on the fibril surface. Indeed, OPEs have been shown to form J-dimers upon binding to HEWL
fibrils

81

. As described previously, the ethyl ester terminated OPEs have multiple binding-

induced unquenching modes, including backbone planarization, hydrophobic unquenching,
and formation of super-luminescent OPE-complexes. Each mode contributes to fluorescence
enhancement, and backbone planarization and OPE-complexation additionally result in
spectral shifts. To account for potential OPE-complexation, binding curves were fitted with a
Hill coefficient (h) (Figure S6). Fitted parameters are summarized in Figure S6 and Table
4-3. Values of h for ThT are close to 1, indicating independent binding of ThT to fibrils. h
values for the OPEs were around 1.5, indicating moderate positive cooperativity binding,
which could be contributed by OPE-complexation. Importantly, kd values for OPE1- and
OPE2+ were in the sub-micromolar range (Table 4-3). These values were lower than that
obtained from ThT, indicating that the OPEs exhibit higher affinity toward Aβ fibrils.
Taken together, both OPEs display higher selectivity and affinity than ThT toward
Aβ40 fibrils when tested at 1 µM sensor concentration. While sensing parameters of ThT were
similar between the fibrils produced in the two different buffer conditions, some variabilities
in OPE sensing parameters were seen. OPE2+ exhibited higher selectivity for the longer fibrils
prepared in Tris than the shorter fibrils prepared in PB. OPE1- exhibited higher binding affinity
toward the shorter fibrils than the longer fibrils. To resolve the cause of these differences,
additional investigations of OPE-fibril binding and fibril structures are needed.
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OPE Sensing of Aβ42 oligomers and fibrils
In addition to high selectively, sensitivity and affinity, useful amyloid sensors also need to be
non-protein specific, that is, capable of sensing the common amyloid conformation of a range
of proteins involved in neurodegenerative diseases. To this end, we evaluated the capability of
OPE1- and OPE2+ to detect aggregates of two additional amyloid proteins: amyloid-β (1-42)
(Aβ42) and α-synuclein. Aβ42 is the more amyloidogenic form of Aβ 196 and α-synuclein forms
the Lewy bodies found in the brains of PD patients 18. The deposition of Aβ40 and Aβ42 in the
brain as amyloid plaques is a pathological hallmark of AD 197. Because the deposition of Aβ42
starts prior to Aβ40, these fibrils constitute a suitable target for testing OPEs sensing 197-200.
Aβ42 fibrils were produced by incubating 45 µM peptide in pH 7.4 20 mM PB at room
temperature for 72 h. Unincubated and incubated samples were imaged using TEM (Figure
4-6). In contrast to unincubated Aβ40 samples where very few features were seen (Figure 4-2
A and C), unincubated Aβ42 samples showed a large number of globular features of about
10.6 ± 1.9 nm in diameter (Figure 4-6 A). These are likely oligomeric aggregates from either
the incomplete solubilization of the peptide or aggregates that were already formed due to the
peptide’s high aggregation propensity 201, 202. Incubated samples showed an abundance of long
fibrils with characteristic twists (Figure 4-6 B). To further characterize the unincubated Aβ42
sample, the sample was centrifuged and the supernatant was analyzed by SEC (Figure S7) and
dynamic light scattering (DLS). SEC chromatograms of unincubated Aβ42 show the presence
of a large peak at 21 minutes that likely corresponds to monomeric Aβ42. However, this peak
is broad and with shoulders at 17 and 20 minutes, indicating the presence of larger size species.
Additionally, the hydrodynamic radius (Rh) of the unincubated Aβ42 sample measured by DLS
was around 30 nm. Taken together, both results revealed the presence of soluble and
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heterogeneous higher molecular weight species in the unincubated Aβ42 sample, or soluble
oligomers. With incubation, the oligomer population first became enriched (blue
chromatograph of 2.4 h incubated sample in Figure S7) before they are depleted with fibril
formation, where only one smaller monomer peak was observed after 72 h incubation (red
chromatograph in Figure S7). The Rh value of the 72 h incubated sample, after centrifugation
to remove insoluble aggregates, was around 3 nm, corroborating the loss of soluble oligomers
with the formation of Aβ42 fibrils. Our results thus indicate that there were abundant
oligomeric, pre-fibrillar aggregates present in the unincubated Aβ42 sample and that after
incubation most of the soluble Aβ42 formed fibrils.

Figure 4-6: TEM images of unincubated (A) and incubated (B) Aβ42. Scale bars represent
200 nm.

Fluorescence spectra of ThT, OPE1- and OPE2+ were measured in the presence of
unincubated (oligomeric) and incubated (fibrillar) Aβ42 at 5 µM peptide with either 1 µM OPE
or 20 µM ThT (Figure 4-7). As shown in Figure 4-7, ThT and OPE1- exhibited small
fluorescence increases with oligomeric Aβ42 and displayed large fluorescence increases in the
presence of fibrils. Strikingly, OPE2+ showed large fluorescence enhancements with both prefibrillar and fibrillar aggregates of Aβ42. Thus, all three sensors effectively detected the
fibrillar conformation of Aβ42. The cationic and larger OPE2+ additionally detected Aβ42
oligomers, making it potentially a more useful sensor for disease detection. The emission peak
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of OPE2+ in the presence of Aβ42 oligomers is slightly red-shifted from that measured for the
sensor alone (462 nm to 469 nm), and is blue shifted from its emission peak in the presence of
Aβ42 fibrils (462 nm to 445 nm) (Table 4-4). These different spectral features indicate
different modes of binding-induced fluorescence turn-on, which could be due to differences in
binding sites (hydrophobic grooves vs. planar binding sites for example) that promote different
photophysical changes in the bound OPE or OPE complexes. More detailed studies on dyeprotein interactions will be needed to resolve the different dye binding modes. Although the
spectral difference of OPE2+ binding to oligomers vs. fibrils demonstrated here is not large (~
25 nm), it does demonstrate the potential of OPEs to detect and distinguish between different
conformational states of Aβ42 aggregates.

Figure 4-7: Excitation (dashed lines) and emission spectra (solid lines) of ThT (A1), OPE1(A2) and OPE2+ (A3) alone (black), in the presence of Aβ42 monomers (blue) and Aβ42 fibrils
(red). Fluorescence was recorded in the presence of 5 µM protein and 1 µM OPEs or 5 µM
protein and 20 µM ThT.

Table 4-4: Maximum excitation and emission wavelengths of ThT, OPE1- and OPE2+ sensors
in the presence of Aβ42 unincubated and fibrils
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OPE sensing α-synuclein aggregates
The main pathological hallmark of Parkinson’s disease is Lewy bodies composed of αsynuclein fibrils 203, 204. However, oligomeric α-synuclein aggregates have been found to play
a central role in Parkinson’s disease neurodegeneration including disrupting mitochondrial
function, autophagy and lysosomal degradation, membrane homeostasis, endoplasmic
reticulum function and synapses, and can induce inflammation

17-20

. Furthermore, oligomers

can also propagate between neurons leading to cell-to-cell spreading of α-synuclein pathology
17-19

. In this study, the wild type (WT), as well as three single mutants, A30P and A53T

involved in early onset of Parkinson’s disease
oligomers

19, 204

203, 204

, and E35K designed to produce small

, were used to test OPE sensing. A30P has been shown to aggregate slower

than WT 205, while A53T has been reported to exhibit faster fibrillization 206. To evaluate the
efficacy of OPE sensing of early aggregates and mature fibrils, we evaluated the binding
selectivity of both OPEs toward pre-fibrillar and fibrillar α-synuclein aggregates over
monomers and compare them to ThT.
As shown by TEM images in Figure 4-8, except A53T, all other α-synuclein proteins
appeared monomeric at day 0. After 6 days of incubation, pre-fibrillar aggregates (> 30 nm of
diameter) were present, and after 16 days of incubation, mature fibrils were observed. In the
case of the fast aggregating A53T, at day 0, the protein was already in an elongated aggregate,
and after 6 days of incubation, fibrils were present. Emission and excitation spectra were
recorded for ThT, OPE1- and OPE2+ in the presence of the four α-synuclein proteins at days
0, 6 and 16 (Figure 4-9) at 1 µM sensor and 5 µM protein concentrations. The ADF values of
the three sensors were calculated (Table 4-5) and dyes that exhibited positive sensing (ADF >
1) are indicated in yellow on the TEM images.
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In the presence of unincubated (day 0) WT, A30P and E35K proteins, fluorescence
spectra close to background were obtained for all three sensors, indicating no sensing of
monomers. In the presence of fibrils made from all four proteins (day 16), all three sensors
displayed fluorescence enhancements. Similar to the sensing of Aβ40 and Aβ42 fibrils, OPEs
exhibited larger fluorescence enhancements compared to ThT (2 to 20-fold higher for OPE1-,
6 to 100-fold higher for OPE2+). Although fluorescence enhancements were observed from
ThT, ADF values lower than 1 were obtained in the presence of WT and E35K fibrils which
indicates poor fibril selectivity, while both OPEs showed higher fibril selectivity of all αsynuclein proteins tested (ADF value > 1). Thus, compared to ThT, OPEs are superior sensors
for α-synuclein fibrils and exhibit higher selectively, higher fluorescence signal, and are more
robust, that is, capable of sensing fibrils of all α-synuclein proteins tested.
Importantly, the capability of the three sensors to detect pre-fibrillar α-synuclein
aggregates was tested. ThT was only able to detect A53T aggregates after 6 days of incubation
(ADF > 1), while both OPEs detected pre-fibrillar aggregates of WT, E35K and A53T (Figure
4-9 and Table 4-5). No significant fluorescence enhancement was observed for the 6-day
incubated A30P sample where some oligomers were observed by TEM (Figure 4-8 E). This
could be due to the lower abundance of oligomers as A30P exhibits a slower aggregation rate
(Figure S8). Finally, despite the high OPE fluorescence enhancements observed in the
presence of both pre-fibrillar and fibrillar conformations of α-synuclein, no significant
differences in the features of OPE spectra (for example, shifts in excitation or emission peaks)
were seen between sensors bound to oligomers and fibrils. Thus, although OPEs can selectively
detect both pre-fibrillar and fibrillar aggregates of α-synuclein, these sensors cannot distinguish
between the different aggregate conformations.
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Figure 4-8: TEM images of unincubated (A, D, G, J), 6-day (B, E, H and K) and 16-day
incubated (D, F, I, L) α-synuclein. Four different isoforms of α-synuclein were images: wild
type (A, B, C), A30P (D, E, F), E35K (G, H, I) and A53T (J, K, L). The name of the sensor
capable to detect the different forms of α-synuclein appears in each TEM image in yellow
(ADF > 1). The asterisk indicates that A53T at day 0 was not completely monomeric. Scale
bar represents 200 nm.
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Figure 4-9: Excitation (dashed lines) and emission spectra (solid lines) of ThT (A1, B1, C1
and D1), OPE1- (A2, B2, C2 and D2) and OPE2+ (A3, B3, C3 and D3) alone (black), in the
presence of α-synuclein at day 0 (blue lines), day 6 (red) and day 16 (green) of incubation.
Four isoforms of α-synuclein were evaluated: WT (A), A30P (B), E35K (C) and A53T (D).
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Table 4-5: Amyloid detector factor (ADF) of ThT, OPE1- and OPE2+ in the presence of αsynuclein aggregates produced at day 6, and fibrils produced at day 16 of incubation.

The ADF was measured for a molar ratio 1µM sensor to 5µM protein. Errors reported are
standard errors.
* The ADF measured for A53T was calculated by using day 0 as monomeric protein whereas
it is actually an oligomer-like species.

4.4 Conclusions
In this study, we investigated two novel PE-based sensors, OPE1- and OPE2+, for the selective
detection of amyloid protein aggregates over monomers and compared their performance to
the widely used ThT dye. Pre-fibrillar and fibrillar aggregates of six AD and PD associated
amyloid proteins were tested, Aβ40, Aβ42, wildtype α-synuclein, and 3 α-synuclein mutants.
Compared to ThT, OPE1- and OPE2+ are more selective sensors for Aβ40, Aβ42 and αsynuclein fibrils. OPEs displayed sub-µM binding constant and protein concentration limits of
detection of Aβ40 fibrils, both of which are lower than those determined for ThT. OPE2+
exhibited the highest sensitivity and significantly detected pre-fibrillar Aβ42 and α-synuclein
aggregates that ThT did not detect. OPE1- also selectively detected α-synuclein pre-fibrillar
aggregates. ThT is known to detect fibrillar aggregates by intercalating into the β-strands in
the β-sheets. 43, 44 Due to the multiple binding-induced unquenching modes of OPEs, including
backbone planarization, hydrophobic unquenching, and formation of super-luminescent OPEcomplexes, our results show that OPEs bound to and detected a wider range of aggregate
conformations compared to ThT. Although the exact nature of the binding mechanisms are
unclear, planar features on fibril surface can serve as sites for OPE binding, which can lead to
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backbone planarization induced fluorescence enhancement. Binding to pre-fibrillar aggregates,
particularly those with increased surface hydrophobicity, could be mediated by hydrophobic
interactions which result in hydrophobic unquenching. The superior sensing capability of
OPEs demonstrated in this study point to the potential of these new sensors to overcome the
two major limitations of current probes, the inability to detect a wide range of amyloid
aggregate conformations, including the more disease relevant oligomeric, pre-fibrillar
aggregates, and the inability to simultaneously detect aggregates of different proteins.
Overcoming these limitations promises significant advancement in the detection of the myriad
of protein aggregates involved in the early stages of AD and PD.

4.5 Experimental Methods
Materials
Synthetic amyloid β-40 (Aβ40) purified by reverse phase HPLC (purity > 95 %) was purchased
from Peptide 2.0 (Chantilly, VA). The recombinant amyloid β-42 (Aβ42) and α-synuclein
proteins were produced and purified as previously described 20, 207. The plasmids coding for αsynuclein wild type (WT) and three mutants (A30P, E35K and A53T) were generously
provided by Dr. Roland Riek (ETH Zurich) and the plasmid coding for Aβ42 was provided by
Dr. Park (Chosun University, South Korea). Phosphate buffer (PB) was prepared with sodium
phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous purchased from
Thermo Fisher Scientific (Waltham, MA). Tris was purchased from BioRad (Hercules, CA).
Sodium chloride (NaCl), ammonium hydroxide (NH40H) and dimethyl sulfoxide (DMSO)
were acquired from EMD Millipore (Burlington, MA). 1,1,1,3,3,3 Hexafluoro-2-propanol
(HFIP) was purchased from Sigma-Aldrich (St. Louis, MO). Copper grids, 400 mesh, covered
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by a Formvar film and 5-10 mm carbon layer were purchased from Ted Pella (Redding, CA).
2% aqueous uranyl acetate was purchased from Electron Microscopy Sciences (Hatfield, PA).
Thioflavin T (ThT) (MW: 318.85 g/mol, extinction coefficient at 412 nm (ɛ412nm) in water:
3.6 x 104 M−1cm−1) 43 was acquired from ACROS Organics (Belgium). OPEs were synthesized
and purified by previously published procedures

181

(OPE1-: 724.79 g/mol and ɛ370 nm in

water (3.92 ± 0.013) x 104 M−1.cm−1; OPE2+: 1002.64 g/mol and ɛ378nm in water (8.29 ±
0.033) x 104 M−1.cm−1).
Aβ40 aggregation
Synthetic Aβ40 (4,329 g/mol, ɛ280nm = 1,490 M-1cm-1, pI = 5.5) 208 was solubilized in DMSO
at 50 mg/mL. The peptide was sonicated in a bath sonicator for 1 min and was centrifuged at
14,000 g for 15 min. The supernatant was collected and the peptide concentration was
determined by measuring the absorbance at 280 nm with a Nanodrop (Thermo Fisher
Scientific, Waltham, MA). Aβ40 was then stored in -70˚C until use. Two incubations were set
up. First the protein was diluted in 40 mM Tris pH 8.0 buffer containing 150 mM NaCl and
0.01 % w/v sodium azide

65

. Second, the protein was diluted in 50 mM PB pH 7.4 buffer

containing 100 mM NaCl and 0.01 % w/v sodium azide

186

. For both incubations, the final

protein concentration was 100 µM and the protein was incubated at 37 ˚C for 21 days under
quiescent condition. Every 2 to 3 days a sample was collected for characterization.
Aβ42 aggregation
Purified and lyophilized Aβ42 was solubilized in 100 % HFIP at 1 mg/mL and was sonicated
for 30 s. Then, the protein was dried under vacuum overnight and stored at -70 ˚C for up to 1
month. Aβ42 was solubilized in 0.1 % NH4OH at 1 mg/mL (222 µM) and was then diluted to
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45 µM in pH 7.4 20 mM PB. Protein was incubated at room temperature for three days under
quiescent condition.
α-synuclein aggregation
Four isoforms of α-synuclein proteins were used: wild type (WT) and 3 single point mutants
(A30P, E35K and A53T). The lyophilized α-synuclein protein was first solubilized to 300 µM
in pH 7.4 10 mM PB, 300 mM NaCl and then incubated at 37 ˚C on a vertical rotor at 50 rpm
for 16 days 209.
Fluorescence and absorbance measurements
ThT and OPEs fluorescence spectra in the presence of Aβ40 was measured with the PTI
QuantaMaster 40 steady state spectrofluorometer (HORIBA Scientific, Edison, NJ). ThT was
mixed with Aβ40 at a 4 to 1 molar ratio (20 µM ThT to 5 µM protein) or 1 to 5 molar ratio (1
µM ThT to 5 µM protein) in 10 mM PB. OPE1- and OPE2+ were mixed with the protein at a
1 to 5 molar ratio (1 µM OPEs to 5 µM protein) in 10 mM PB. After 30 minutes of incubation
at room temperature in the dark, samples were transferred to a quartz cuvette (Starna cells Inc.,
Atascadero, CA) and the emission and excitation spectra were recorded. The emission spectra
were obtained at excitation wavelengths 440, 390, and 414 nm, for ThT, OPE1- and OPE2+,
respectively. The excitation spectra were recorded at emission wavelengths of 480, 450, and
470 nm for ThT, OPE1- and OPE2+, respectively. Experiments were performed in triplicates.
Absorbance spectra were measured in a quartz cuvette (PerkinElmer, Waltham, MA) on a
Lambda 35 UV/VIS spectrometer (PerkinElmer, Waltham, MA) at a molar ratio of 1 to 5 (1
µM sensor to 5 µM protein) between 250 nm – 700 nm.
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TEM imaging
Aliquots of protein solutions were first diluted in Milli Q water to 5 μM and 4 μL of the diluted
solution was added to a glow discharged (Harrick Plasma Cleaner, Carson City, NV) copper
grid. The protein was allowed to adsorb for 5 min. After wicking away the excess solution with
a blotting paper, the grid was negatively stained four times, each time using 4 μL of 2 %
aqueous uranyl acetate for 1 min. Between each staining step, the excess of uranyl acetate was
wicked away with a blotting paper. Finally, the grid was air dried for 30 min before imaging.
TEM images were taken with the HITACHI HT7700 transmission electron microscope
(Hitachi High Technologies Corp., Tokyo, Japan). The beam current and the accelerating
voltage were 8.0 µA and 80 keV, respectively. Images were analyzed by using ImageJ 210. The
fibril widths and lengths were estimated from 5 different images.
Circular dichroism spectroscopy
The secondary structures of unincubated Aβ40 monomers and fibrils produced after 21 days
of incubation were analyzed by circular dichroism spectroscopy (CD). The protein solution
was first desalted by transferring 250 µL of Aβ at 100 µM into an Amicon Centrifugal Filter
(Millipore Sigma, Burlington, MA) with 3 KDa cutoff. 4 mL of 10 mM PB was added and the
protein was centrifuged at 3,500 rpm for 10 min. This washing step was done twice and the
final protein-containing retentate was brought back to 250 µL. The protein concentration was
checked by Bradford assay (Sigma-Aldrich, St. Louis, MO) and the protein was diluted to 25
µM (108 µg/mL) in 10 mM PB and analyzed on AVIV 410 CD Spectrometer (AVIV,
Lakewood, NJ) in a quartz spectrophotometer cell with a path length of 1 mm (Starna cells Inc,
Atascadero, CA). CD spectra were collected between 190 - 300 nm with an average reading
time of 15 s. Data were then converted into molar ellipticity [θ] 119.
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Binding constants
The binding constants of ThT, OPE1- and OPE2+ to fibrillar Aβ40 was obtained from a
constant protein concentration binding assay 211. Triplet samples of 5 µM protein and varying
concentrations of sensor (0 to 30 µM for ThT, or 0 to 2 µM for OPE1- and OPE2+) were
prepared and emission spectra were obtained for each sample. Background (sensors alone)
subtracted integrated intensities were calculated and plotted against sensor concentration for
each sensor and the binding constants were fitted using a nonlinear regression curve assuming
site specific binding and using a Hill coefficient to account for any binding cooperativity.
Size exclusion high performance liquid chromatography (SEC)
The unincubated and incubated Aβ40 and Aβ42 samples were analyzed by SEC to separate
and quantify the amounts of soluble oligomers and monomers present in the samples. Before
injecting the sample on the HPLC column, 70 µL of 100 µM (Aβ40) or 45 µM (Aβ42) was
centrifuged for 15 min at 14,000 rpm. Supernatant (65 µL) was injected on a BioSec-SECs3000 (Phenomenex, Torrance, CA) column that was already equilibrated with 10 mM
phosphate buffer saline (PBS) at pH 7.4 at 0.5 mL/min on Agilent 1100 series system (Agilent
Technology, Santa Clara, CA). Absorbance at 215 nm was monitored. Background signal was
subtracted using Agilent ChemStation software and percentage of soluble protein was
calculated relative to the proteins present in the unincubated samples.
Dynamic light scattering (DLS)
The hydrodynamic radii (RH) of Aβ42 samples were determined by DLS. Samples at 45 µM
were centrifuged (15 min at 14,000 rpm) to remove large particles and dust. Supernatant was
loaded into a quartz microcuvette and analyzed with a DAWN HELEOS II light scattering
detector (Wyatt Technology Corporation, Santa Barbara, CA). Scattering intensity was
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collected at 90 ˚ of the incident beam and recorded for 10 min. Data were analyzed using the
cumulant analysis method using the ASTRA 5.3.4.20 software to yield RH values 212.
Statistical analysis
Statistical analysis was carried out using JMP Pro 13 (Cary, NC). The integrated intensities of
the emission spectra obtained from the sensor alone, the sensor in the presence of monomers
or fibrils were compared by using a two-tailed t-test with a p-value ≤ 0.05.
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4.8 Supplementary Information

Figure S1: Size exclusion chromatograms of Aβ40 monomers (unincubated) and fibrils
(incubated for 21 days) in Tris buffer (A) or PB buffer (B). 65 µL at 100 µM samples were
centrifuged and analyzed by HPLC SEC.

92

Figure S2: Circular dichroism spectra of unincubated Aβ40 in two different solutions.
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Figure S3: Absorbance spectra of ThT (A1 and B1), OPE1- (A2 and B2) and OPE2+ (A3 and
B3) in the presence of monomeric (blue) and fibrillar (red) Aβ40 incubated in pH 8.0 Tris (A)
or pH 7.4 PB (B), compared to sensor alone (black). The sensor concentration was 1 µM and
the protein concentration was 5 µM.
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Figure S4: Integrated intensity of ThT, OPE1-or OPE2+ (1 µM) in the presence of monomeric
and fibrillar Aβ40 (5 µM) incubated in pH 8.0 Tris (A) and pH 7.4 PB (B). A t-test was run to
evaluate the significance of the difference between sensor alone, un-incubated (Day 0) and 21day incubated (Day 21) Aβ40. The asterisks indicate a significance difference between two
conditions compared with a p-value ≤ 0.05.

Figure S5: Linear correlations between fluorescence integrated area of ThT (A), OPE1- (B)
and OPE2+ (C) (1 µM) versus Aβ40 concentration. Data were fitted to a linear fit on OriginPro
with R2 ≥ 0.95. The intercept and slopes values are summarized in the table below.
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Figure S6: Binding assay profiles of ThT (A1 and B1), OPE1- (A2 and B2) and OPE2+ (A3
and B3) to Aβ40 fibrils produced in pH 8.0 Tris (A) or pH 7.0 PB (B). These saturation binding
assay curves were obtained by fitting the data to a nonlinear regression assuming site specific
binding with binding cooperativity on OriginPro 9. Experiments were performed in duplicates
and error bars represent standard deviations. The maximum specific binding (Bmax), the Hill
coefficient (h), the dissociation constant (Kd) and the R2 values are summarized in the table
above. OPE has been shown to form complexes at concentration higher than 10 µM which
leads to fluorescence red-shift and peak sharpening. To isolate OPE/fibrils binding from OPE
complexation the binding assay was done at OPE concentration lower than 2 µM.
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Figure S7: Size exclusion chromatograms of Aβ42 unincubated, 2.4 hr incubated and 24 hr
incubated at room temperature. 65 µL of 45 µM samples were centrifuged (15 min at 14,000
rpm) to remove insoluble species and the supernatant was injected into the size exclusion
column (BioSep-SEC-S3000 from Phenomenex).

Figure S8: TEM images of α-synuclein WT (A) and A30P (B) after 6 days of incubation.
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5.1 Abstract
Amyloid aggregates are believed to play a key role in the development of neurodegenerative
disorders. Currently, amyloid aggregation is mainly investigated by using fluorescent amyloid
probes such as Thioflavin T (ThT). These probes lack sensitivity for the detection of early
aggregates (oligomers and protofibrils) causing a poor characterization of the early event of
protein aggregation. Oligomeric p-phenylene ethynylenes (OPE) are a class of fluorescent
probe previously described to detect selectively both fibrillar and pre-fibrillar conformations
of amyloid proteins over their monomeric counterpart. The detection of early pre-fibrillar
aggregates makes OPE highly promising to shine light on amyloid aggregation kinetic and
pathways. In this study, we further characterized the negatively charged OPE12- as an amyloid
probe. We found that OPE optimal concentration for amyloid aggregates sensing was below 8
µM at which OPE12- background fluorescence was minimal. At concentration higher than 10
µM, OPE12- formed super-luminescent complexes which might interfere with its sensing
properties. We also evaluated the effect of OPE12- on Aβ fibrillation during co-incubation at
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molar ratio OPE to protein 1:2, 1:5 and 1:10. During co-incubation OPE12- did not alter neither
the fibrillation kinetic nor the aggregates morphology, hydrophobicity or neurotoxicity. These
results indicate that OPE12- could be used in a co-incubation system to track protein
aggregation through real-time fluorescence imaging which could lead to a better understanding
of amyloid aggregation kinetic essential for the development of novel therapeutic strategy.

Keywords: neurodegenerative diseases, protein aggregate detection, fluorescent optical
probes, oligomeric p-phenylene ethynylenes, amyloid aggregation, neurotoxicity

5.2 Introduction
Abnormal protein misfolding and aggregation into β-sheet rich aggregates or amyloids, is a
common pathological hallmark of neurodegenerative disorders (ND) such as Alzheimer’s
(AD) and Parkinson’s (PD) diseases61, 213. A large array of proteins have been found to form
amyloid aggregates in ND including amyloid-β (Aβ), tau and α-synuclein proteins.213 Amyloid
aggregates are believed to be produced through a nucleation-dependent fibrillation mechanism
where the misfolded protein forms small oligomers and protofibrils which act as seed for the
growth of long fibrillar aggregates rich in β-sheet6-8, 10, 11. This aggregation mechanism is
complex and is still poorly understood.
The current understanding of amyloid aggregation is mainly based on the use of
amyloid probes such as Thioflavin T (ThT). This histological probe detects amyloid aggregates
through hydrophobic interaction which results into fluorescence turn-on and spectral shift47.
Recently ThT’s fluorescent turn-on property was also used to image protein fibrillation in realtime through fluorescence-based microscopy methods such as internal reflection fluorescence
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microscopy (TIRFM), 214 or polarized super-resolution structural imaging215, 216. By using ThT
in real-time imaging, amyloid fibrillation rate was extracted and the heterogeneity of the
amyloid structures was revealed214. Despite the efficiency of ThT as an amyloid protein,217
ThT lacks of sensitivity for the detection of early aggregates (oligomers and protofibrils)218, 219
which limits its use to monitor early aggregation events essential to shine light on the
aggregation dynamic.
Oligomeric p-phenylene ethynylenes (OPEs) are novel fluorescence sensors previously
described to selectively detect fibrillar and pre-fibrillar aggregates made of two diseaserelevant proteins, Aβ and α-synuclein proteins220. The negatively charged OPE12- characterized
by one repeat unit and two side chains both terminated with a sulfonate group (Figure 5-1),
was characterized by higher selectivity and affinity for the detection of Aβ fibrils than ThT.
Also, OPE12- was shown to interact with pre-fibrillar aggregates that ThT failed to detect220.
This selective sensing is based on OPE12- interaction with the hydrophobic β-sheet structure of
amyloid aggregates causing OPE’s backbone planarization, hydrophobic unquenching and
formation of super-luminescent complexes81, 82, 84. OPE’s high fluorescence enhancement and
its capability to detect early aggregates makes it highly promising to better understand amyloid
aggregation kinetic through real-time imaging.
In this study, we propose to further characterize OPE12- as an amyloid sensor. This
characterization consisted in first evaluating OPE12- background fluorescence to determine
optimal OPE12- concentration for amyloid sensing. Secondly, the effect of OPE on amyloid
aggregation when co-incubated with Aβ40 was analyzed. Finally, the effect of co-incubation
on fibrils morphology, hydrophobicity and toxicity were investigated. Thanks to this study, we

100

gained a better understanding of OPE as an amyloid sensor which opens the door to their use
in real-time fluorescence microscopy for amyloid aggregation monitoring.

Figure 5-1: OPE12- structure

5.3 Results and Discussion
OPE was previously described to detect selectively fibrillar and pre-fibrillar aggregates made
of Aβ40 and α-synuclein proteins over the monomeric counterpart through fluorescence turnon220. This selective binding makes OPE promising to track amyloid aggregation. This study
consisted in further characterizing the negatively charged OPE12- as an amyloid probe.

OPE12- forms super-luminescent aggregates above 10 µM
The efficacy of a fluorescence-based amyloid probe such as OPE12- depends on its low
background fluorescence when free in solution. To determine the optimal OPE concentration
for amyloid sensing, we investigated its background fluorescence in phosphate buffer (PB)
between 0 to 15 µM (Figure 5-2).
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Figure 5-2: OPE12- background fluorescence in phosphate buffer. OPE12- emission spectra
between 0 to 15 µM (A) was recorded. (B) and (C) are zoom-in of the emission spectra
obtained at concentration between 0 and 10 µM (B) or between 0 and 1 µM (C). (D) Integrated
emission areas were plotted in function of OPE concentration.

At concentration below 0.2 µM (Figure 5-2C), OPE12- background fluorescence was
similar to phosphate buffer (PB) fluorescence indicating that OPE12- was fully quenched by
water molecules. This efficient quenching is ensured by a rapid deactivation of OPE12- excited
singlet state through proton transfer with the surrounding water molecules83, 84, 221. At 0.5 µM
OPE12- background emission intensity increased by 1 fold and gave rise to a broad emission
peak centered at around 470 nm (Figure 5-2 C) which indicates the formation of disordered
micelle-like structure likely made of H-type aggregates192. The intensity of this emission peak
linearly increased and red shifted (~ 495 nm) with increase in OPE concentration up to 10 µM
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(Figure 5-2D). At 10 µM a new shoulder appeared on the emission spectrum at around 445
nm and became sharper at 15 µM where the fluorescence intensity increased by more than 100fold compared to PB background (Figure 5-2A and B). This large fluorescence enhancement
accompanied by an emission blue shift and peak sharpening indicate the formation of OPE 12super-luminescent complexes mainly made of J-aggregates.85
The formation of super luminescent complexes at concentration above 10 µM might
interfere with OPE12- sensing properties. These data allowed us to set up an optimal OPE12concentration range for amyloid sensing between 0.1 – 8 µM, which supports previous studies
where OPE12- was commonly used at 1 µM81, 82, 220.

OPE12- does not alter Aβ40 fibrillation kinetic and aggregates morphology
Amyloid aggregation is commonly monitored by using amyloid fluorescent probe in a coincubation system where both the probe (ThT or Congo Red) and amyloid protein are
incubated together during aggregation222, 223. The risk of co-incubation is that the probe can
interfere with the aggregation. In this study, we are evaluating the effect of OPE12- on
fibrillation kinetic in a co-incubation system. We compared Aβ40 aggregation in the absence
and presence of OPE12- at three different molar ratio Aβ to OPE12-: 2 to 1, 5 to 1, and 10 to 1
(Table 5-1). Fibrillation of Aβ40 incubated alone was monitored by using the well-known
amyloid probe ThT at 20 µM in the presence of 5 µM Aβ as well as with 1 µM OPE in the
presence of 2, 5 or 10 µM Aβ. For the co-incubated conditions, Aβ aggregation was only
monitored through OPE fluorescence after diluting the sample to reach 1 µM OPE which led
to Aβ concentration of 2, 5 or 10 µM depending on the co-incubation condition. The integrated
emission areas of ThT and OPE were calculated after background subtracted and are reported
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Figure 5-3A1 and B1. Integrated emission areas were also normalized with the average value
measured during the last two days of incubation as the aggregation kinetic reached plateau at
this stage (Figure 5-3A2 and B2). The large standard deviations of the fluorescence data
prevented any fitting to extract the aggregation growth parameters such as lag phase or growth
rate.

Table 5-1: Aβ and OPE12- concentrations used for the four tested conditions
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Figure 5-3: A: Integrated fluorescence intensity profiles (A1) and normalized fluorescence
profiles (A2) of ThT or OPE12- in the presence of Aβ40 (80 µM) incubated in 50 mM PB pH
7.4 buffer containing 100 mM NaCl at different time points. Fluorescence was recorded at 20
µM ThT and 5 µM Aβ or 1 µM OPE12- and varying concentration of Aβ40 (2, 5 or 10 µM). B:
Integrated fluorescence intensity profiles (B1) and normalized fluorescence profiles (B2) of
Aβ (80 µM) incubated alone (black solid line) or co-incubated with varying concentration of
OPE12- (40, 16 and 8 µM) in 50 mM PB and 100 mM NaCl at 37 ˚C at different time points.
Fluorescence of Aβ incubated alone was collected in the presence of 20 µM ThT and 5 µM Aβ
(black solid line). Fluorescence of co-incubated samples diluted to 1 µM OPE12- was also
collected at varying Aβ concentration (dashed lines).

To compare ThT and OPE12- sensing properties, the aggregation of Aβ40 incubated
alone was monitored by using both sensors (Figure 5-3A1 and A2). ThT fluorescence was
recorded at 20 µM which is commonly used for this probe to ensure maximal fluorescence
enhancement,217 while OPE12- was used at 1µM. The aggregation profile generated with ThT
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showed an exponential aggregation without a lag phase which reached plateau after around 6
days (Figure 5-3A2). When OPE was used at 1 µM to track the aggregation of the same
protein, a similar aggregation profile was observed. OPE was previously described to detect
early aggregates that ThT failed to detect (α-synuclein oligomers and Aβ42 oligomers)220.
Similar aggregation profiles obtained by both ThT and OPE might indicate a low percentage
of oligomers that OPE was not able to detect. Additionally, as shown Figure 5-3A1, ThT
emission intensity recorded in the presence of 20 µM ThT and 5 µM protein (black line) was
two-fold lower than OPE fluorescence recorded in the presence of the same protein
concentration but with 20-fold less OPE concentration (1 µM OPE 5 µM Aβ - red line). OPE
stronger fluorescence signal makes this probe superior than ThT to track amyloid fibrillation.
The effect of OPE12- on Aβ40 aggregation was then investigated by monitoring OPE12fluorescence in co-incubated samples and by comparing this kinetic to the one obtained from
Aβ incubated alone through ThT fluorescence (Figure 5-3B1 and B2). As previously
observed, OPE fluorescence intensity was higher than ThT (Figure 5-3B1). Despite this
difference in emission intensity, fluorescence profiles obtained from all three co-incubated
conditions (2:1, 5:1 and 10:1 molar concentration Aβ to OPE12-) showed a similar aggregation
kinetic compared to Aβ incubated alone characterized by a rapid exponential growth of fibrils
that reached plateau at around day 6 (Figure 5-3B2). These data indicate that OPE12- did not
alter Aβ fibrillation. To further characterize the effect of OPE on aggregation kinetic, more
particularly on the formation of oligomers, Aβ40 should be analyzed during aggregation by
size exclusion (SE) HPLC or by western-blot using the appropriate antibodies (anti-Aβ 6E10,
anti-amyloid fibrils OC and anti-amyloid oligomers A11)65, 70.
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To further evaluate the effect of OPE12- on Aβ aggregates morphology, TEM images
were taken during the incubation. As shown Figure 5-4, when Aβ40 was incubated alone,
small oligomers were produced after 2 days of incubation. At day 5 and 9 longer protofibrils
were present and after 14 days, mature fibrils were observed. Interestingly, no difference
between day 9 and day 14 was observed through ThT and OPE fluorescence which might
indicate that the amount of protofibrils present at day 9 might be similar to the quantity of
mature fibrils present at days 15. When Aβ40 was co-incubated with OPE12- (2:1, 5:1 and 10:1
molar ratio Aβ to OPE), similar aggregates size and morphology were observed compared to
Aβ incubated alone, indicating that OPE12- did not alter the aggregation kinetic nor the
aggregation pathway. These results show that OPE12- can be used in a co-incubation
experiment to track amyloid fibrillation without altering amyloid aggregation.
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Figure 5-4: TEM images of Aβ alone and Aβ co-incubated with OPE12- at 2:1, 5:1 and 10:1
molar concentration over 14 days of incubation at 37 ˚C.

OPE12- displays a different binding mode when co-incubated with Aβ40 during
fibrillation
When co-incubated with Aβ40 peptide, OPE12- is an efficient probe to track fibrillation as it
does not alter protein aggregation and maintains its selective fluorescence turn-on properties.
We previously observed that OPE12- forms super-luminescent complexes at concentration
higher than 10 µM, which leads to high background fluorescence and red shift in the emission
spectrum. During co-incubation with Aβ40 at 80 µM, OPE12- concentration was between 8 to
40 µM. At these concentrations OPE12- might have formed super-luminescent complexes
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which might have influenced OPE12- binding to the amyloid aggregates. To further understand
OPE12- binding mode, we reported OPE12- emission spectra obtained from Aβ40 incubated
alone and from co-incubated samples (Figure 5-5). OPE fluorescence was monitored at 1 µM
in the presence of 2, 5 or 10 µM peptide.

Figure 5-5: OPE12- emission spectra (1 µM) generated in the presence of pre-formed
aggregates (Aβ40 incubated alone) (A, B and C) or from co-incubation (D, E and F). Three
OPE to peptide ratios were used for fluorescence monitoring 2:1, 5:1 and 10:1. OPE and Aβ
concentrations used for fluorescence analysis are reported on the left inside. The concentration
of Aβ and OPE used during incubation are reported on the top left of each plot.
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At 1 µM OPE12- was highly quenched in phosphate buffer with a weak emission peak
centered at 471 nm (Figure 5-5). OPE12- fluorescence significantly increased in the presence
of Aβ40 aggregates generated after 1, 5, 9 and 14 days of incubation (Aβ40 alone) (Figure 5-5
A, B and C). Overall, in the presence of pre-formed Aβ40 aggregates OPE12- emission peak
was sharper and was blue shifted at around 450 nm (between 444 - 453 nm depending on the
incubation days and protein concentration), which indicates the formation of OPE J-dimers, as
previously described220.
Aβ samples obtained from co-incubation with OPE12- were also analyzed after dilution
in phosphate buffer to reach 1 µM OPE. In this condition, OPE12- fluorescence had
significantly higher intensity compared to OPE12- fluorescence generated in the presence of
pre-formed Aβ40 aggregates (1.5 to 6-fold higher). The conditions 1:2 and 1:5 OPE12- to
peptide were characterized by the appearance of a new spectral signature in addition to the
increase in fluorescence intensity (Figure 5-5 D and E). This new emission spectrum was
characterized by the presence of a sharp peak centered at around 450 nm indicating the
presence of rigid J-aggregates and a shoulder located at 476 nm representative of disordered
H-aggregates. OPE was previously described to form J-aggregates when present at
concentration above 10 µM (Figure 5-2). Based on this information and the observation of a
sharper peak at 450 nm after co-incubation, we hypothesized that OPE interacted with the
fibrils as a complex made of J-aggregates which did not breakdown after dilution in PB. This
observation indicates that OPE can sense Aβ40 aggregates as a single molecule or as a
complex, similarly to what was reported for other small molecules such as curcumin224.
Despite a difference in the binding mode, OPE12- maintained its sensing propriety to track
amyloid aggregation during co-incubation.
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OPE12- does not alter fibrils hydrophobicity
The effect of OPE12- on Aβ fibrils hydrophobicity was also investigated with the fluorescent
probe Nile Red (NR). NR was previously described to interact selectively to hydrophobic
surfaces leading to fluorescence turn-on as well as emission blue shift225. Additionally, NR
fluorescence does not overlap with OPE12- and no fluorescence resonance energy transfer
(FRET) are expected when measuring NR fluorescence (NR excitation: 550 nm, NR emission:
620 nm) in the presence of OPE12- (OPE12- excitation: 380 nm, OPE12- emission: 450 nm). NR
fluorescence was monitored at 1 µM in the presence of 10 µM Aβ40 monomers or 10 µM
Aβ40 fibrils produced in the absence and presence of OPE (Figure 5-6A and B).

Figure 5-6: Nile red emission spectra in the presence of Aβ monomers and Aβ fibrils generated
from Aβ incubated alone and OPE:Aβ co-incubated at 1:2, 1:5 and 1:10. Aβ monomers and
fibrils were washed with PB by using an Amicon falcon to remove any excess of free OPE 12-,
DMSO and sodium azide. NR emission was monitored at 1 µM in the presence of 10 µM Aβ
peptide at the excitation wavelength 550 nm. A. NR emission spectra. B. Bar plot of NR
integrated emission intensity from triplicate samples.

NR was fully quenched in phosphate buffer with a weak emission peak centered at
around 650 nm (Figure 5-6A). In the presence of Aβ40 monomers, NR fluorescence stayed
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unchanged. NR fluorescence drastically increased in the presence of Aβ40 fibrils to reach
around 2,000 counts/sec which was accompanied by an emission blue shift at around 611 nm
(Figure 5-6A). This change in NR fluorescence signature indicates that Aβ40 fibrils are more
hydrophobic than Aβ40 monomers.
The influence of OPE12- on NR binding to Aβ fibrils was evaluated by recording NR
fluorescence in the presence of pre-formed Aβ fibrils to which OPE12- was added at a final
concentration of 5 µM. NR fluorescence generated in the presence of OPE was similar to the
fluorescence spectra obtained in the presence of Aβ fibrils alone, indicating that OPE12interaction with Aβ fibrils did not induce any changes in NR binding. NR fluorescence was
also monitored in the presence of Aβ40 fibrils produced from co-incubation with OPE12-. No
significant difference was observed in terms of NR fluorescence intensity (Figure 5-6B) or
emission shift (Figure 5-6A) by comparison with pre-formed fibrils.
Overall, we observed that Aβ40 fibrils were intrinsically more hydrophobic than the
monomeric species. More importantly, OPE12- did not alter fibrils hydrophobicity when coincubated with the peptide.

OPE12- does not modify Aβ cytotoxicity
When co-incubated with Aβ, OPE12- did not alter neither the aggregation kinetic nor the overall
hydrophobicity. In order to investigate the effect of OPE12- on fibrils neurotoxicity we
evaluated both OPE12- and fibrils toxicity on SHSY-5Y neuroblastoma cells (Figure 5-7A and
B).
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Figure 5-7: SHSY-5Y cell viability after treatment with OPE12- and Aβ40 fibrils. A. OPE12cell toxicity was investigated at concentration between 1 to 10 µM after 24 hours treatment. B.
Aβ fibrils toxicity was evaluated after 48 hours at 20 µM. Before treatment, Aβ fibrils were
washed with 10 mM PB at pH7.4. Cell viability was normalized to the negative control,
untreated cells. Error bars represent standard deviations between quintuplet experiments. The
red line represents 70% cell viability, which is used as a threshold for cytotoxicity.

As shown Figure 5-7A, cell treated with OPE12- at concentration between 1 to 10 µM
displayed similar viabilities compared to the untreated cells indicating that OPE12- is not
cytotoxic. Aβ fibrils generated from the four incubations previously described were also tested.
These fibrils were first washed with 10 mM PB pH 7.4 to remove any free OPE12-, DMSO,
and sodium azide. Protein concentration was then determined by Bradford assay and
neuroblastoma cells were treated with 20 µM fibrils. As shown Figure 5-7B, cell viability was
not affected by the presence of Aβ fibrils produced from Aβ incubated alone. Aβ fibrils low
neurotoxicity corroborates previous studies showing that the most toxic species are Aβ
oligomers226-228. When neuroblastoma cells were treated with Aβ fibrils produced in the
presence of OPE12- at molar ratio 2:1, 5:1 and 10:1, no change in cell toxicity was observed
indicating that the binding of OPE12- to Aβ fibrils during aggregation, did not modify their
toxicity.
113

These results indicate that OPE12- is not cytotoxic and it does not change fibrils overall
toxicity which make this probe applicable to track Aβ fibrillation in a cell culture environment.

5.4 Conclusion
This study consisted in characterizing OPE as an amyloid probe in terms of background
fluorescence, effect on amyloid aggregation and cell toxicity. We showed that OPE 12background fluorescence was minimal at concentration below 8 µM which supports the use of
this probe at 1 µM as previously reported81, 82, 220. Besides, OPE12- formed J-aggregates at
concentration higher than 10 µM leading to high fluorescence turn-on which might interfere
with its sensing properties. Additionally, we evaluated OPE12- sensing of Aβ40 fibrillation
during co-incubation with the peptide. We found that OPE12- did not alter the aggregation
kinetic even when co-incubated at the high molar ratio 1:2 OPE12- to protein and maintained
its sensing properties, indicating that OPE12- could be used to monitor protein aggregation
through real-time fluorescence microscopy. Finally, we showed that OPE12- did not display
any cell toxicity and more importantly did not affect fibrils neurotoxicity. The fact that OPE12can detect early aggregates and does not alter neither amyloid aggregation nor aggregates
toxicity makes this probe highly promising to shine light on amyloid aggregation kinetic
implicated in the development of neurodegenerative disorders.

5.5 Experimental Methods
Material
Synthetic amyloid β-40 (Aβ40) was purchased form Peptide2.0 (Chantilly, VA). Dimethyl
sulfoxide (DMSO), sodium chloride (NaCl) and sodium azide were acquired from EMD
114

Millipore (Burlington, MA). Sodium phosphate monobasic monohydrate and sodium
phosphate dibasic anhydrous used to prepare phosphate buffer were purchased from Thermo
Fisher Scientific (Waltham, MA). 400 mesh copper grids covered by 5-10 nm formvar/carbon
film were purchased from Ted Pella (Redding, CA). 2% aqueous uranyl acetate was purchased
from Electron Microscopy Sciences (Hatfield, PA). Thioflavin T (ThT) and Nile red (NR) were
acquired from ACROS Organics (Belgium) and Sigma-Aldrich (St. Louis, MO), respectively.
OPE12- was synthesized and purified by previously published procedures (MW: 724.79 g/mol;
ɛ370 nm in water: (3.92 ± 0.013) x 104 M−1.cm−1)181. SH-SY5Y neuroblastoma cells,
Dulbecco’s Modified Eagle’s Medium (DMEM) F12 media, and fetal bovine serum (FBS)
were purchased from Sigma-Aldrich (St. Louis, MO). Penicillin-streptomycin (PS) at 10,000
U/mL was purchased from Thermo Fisher Scientific (Waltham, MA). The CellTiter 96®
AQueous One Solution Cell Proliferation Assay was acquired form Promega (Madison, WI).
Aβ40 preparation and incubation
The lyophilized Aβ40 peptide was solubilized in DMSO at 50 mg/mL and was centrifuged for
10 min at 14,000 rpm. The soluble peptide was transferred in a new vial and the protein
concentration was determined by measuring the absorbance at 280 nm with the Nanodrop
(Thermo Fisher Scientific, Waltham, MA) and using Aβ40 coefficient of extinction and
molecular weight (ɛ280nm = 1,490 M-1cm-1; MW: 4,329 g/mol). Aβ40 was then diluted to reach
80 µM in 50 mM PB pH 7.4 buffer containing 100 mM NaCl and 0.01 % w/v sodium azide
and was incubated at 37 ˚C under quiescent condition for up to 15 days.
Fluorescence measurement
Fibrils formation was monitored by using Thioflavin T and OPE12- fluorescence. Fluorescence
spectra were recorded with the PTI QuantaMaster 40 steady state spectrofluorometer
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(HORIBA Scientific, Edison, NJ). ThT and OPE12- were mixed with Aβ40 peptide at the
following concentration: 20 µM ThT with 5 µM Aβ and 1 µM OPE with 2, 5 or 10 µM Aβ.
After incubating the sample for 30 min at room temperature, the emission spectra were
recorded by using the excitation wavelengths of 440 and 390 nm for ThT and OPE 12-,
respectively.
Nile red (NR) was used to monitor fibrils hydrophobicity by mixing NR with Aβ40 sample at
1 to 10 molar ratio (1 µM NR with10 µM Aβ40). After incubating the sample for 30 min at
room temperature, NR emission spectrum was recorded at 550 nm.
TEM imaging
Aβ40 was imaged during incubation by Transmission Electron Microscopy (TEM). The
peptide diluted at 5 µM in MilliQ water was loaded onto a carbon grid exposed to glow
discharge for 30 sec. The peptide was let to adsorb for 5 min after which the excess of solution
was wick away. The peptide was then stained by using uranyl acetate at 2% through four
consecutive staining steps: the first one consisted in staining the sample with 4 µL of uranyl
acetate for 3 min, the last three staining were done for 1 min. After wicking away the excess
of stain the grid was air dried for 30 min before imaging with the HITACHI HT7700
transmission electron microscope (Hitachi High Technologies Corp., Tokyo, Japan). The beam
current and the accelerating voltage used during imaging were 8.0 µA and 80 keV, respectively
Cell toxicity
SHSY-5Y cells were used to evaluate OPE12- cell toxicity. The neuroblastoma cells were
cultivated in a T-75 flask (Thermo Fisher Scientific, Waltham, MA) up to 80% confluency.
After detaching the cells with 0.25% trypsin solution, media was added to the flask and the
floating cells were centrifuged at 2,000 rpm for 5 min. Cells were resuspending in a fresh

116

DMEM media containing 1% PS and 10% FBS, and cell density was measured by using a
hemocytometer. Cells were diluted to 200,000 cells/mL, were loaded in a 96 well plate (100
µL/well) and were then incubated overnight at 37 ˚C and 5% CO2. Media was changed with
DMEM media containing 1%PS but depraved in FBS to ensure cell synchronization to a
quiescent stage G0. Cells were incubated overnight after which fresh media containing OPE12at different concentrations were added to the cells. Cell viability was monitored after 24 hours
of incubation with MTS assay. Briefly, 20 µL of MTS reagent was added to the 100 µL media
present in each well and the 96 well plate was further incubated at 37˚C for another 3 hours.
Absorbance at 490 nm was monitored. MTS background absorbance was subtracted, and cell
alone were used as 100%.
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6.1 Abstract
Amyloid aggregates deposition in the brain and increase in amyloid-β oligomers concentration
in cerebrospinal fluid (CSF) to reach pg/mL range have been correlated with cognitive
impairment which make them ideal biomarkers for early Alzheimer’s disease (AD) diagnosis.
In this study, we reported the sensing properties of a fluorescent probe, oligomer p-phenylene
ethylene (OPE), for the detection of a large array of amyloid aggregates in phosphate buffer
(PB) and in CSF. We also investigated OPE for the detection of pathologic oligomers in CSF
isolated from patient diagnosed with dementia through the Aβ-protein misfolding cyclic
amplification (Aβ-PMCA) assay. Two oppositely charged OPE were tested, the negatively
charged OPE12- and the positively charged OPE24+. In phosphate buffer OPE12- was a superior
sensor for the detection of a large array of amyloid aggregates compared to OPE24+. In fact,
OPE12- detected fibrils made of insulin, lysozyme, Aβ40 and PHF6 as well as htau oligomers,
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while OPE24+ only detected fibrils composed of insulin, lysozyme and Aβ40. Despite
superiority of OPE12- in PB, this sensor was more sensitive to its microenvironment as it lost
its sensing properties in CSF, while OPE24+ maintained its selective sensing. Finally, OPE
sensing properties were evaluated in CSF isolated from patients with dementia through the AβPMCA assay after spiking the samples with Aβ40 monomers. No detectable fibrillation was
observed neither from TEM imaging nor from OPE fluorescence. Further evaluation of the
Aβ-PMCA assay would be required to determine the feasibility of this assay to detect picogram
range oligomers. Despite OPEs poor performance in CSF isolated from patient with dementia,
OPE24+’s sensing properties in a complex environment could lead to other applications such as
the detection of amorphous protein aggregates in protein-based pharmaceuticals.

Keywords: oligomer p-phenylene ethylene, fluorescent probe, amyloid aggregates detection,
cerebrospinal fluids, protein misfolding cyclic amplification

6.2 Introduction
Abnormal protein misfolding and aggregation into β-sheet rich aggregates or amyloids, is one
of the main pathological hallmark of Alzheimer’s disease (AD)61, 213. In AD, two main proteins
have been found to form amyloid aggregates, Amyloid-β (Aβ) and tau proteins which
accumulate under the form of amyloid plaques and neurofibrillary tangles in AD brains,
respectively213,

229,

230

. These aggregates are produced through a nucleation-based

polymerization mechanism in which misfolded proteins aggregate into small oligomers and
protofibrils which are then used as seeds to form stable amyloid fibrils6-8,

10, 11

. Theses

aggregates have been found to accumulate in the brain7 and more recently, Aβ oligomers have
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been found to increase in cerebrospinal fluid (CSF)

41, 231-233

to reach a concentration in the

order of pg/mL234. The accumulation of amyloid aggregates in both the brain and CSF of
patients suffering of AD was directly correlated with cognitive decline and is believed to start
decades before the development of the symptoms, 88, 89 which make them ideal biomarkers for
early disease detection.
To this day, there is a lack of a sensitive method for early diagnosis of AD. Disease
diagnosis is mainly based on symptoms evaluation and is confirmed through the detection of
amyloid plaques in vivo which can be accomplished via Positron Emission Tomography
(PET)50, 52, 235-237. Additionally, other non-PET sensors such as Thioflavin T (ThT) are used for
post-mortem tissue analysis and definitive diagnosis238. Current PET and histological probes
are of limited application as FDA approved PET probes only detect amyloid plaques made of
Aβ protein54-56,

239

and current histological probes are not good at detecting the early

aggregates, oligomers and protofibrils56. More studies are currently investigating the detection
of Aβ oligomers in CSF for AD diagnosis. A promising method which would ensure the
detection of Aβ oligomers at concentration as low as pg/mL is based on the Aβ protein
misfolding cyclic amplification assay (Aβ-PMCA)240, 241. This method consists in using the
seeding potency of the oligomers and tracking the formation of amyloid fibrils in CSF with
ThT after spiking the sample with monomeric Aβ42241. To ensure efficient detection of protein
aggregates in the brain and in CSF, there is a need to develop new conformation-specific probe
highly selective toward amyloid aggregates made of different proteins, with low limit of
detection, superior selectivity to amyloid aggregates and low sensitivity to its
microenvironment such as the presence of glucose, salt, or non-amyloidogenic protein
(albumin).
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Oligomeric p-phenylene ethynylenes (OPEs) are water-soluble fluorescent probes
which were previously described to selectively detect amyloid fibrils rich in β-sheet over their
monomeric counterpart81,

82, 220

. OPE sensing of amyloid fibrils is ensured through its

quenching by water molecules when free in solution and its large fluorescence turn-on upon
interaction to the hydrophobic β-sheet structures composing the amyloid aggregates83, 178, 181,
182

. This fluorescence enhancement is driven by three main mechanisms: (1) hydrophobic

unquenching, (2) backbone planarization and (3) formation of OPE super-luminescent
complexes81, 82, 87. The negatively charged OPE12- and the positively charged OPE24+ (Table
6-1) have been shown to detect amyloid aggregates made of a large variety of proteins: hen
egg-white lysozyme, bovine insulin, Aβ and α-synuclein proteins81, 82, 220. OPE12- presents high
binding selectivity toward the fibrillar conformation of all tested proteins, 81, 82, 220 and was able
to detect α-synuclein oligomers but not Aβ42 oligomers220. OPE24+ displayed higher
fluorescence enhancement compared to OPE12- in the presence of fibrillar aggregates. OPE24+
was also better at detecting oligomers made of Aβ42 proteins,220 but also presented nonselectively binding to the negatively charged insulin monomers which limited the selective
detection of insulin fibrils. 82
In this study, we are evaluating the robustness of OPE for the detection of amyloid
aggregates in a complex physiological sample, CSF. OPE sensing of amyloid aggregates
(fibrils and oligomers) made of a large array of proteins (lysozyme, insulin, tau and Aβ) was
quantitatively characterized in terms of selectivity, sensitivity and affinity. OPE background
fluorescence and sensing properties were evaluated in CSF. Finally, OPE sensing of amyloid
oligomers in CSF isolated from patients with dementia was investigated through the AβPMCA assay.
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Table 6-1: OPE12- and OPE24+ structures. OPE12- is made of one repeat unit and present two
side chains each terminated with a sulfonate group. The positively charged OPE24+ is composed
of two repeat units and four side chains each terminated with a quaternary ammonium group.

6.3 Results and Discussion
Quantitative characterization of OPE sensing of amyloid aggregates
OPE12- and OPE24+ are two fluorescent probes previously described to selectively detect the
fibrillar conformation of a variety of amyloid proteins over the monomeric counterpart. To
further understand their sensing properties, we evaluated them in the presence of five amyloid
aggregates: lysozyme fibrils, insulin fibrils, Aβ40 fibrils, tau PHF6 fibrils and human isolated
tau (htau) oligomers (Figure 6-1). Tau PHF6 is the hexapeptide 306VQIVYK311 located in the
third repeat unit of the tau microtubule binding domain known to form the main core of tau
paired helical filaments (PHF),99, 101 and was shown to be a relevant tau aggregation model.
This large array of amyloid aggregates was used to evaluate the robustness of OPE sensing
properties for the detection of highly polymorphic amyloid aggregates characterized by
different morphology (Figure 6-1) and net charge (Table 6-2). OPEs sensing was
characterized in terms of spectral signature, binding constant and limit of detection.
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Figure 6-1: TEM images of lysozyme fibrils (A), insulin fibrils (B), Aβ40 fibrils (C), PHF6
fibrils (D) and human isolated tau (hTau) oligomers (E).

Table 6-2: Protein monomers characteristics: molecular weight (MW), isoelectric point (pI)
and net charge at pH7.4

OPE12- and OPE24+ fluorescence was recorded at 1 µM in the presence of the
monomeric or aggregated proteins at 21 µg/mL. OPE emission and excitation spectra are
presented in Figure 6-2. To quantify the selective detection of the aggregated conformer over
the monomeric counterpart, we used the amyloid detection factor (ADF) (Equation 1). 82, 220
𝐴𝐷𝐹 =

𝐹(𝑑𝑦𝑒+𝑓𝑖𝑏𝑟𝑖𝑙𝑠) − 𝐹(𝑑𝑦𝑒+𝑚𝑜𝑛𝑜𝑚𝑒𝑟𝑠)
𝐹(𝑑𝑦𝑒 𝑖𝑛 𝑏𝑢𝑓𝑓𝑒𝑟)

(1)

with F(dye in buffer), F(dye+fibrils) and F(dye+monomers) being the integrated emission intensities of the
sensor alone, sensor in the presence of fibrils, and sensor in the presence of monomers,
respectively. Based on this equation, positive ADF (>1) indicates selective detection of the
fibrillar conformers while negative value (<1) indicates higher detection of the monomeric
counterpart and ADF value close to 0 (-1<x<1) indicates no selective sensing of either protein
conformations. The ADF values generated for both OPE12- and OPE24+ are summarized in
Table 6-3.
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Table 6-3: OPE12- and OPE24+ sensing parameters – amyloid detection factor (ADF),
dissociation constant (kd) and limit of detection (LOD)

As shown Figure 6-2, at 1 µM both OPE12- and OPE24+ were highly quenched in water
with a weak emission peak centered at 470 nm and an intensity of around 5x103 and 9x103
counts/sec, respectively. OPE quenching was assured through partial proton transfer with the
surrounding water molecules deactivating rapidly OPE excited state83, 182. OPE12- displayed no
fluorescence enhancement in the presence of the monomeric proteins except for lysozyme
(Figure 6-2A). The weak OPE fluorescence turn-on in the presence of the monomeric
lysozyme might be driven by electrostatic interactions between the positively charged protein
(Table 6-2) and the negatively charged OPE. OPE12- displayed larger fluorescence
enhancement in the presence of all amyloid aggregates resulting in ADF values superior to 1
(Table 6-3) indicative of positive sensing. These results show that OPE12- sensing is not
affected by the charge or the morphology of the aggregates. Additionally, OPE12- was
characterized by different spectral signatures depending on the aggregates. In the presence of
fibrils made of Aβ40 and insulin, OPE12- excitation peak was red-shifted (375 nm to 394 nm)
while its emission peak was broad and blue shifted (447 nm). This bathochromic red shift
indicates the formation of J-dimers, as previously described81, 220. In the presence of the htau
oligomers and lysozyme fibrils, OPE fluorescence was also characterized by a bathochromic
red shift but OPE emission was now characterized by two distinct features: one sharp peak at
442 nm and a shoulder at around 470 nm. The presence of two spectral features might indicate
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two distinct binding modes. The sharper peak might be caused by the formation of more stable
J-dimers, while the shoulder at 470 nm might result from more disordered OPE complexes.
Finally, in the presence of PHF6 fibrils, OPE12- emission was red shifted (510 nm) and his peak
was broader which might indicate the formation of H-aggregates or more disordered OPE
agglomerates. The formation of H-aggregates in the presence of PHF6 fibrils might be related
to a difference in the fibrillar structure. To better understand these different binding modes of
OPE12-, the structure of the amyloid aggregates should be characterized at a molecular-level.
In contrast, OPE24+ only selectively detected three amyloid aggregates out of five:
fibrils made of lysozyme, insulin and Aβ40 (Table 6-3). The lack of detection of htau
oligomers and PHF6 fibrils by OPE24+ might be caused by the size and/or the morphology of
the scaffold. Indeed, the small β-sheet scaffold generated by the hexapeptide PHF6 and the
globular structure of htau oligomers might not be suitable for optimal binding of the large
OPE24+. Additionally, similar fluorescence intensity and spectral signature were observed in
the presence of all three fibrils made of insulin, lysozyme and Aβ, characterized by a sharp
emission peak at around 450 nm and a red shifted excitation peak indicating the formation of
highly stable OPE24+ J-dimers. Finally, a weak OPE24+ fluorescence turn-on was also observed
in the presence of monomeric Aβ and monomeric insulin which might be due to electrostatic
interactions between the negatively charged proteins and the positively charged OPE, as
previously described.82, 220
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Figure 6-2: OPE12- and OPE24+ fluorescence spectra at 1 µM in the presence of six amyloid
proteins (lysozyme, insulin, Aβ40, Ac-PHF6 and hTau) under the monomeric (blue) or
aggregated (red) form. In the case of lysozyme, Insulin, Aβ40 and PHF6, the aggregated forms
corresponded to the fibrillar conformation, while the oligomeric conformation was tested for
hTau*. For PHF6, the non-acetylated peptide was used as monomers and the N-acetylated
isoform was used to form fibrils. The unincubated recombinant 441 tau protein was used as
the monomeric control for hTau oligomers.
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To further characterize OPE sensing of amyloid aggregates, we determined both the
dissociation constant and the limit of detection (Table 6-3). An efficient amyloid probe needs
to have high affinity toward the aggregated conformation which can be characterized by the
dissociation constant (kd). As shown in Table 6-3, in the presence of fibrillar aggregates both
OPE12- and OPE24+ present a kd value in the sub-micro molar range (0.16- 0.96 µM) and a Hill
coefficient “h” of 1.5 (Figure S1) indicative of positive binding cooperativity. In contrast, the
binding of OPE12- to htau oligomers is characterized by higher kd (1.23 µM) indicating lower
affinity, and larger h coefficient (4.17) showing higher level of cooperativity. The difference
in kd between fibrillar and oligomeric aggregates indicates that OPE12- binding affinity is
affected by the size and morphology of the scaffold.
The limit of detection (LOD) indicating the smallest protein concentration that OPE
can detect with high certainty, was also calculated as previously described220. LOD values
calculated for both OPEs were in the micro or sub-micromolar range (Table 6-3 and Figure
S2), with OPE24+ having the lowest LOD. Interestingly OPE12- presented similar LOD values
for lysozyme, insulin and PHF6 (between 0.52-0.85 µg/mL) but the LOD values were much
higher for both Aβ40 fibrils (2.24 µg/mL) and hTau oligomers (4.25 µg/mL). These results
indicate that OPE12- is less sensitive to hTau oligomers which is also supported by a lower
affinity (higher kd).
Overall, OPE12- was more efficient at detecting a wide range of amyloid aggregates
characterized by different morphology and charge compared to OPE24+. OPE12- also displayed
a fluorescence signature that can be used to distinguish amyloid aggregates (oligomers vs
fibrils). This signature indicates different binding modes which is mainly the result of different
aggregate morphologies.
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OPE’s sensing of a mixture of fibrillar aggregates
OPEs are efficient probes for selectively detecting amyloid aggregates over their monomeric
counterparts. As neurodegenerative disorders are often characterized by the co-deposition of
amyloid aggregates made of different proteins,151-153 we evaluated OPE sensing properties in
the presence of a mixture of amyloid fibrils (Figure 6-3). OPE spectral features were
summarized in Table 6-4.

Figure 6-3: OPE12- (1) and OPE24+ (2) fluorescence spectra in the presence of a mixture of
amyloid aggregates. A. 21 µg/mL Aβ40 fibrils and 21 µg/mL PHF6 fibrils. B. 21 µg/mL Aβ40
fibrils and 90 µg/mL PHF6 fibrils. C. 21 µg/mL Aβ40 fibrils and 21 µg/mL insulin fibrils.
OPE fluorescence was analyzed for the sensor alone at 1 µM (black), in the presence of Aβ40
fibrils (blue), PHF6 fibrils (red), insulin fibrils (orange), both Aβ40 and PHF6 fibrils (green),
and both Aβ40 and insulin fibrils (purple). The excitation (dot line) and emission (solid line)
spectra were recorded for both sensors.
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Table 6-4: Summary of OPE12- and OPE24+ spectral features observed at 1 µM when incubated
alone (OPE background) or in the presence of a mixture of fibrils. A. OPE spectral signature
in the presence of 21 µg/mL Aβ40 fibrils and 21 µg/mL PHF6 fibrils. B. OPE spectral signature
in the presence of 90 µg/mL Aβ40 fibrils and 21 µg/mL PHF6 fibrils. C. OPE spectral signature
in the presence of 21 µg/mL Aβ40 fibrils and 21 µg/mL insulin fibrils.

OPE sensing properties were first evaluated in the presence of both Aβ40 and PHF6
fibrils (Figure 6-3 A and Figure 6-3 B). OPE12- was previously shown to selectively detect
both amyloid fibrils with similar kd (Table 6-3) but the fluorescence intensity and spectral
signature generated with both aggregates were different: in the presence of PHF6 fibrils,
OPE12- had higher ADF value, its emission peak was broad and red-shifted indicating the
formation of H-aggregates; in the presence of Aβ40 fibrils, OPE12- emission peak was sharper
and was blue-shifted characteristic of J-aggregates (Figure 6-2 and Table 6-4). In contrast,
OPE24+ only detected Aβ40 fibrils and only weakly bound to PHF6 fibrils as shown by an ADF
value of 0.72 (Table 6-3). When both amyloid fibrils were present at equal concentration
(Figure 6-3A), OPE12- and OPE24+ emission intensities were similar to the sum of the
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emissions recorded for both aggregates separately (OPE12𝐹𝐴𝛽𝑓:𝑂𝑃𝐸 + 𝐹𝑃𝐻𝐹6𝑓:𝑂𝑃𝐸
𝐹(𝐴𝛽𝑓+𝑃𝐻𝐹6𝑓):𝑂𝑃𝐸

𝐹𝐴𝛽𝑓:𝑂𝑃𝐸 + 𝐹𝑃𝐻𝐹6𝑓:𝑂𝑃𝐸
𝐹(𝐴𝛽𝑓+𝑃𝐻𝐹6𝑓):𝑂𝑃𝐸

= 0.93; OPE24+

= 0.93). OPE12- fluorescence signature generated in the presence of both

aggregates was similar to the one obtained in the presence of PHF6 fibrils alone with a peak
centered at 510 nm (Figure 6-3 A1). Interestingly, when Aβ40 fibrils concentration was fourtime PHF6 fibrils (Figure 6-3 B1), OPE12- emission was blue shifted and the spectral signature
was characterized by a sharp peak at 443 nm and a new shoulder at around 475 nm.
Additionally, OPE12- emission intensity generated in the presence of both fibrils was only half
of the sum of the emission recorded for PHF6 and Aβ fibrils separately (OPE12𝐹𝐴𝛽𝑓:𝑂𝑃𝐸 + 𝐹𝑃𝐻𝐹6𝑓:𝑂𝑃𝐸
𝐹(𝐴𝛽𝑓+𝑃𝐻𝐹6𝑓):𝑂𝑃𝐸

= 0.54). The low fluorescence intensity in the presence of both fibrils and

the presence of a sharp emission peak at 443 nm and a shoulder at 475 nm might be explained
by the presence of both H and J-aggregates. These two types of aggregates are characterized
by different energy (J-aggregates display higher energy and so higher fluorescence increase)
and different life time (J aggregates have shorter lifetime)86. The presence of J-aggregates in
the sample would dominate the fluorescence and so the fluorescence generated by Haggregates might not be detectable. The contribution of both H- and J-aggregates could be
further analyzed through time-resolved fluorescence242. In the case of OPE24+, the emission
spectra obtained in the presence of both aggregates were similar to the one generated in the
presence of Aβ40 and PHF6 fibrils separately (OPE24+

𝐹𝐴𝛽𝑓−𝑂𝑃𝐸 + 𝐹𝑃𝐻𝐹6𝑓−𝑂𝑃𝐸
𝐹(𝐴𝛽𝑓+𝑃𝐻𝐹6𝑓)−𝑂𝑃𝐸

= 0.93).

OPE sensing properties were also evaluated in the presence of both Aβ40 and insulin
fibrils (Figure 6-3 C). OPE12- displayed similar spectral signature in the presence of both fibrils
with an emission peak centered at around 442 nm. OPE24+ also had similar fluorescence
spectrum for both aggregates with a sharp emission peak at around 450 nm and a shoulder at
130

470 nm. Both sensors were able to detect the mixture of Aβ40 fibrils and insulin fibrils with
an emission intensity similar to the sum of the emission generated for both fibrils separately
(OPE12-

𝐹𝐴𝛽𝑓:𝑂𝑃𝐸 + 𝐹𝐼𝑛𝑠𝑢𝑙𝑖𝑛𝑓:𝑂𝑃𝐸
𝐹(𝐴𝛽𝑓+𝐼𝑛𝑠𝑢𝑙𝑖𝑛𝑓):𝑂𝑃𝐸

= 0.95; OPE24+

𝐹𝐴𝛽𝑓:𝑂𝑃𝐸 + 𝐹𝐼𝑛𝑠𝑢𝑙𝑖𝑛𝑓:𝑂𝑃𝐸
𝐹(𝐴𝛽𝑓+𝐼𝑛𝑠𝑢𝑙𝑖𝑛𝑓):𝑂𝑃𝐸

= 0.71).

Overall, both OPEs detected a mixture of fibrils. OPE24+ presents a single spectral
signature for the detection of different fibrils however in the presence of a mixture of
aggregates its fluorescence enhancement reflects the amount of each fibrils. OPE12- presents a
distinct spectral signature depending on the aggregates detected. When two aggregates are
present in the samples generating different spectral features, OPE12- can be used to indicate
which aggregates is predominant.

Characterization of OPEs background fluorescence in CSF
The search for a diagnostic tool to track amyloid biomarkers in biological fluids such as CSF
is where the field of dementia diagnosis is moving toward. To evaluate OPE sensing properties
in CSF, we first characterized OPE background fluorescence in healthy CSF at concentration
between 100 nM and 1 µM and compared it to its background fluorescence in phosphate buffer
(PB) (Figure 6-4A and B). CSF samples used in this study were purchased from Lee
Biosolutions and were collected from a pool of healthy patients (≥ 3). This commercialized
healthy CSF had an overall protein concentration of 263 g/mL as defined through Bradford
protein concentration assay and contained highly hydrophobic proteins as observed by reverse
phase HPLC (Supplementary Figure S4).
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Figure 6-4: OPE12- and OPE24+ background fluorescence in 10 mM PB (A), in healthy CSF
(B), in 1X PBS (C) and in the presence of 4.5 g/L of glucose (D). Both sensors were tested at
4 different concentration: 100 nM, 250 nM, 500 nM and 1 µM. The excitation (dashed line)
and emission (solid line) spectra were recorded excepted in the presence of PBS where
emission was only reported.

As shown Figure 6-4A1 and A2, both OPEs had low background fluorescence in PB
at 100 nM which is explained by a rapid quenching of OPE excited singlet state by surrounding
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water molecules trough proton transfer83, 84, 221. Both OPEs displayed a weak fluorescence turnon with increase in concentration characterized by a weak and broad emission peak indicative
of the formation of dye complexes in a disordered micelle-like structure likely made of H-type
aggregates192. In CSF, OPE background fluorescence drastically increased by comparison with
PB (3 to 7-fold increase for OPE12- and 2 to 3-fold increase for OPE24+). For both sensors, this
increase in fluorescence intensity was also accompanied by a sharpening of the emission
spectra which might indicate the formation of J-aggregates. OPEs higher fluorescence in CSF
could be explained by a non-selective interaction with other biomolecules such as salt, glucose
or non-amyloidogenic protein243.
To further understand which biomolecules found in CSF is responsible for OPEs
fluorescence turn-on, we investigated OPE fluorescence in the presence of salt, glucose and
albumin (Figure 6-4 and Figure 6-5). To evaluate the effect of salt on OPE fluorescence, we
tested phosphate buffer solution (PBS) containing 137 mM NaCl and 2.7 mM KCl, a
comparable salt concentration to what is found in CSF (150 mM Na+, 3 mM K+ and 1.2 mM
Ca+)243. OPE12- did not display any increase in fluorescence intensity or change in spectral
signature in PBS, indicating that OPE12- fluorescence turn-on in CSF is not caused by the
presence of salt. In contrast, OPE24+ display large fluorescence enhancement in PBS at OPE
concentration higher than 500 nM which mimics closely the fluorescence spectrum generated
in CSF. Overall, the presence of salt might be one of the biomolecules responsible of OPE 24+
fluorescence turn-on in CSF.
Glucose is another molecule found in CSF at a concentration typically close to 4 mM
(0.72 mg/mL)243. To evaluate the interactions of OPE with glucose we tested a high glucose
concentration solution (4.5 g/L ~ 24.75 mM), higher than that found in CSF but also a middle
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ground for glucose concentrations in cell culture formulations such as in Dulbecco’s Modified
Eagle’s Medium high glucose formulation in which OPE12- was also tested (Figure S5). In the
presence of 4.5 g/L of glucose, OPE12- (Figure 6-4 D1) and OPE24+ (Figure 6-4 D2) displayed
similar fluorescence intensity and spectral shifts compared to background fluorescence in PB,
indicating a lack of interaction of OPEs with glucose.
CSF is also known to be rich in protein (0.1-0.6 g/L). The most predominant protein in
CSF is albumin which is characterized by a cylindrical structure with polar outer walls and a
hydrophobic central core244. Knowing that OPE sensing of amyloid aggregates relies on
binding to their hydrophobic β-sheet structure, the hydrophobicity of albumin might lead to
non-selective interaction and non-selective fluorescence turn-on. To evaluate the interaction
of OPE to albumin we measured OPE fluorescence in the presence of bovine serum albumin
(BSA) known to present a similar helical structure than human serum albumin (HSA) and share
76% of sequence identity with the human isoform245, 246. For this assay, OPEs fluorescence
was measured in the presence of 263 g/mL of BSA which compare with the protein
concentration found in healthy CSF. In the presence of BSA, both sensors displayed enhanced
fluorescence similar to that seen in healthy CSF samples (Figure 6-5) suggesting that the main
factor leading to OPEs fluorescence turn-on in CSF is probably their interaction with albumin.
This interaction to non-amyloidogenic proteins might lead to a poor sensing of amyloid
aggregates in CSF. To compare OPEs interactions to BSA with amyloid aggregates, we
analyzed their binding constant and limit of detection (Figure S1 and S2). In the presence of
BSA, OPE12- and OPE24+ were characterized by kd values in the sub-micromolar range (0.78 ±
0.07 and 0.19 ± 0.06 µM respectively), similar to the kd calculated in the presence of amyloid
aggregates previously described (Table 6-3). Additionally, both sensors had a hill coefficient
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close to 2 in the case of BSA and close to 1.5 in the presence of amyloid aggregates, indicating
higher cooperativity with BSA. Finally, the LOD for BSA was found to be 1.64 ± 0.2 µg/mL
and 3.50 ± 0.6 µg/mL for both OPE12- and OPE24+, respectively. This LOD was higher than
the one calculated in the presence of amyloid aggregates (Table 6-3) indicating that both OPEs
can detect pathological protein aggregates at much lower concentration than BSA.

Figure 6-5: OPEs fluorescence at 100 nM in the presence of 263 ug/mL BSA and in CSF
(containing 263 ug/mL proteins based on Bradford assay). Excitation (dashed line) and
emission (solid line) are represented.

Altogether, we found that both OPEs displayed higher fluorescence turn-on in CSF
compared to PB. For both OPEs, this fluorescence enhancement can be explained by their
interaction to biological molecules more particularly to albumin. Additionally, the presence of
salt seems to affect OPE24+ fluorescence but not OPE12-. Despite OPEs fluorescence turn-on in
CSF, we found that at the low concentration of 100 nM both OPEs present a minimal
background fluorescence which should not alter their sensing properties. For this reason,
OPE’s sensing properties in CSF were investigated at 100 nM and not at the typical 1 µM.
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OPE’s sensing of fibrillar and oligomeric proteins in CSF
OPEs high selectivity, sensitivity and affinity toward amyloid aggregates and their low
fluorescence turn-on in CSF at 100 nM make them promising for the detection of pathological
protein aggregates in this physiological sample. To assess OPE sensing properties in such
complex solution, we evaluated OPE’s detection of 21 µg/mL amyloid aggregates in CSF and
compared it to PB.
Previously described amyloid aggregates (fibrils made from insulin, lysozyme, PHF6
and A40, and oligomers made of htau protein) were spiked in CSF and PB. OPE12- and OPE24+
fluorescence spectra were recorded at 100 nM and are reported in Figure 6-6 and Figure 6-7,
respectively. The integrated emission areas were calculated and are summarized in Figure S6.
The detection of monomeric proteins was not evaluated because of the limited amount of CSF
sample which prevented the calculation of the ADF value. Positive sensing of spiked protein
was determined by using the protein detection factor or PDF, as described in Equation 2
𝑃𝐷𝐹 =

𝐹(𝑑𝑦𝑒+𝑝𝑟𝑜𝑡𝑒𝑖𝑛) − 𝐹(𝑑𝑦𝑒 𝑖𝑛 𝑏𝑢𝑓𝑓𝑒𝑟)
𝐹(𝑑𝑦𝑒 𝑖𝑛 𝑏𝑢𝑓𝑓𝑒𝑟)

(2)

with F(dye in buffer) and F(dye+protein) being the integrated emission intensity of the sensor alone and
sensor in the presence of spiked protein, respectively. Similarly to the ADF, positive PDF value
(> 1) indicates positive protein detection. PDF values recorded in PB and CSF are summarized
in Figure 6-8.

136

Figure 6-6: OPE12- fluorescence at 100 nM in the presence of 21 ug/mL amyloid aggregates
in PB (A and B) and spiked CSF (C and D). Five amyloid aggregates were tested: insulin
fibrils, lysozyme fibrils, PHF6 fibrils, Aβ40 fibrils and hTau oligomers. Both the excitation (A
and C) and emission spectra (B and D) were recorded.

Figure 6-7: OPE24+ fluorescence at 100 nM in the presence of 21 ug/mL amyloid aggregates
in PB (A and B) and spiked CSF (C and D). Five amyloid aggregates were tested: insulin
fibrils, lysozyme fibrils, PHF6 fibrils, Aβ40 fibrils and hTau oligomers. As a control the
monomeric Aβ40 was also evaluated. Both the excitation (A and C) and emission spectra (B
and D) were recorded.
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Figure 6-8: Protein detection factor (PDF) calculated for OPE12- (A) and OPE24+ (B) at 100
nM in the presence of amyloid aggregates (21 µg/mL) in PB (dark gray) or CSF (light gray).
As a control, the PDF value was also determined in the presence of Aβ40 monomers for
OPE24+. The red dashed line represents the PDF value equal to 1 used as a threshold to
determine positive detection.
OPE12- was previously described to detect all amyloid aggregates when tested at 1 µM
in PB. At 100 nM OPE12- still displayed a selective sensing of all fibrillar proteins in PB
(Figure 6-6B) by reaching fluorescence intensities between 5 to 9x103 counts/sec leading to a
PDF value superior to 1 (Figure 6-8A). However, this sensor failed to detect htau oligomers
as its PDF value was below 1. The loss of detection of htau oligomers at the low OPE 12concentration of 100 nM might be explained by its lower affinity (higher kd) and higher LOD
compared to the other fibrillar proteins (Table 6-3). Overall OPE12- spectral signature in the
presence of all 4 proteins fibrils was similar to what was previously observed when OPE was
tested at 1 µM (Figure 6-2). When the amyloid aggregates were spiked in CSF, OPE12fluorescence was similar to its background fluorescence (Figure 6-6C and D) which led to a
PDF value close to 0. This lack of amyloid aggregates detection in CSF might be caused by
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the presence of albumin for which OPE12- was previously described to interact with high
affinity.
The larger cationic OPE24+ was previously described to detect insulin, lysozyme and
Aβ40 fibrils when tested at 1 µM in the presence of 21 µg/mL protein in 10 mM PB (Figure
6-2),82, 220 but was not able to detect either PHF6 fibrils or htau oligomers. Same sensing pattern
was observed when OPE24+ was used at 100 nM in PB (Figure 6-7A and B). When the amyloid
aggregates were spiked in CSF, OPE24+ maintained its sensing properties for the fibrillar
insulin, lysozyme and Aβ40 (PDF > 1) but also gained sensing of PHF6 fibrils (Figure 6-7A
and B, Figure 6-8B). This new detection of PHF6 fibrils could be explained by CSF overall
hydrophobicity. In such hydrophobic environment OPE24+ fluorescence quenching by water
molecules is attenuated which might lead to stronger fluorescence turn-on when bound to
fibrillar PHF6.
The well-known fluorescent probe ThT was also tested at 100 nM in CSF spiked with
Aβ40 fibrils at 21 µg/mL (Figure S6). ThT displayed enhanced-fluorescence in the presence
of Aβ40 fibrils spiked in CSF compared to CSF background. However, this increase in
fluorescence led to a PDF value below 1 (0.72 ± 0.14) indicative of a poor sensing of Aβ40
fibrils in CSF.
Overall, at 100 nM both OPEs detected amyloid aggregates in PB similarly to what
was observed when tested at 1 µM. In CSF, OPE12- lost its sensing properties while OPE24+
was still able to detect fibrillar insulin, lysozyme and Aβ40 and also gained detection of PHF6
fibrils.
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OPE’s sensing of CSF isolated from patients with dementia
With the understanding of background fluorescence of OPE in CSF and with the knowledge
of OPE24+’s capabilities to detect amyloid aggregates in such complex environment, we
evaluated OPEs sensing properties in CSF isolated from two patients diagnosed with dementia
after neurological evaluation. As controls we also tested CSF obtained from two women
patients in labor and delivery units (L&D controls) as well as two older patients without
neuropathology (age-matched controls). All CSF samples were characterized in terms of
albumin, phosphorylated tau on threonine 181 (p-tau 181), A40 and A42 concentrations
(Table 6-5). Samples isolated from both L&D and age-matched controls contained albumin at
concentration between 0.12 and 0.28 mg/mL which is similar to the protein concentration
measured from the commercialized healthy CSF previously tested (0.26 mg/mL). Samples
isolated from patients with dementia contained higher albumin concentration (up to 0.59
mg/mL) compared to the control samples, which might be due to a compromised blood-brain
barrier247. They are also characterized by higher p-tau 181, higher A40 and lower A42
content compared to L&D and age-matched controls.

Table 6-5: Protein concentrations in CSF samples isolated from L&D controls, age-matched
controls and patients with dementia. Four proteins concentrations are reported: albumin,
phosphorylated tau 181, A40, and A42. These concentrations were determined through
western blot analysis.

OPEs fluorescence at 100 nM generated in both L&D and age-matched controls was
measured and compared to the fluorescence recorded in the presence of the commercialized
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healthy CSF (control CSF) (Figure 6-9 and Figure S8). OPE12- background fluorescence in
control patients was lower than the fluorescence measured in the commercialized CSF
(3.5x103 vs 6x103 counts/sec). In the case of OPE24+ the opposite trend was observed (5x103
vs 3x103 counts/sec). The variation in OPE’s background fluorescence in different healthy CSF
samples by almost 2-fold indicates that other biological molecules present in CSF might also
interfere with OPE’s fluorescence.
OPE’s fluorescence was also monitored in CSF isolated from patients with dementia.
No significant difference in terms of intensity or spectral signature with either set of controls
were observed. A similar observation was made after diluting CSF by 10-fold in MilliQ water
to reduce albumin concentration in the sample (Figure S9). ThT fluorescence was also
measured at 100 nM in CSF samples isolated from patients with dementia (Figure S7). No
significant difference between CSF controls and dementia CSF was observed with ThT.
The lack of detection of amyloid aggregates in dementia CSF by OPE12- and OPE24+
might be explained by OPEs limit of detection previously reported to be in the microgram
range, while the expected oligomeric Aβ concentration in AD CSF should be in the picogram
range234. A second likely explanation for the lack of detection would be the absence of
oligomeric protein in CSF samples as the presence of oligomers has not been confirmed in
patients with dementia.
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Figure 6-9: OPE12- (A) and OPE24+ (B) fluorescence at 100 nM in PB and CSF isolated from a
healthy commercialized CSF (control CSF), from L&D controls, age-matched controls and
patients diagnosed with dementia. Both the excitation (dashed line) and emission (solid line)
spectra are reported.

Detection of amyloid aggregates in CSF through protein misfolding cyclic
amplification (PMCA) assay
The lack of OPE fluorescence enhancement in CSF isolated from demented patient might be
due to low oligomer concentration in CSF (pg/mL range) which is below OPE’s LOD (µg/mL
range). To overcome this low oligomer concentration, their seeding potency could be exploited
to promote the aggregation of monomeric Aβ through the protein misfolding cyclic
amplification assay (Aβ-PMCA). This assay was previously introduced by Soto et al., in
2014241. In this study they showed that a low concentration of 3 fM of oligomers can be
detected through the Aβ-PMCA assay. They used the Aβ-PMCA assay in CSF isolated from
patient suffering of AD and found that these samples were characterized by a fast fibrillation
when spiked with Aβ42 monomers which was detectable with the fluorescent amyloid probe
ThT. Overall, they showed a significant difference in protein fibrillation between AD CSF and
control CSF.
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As OPEs were previously described to be superior sensors compared to ThT for the
detection of amyloid aggregates, we investigated OPE sensing properties for the detection of
oligomers in CSF through the Aβ-PMCA. In this study, Aβ-PMCA assay was first evaluated
in PB by incubating 50 µM Aβ40 monomers in the presence of 2.6 µM Aβ40 seed protofibrils
at 37 ˚C for 6 days188. The potential interference of albumin on the Aβ misfolding amplification
was also evaluated by incubating Aβ40 monomers and the seeds in the presence of 300 µg/mL
BSA. The Aβ-PMCA assay was finally assessed in CSF samples isolated from one dementia
patient and two age-matched controls where 50 µM Aβ40 monomers were spiked before
incubation at 37 ˚C for 6 days. The generation of amyloid fibrils through protein misfolding
cycle was analyzed by TEM imaging (Figure 6-10A) and by ThT, OPE12- and OPE24+
fluorescence (Figure 6-10B, C and D).
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Figure 6-10: Detection of the seeding activity of CSF isolated from age-matched controls and
from patients with dementia by Aβ-PMCA through TEM imaging (A) and ThT (B), OPE12(C) and OPE24+ (D) fluorescence. (A) TEM images were taken after 6 days of incubation. (B),
(C) and (D). Fluorescence of the three amyloid sensors was measured at 100 nM in the presence
of 21 µg/mL protein. Error bars represent standard deviation from duplicate. As control, the
seeding activity of Aβ monomers alone (black), Aβ monomers with seed fibrils (dark blue),
and Aβ monomers with seed fibrils and BSA (light blue) were monitored. Three CSF samples
were also tested: two samples from age-matched control (orange and purple) and one sample
from patient with dementia (red). In each CSF sample, Aβ40 monomers were spiked to reach
a final concentration of 50 µM.
As shown on TEM images (Figure 6-10A), Aβ monomers incubated alone after 6 days
at 37 ˚C formed very small features which are likely early oligomers but no large fibrils were
produced. In the presence of Aβ protofibril seeds, Aβ monomers formed long and mature
fibrils. The fast fibrillation in the presence of protofibrillar seed is also supported by ThT,
OPE12- and OPE24+ fluorescent turn-on observed after only 1 day of incubation (Figure 6-10B,
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C and D). The effect of BSA on amyloid fibrillation was tested by incubating Aβ monomers
with Aβ seed protofibrils in the presence of BSA at 300 µg/mL. As shown on TEM, fibrils
were produced in the presence of BSA indicating that the high concentration of albumin found
in CSF should not inhibit the seeding potency of the amyloid aggregates. All three sensors
were tested for the detection of Aβ fibrils produced in the presence of BSA. Both OPE24+ and
ThT detected Aβ fibrils produced in the absence of BSA, while OPE12- exhibited a weaker
fluorescence turn-on. OPE12- poor detection of Aβ fibrils in the presence of BSA supports the
previous observation that OPE12- losses amyloid sensing in CSF due to its non-specific binding
to albumin. Finally, the seeding potency of CSF isolated from patients diagnosed with
dementia was tested and was compared to two CSF samples isolated from age-matched
controls. After 6 days of incubation in the presence of 50 µM Aβ monomers, oligomeric like
structure were observed in all three CSF samples, more importantly it appeared that more
aggregates were present in dementia CSF compared to control samples, however no large
fibrillar structure were observed. To further characterize the difference between all three CSF
samples, the amount of soluble oligomers would need to be quantify by size exclusion HPLC.
Despite a potential difference in the amount of oligomers, none of the amyloid sensors
displayed a selective fluorescence turn-on in demented CSF. The slow protein aggregation in
demented CSF might be related to a low “seedable” oligomer concentration in the sample. To
evaluate this hypothesis, we determined the lowest Aβ40 seed protofibrils concentration
capable of generating detectable Aβ40 fibrils through the Aβ-PMCA assay. As shown Figure
6-11A, Aβ40 seed protofibrils promoted fibrillation at concentration as low as 1 ng/mL which
was detectable by ThT and OPE12- but not OPE24+ (Figure 6-11B, C and D). The lack of
detection by OPE24+ would require further analysis as this experiment was only performed
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once. This seeding concentration of 1 ng/mL is still several order of magnitude higher than the
oligomer concentration reported in AD CSF (pg/mL range). Additionally, the minimal seeding
concentration calculated here is 1,000-fold higher than what was reported by Soto et al. in
2014 (3fM ~ 12.9 fg/mL)241 where Aβ42 monomers were used to spike CSF. This difference
might rely on the lower aggregation potency of Aβ40 compared to Aβ42248. To further evaluate
the Aβ-PMCA assay for the detection of oligomers in CSF, Aβ42 monomers could be used
instead of Aβ40 monomers. Another option would be to further optimize the incubation
condition used for the Aβ-PMCA assay as the temperature, pH and agitation have been
previously reported to have a significant influence on fibrillation kinetic249-251.
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Figure 6-11: Detection of the seeding activity of Aβ40 protofibrils at different concentration
by the Aβ-PMCA assay after 6 days of incubation at 37 ˚C through TEM imaging (A) and ThT
(B), OPE12- (C) and OPE24+ (D) fluorescence. B, C and D. Fluorescence of the three amyloid
sensors was measured in the presence of 100 nM sensor and 21 µg/mL protein.

6.4 Conclusion
There is a continued need for the development of sensing technology for early neurological
disease diagnosis. Previous work demonstrated OPE as a promising sensor for the detection of
fibrillar and oligomeric pathological protein aggregates. In this study we sought to evaluate
OPEs sensing capabilities in a biological fluid, CSF. Through spectroscopic assays, imaging
techniques, and curve fitting we have characterized and gained an understanding on how
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OPE12- and OPE24+ behave in CSF mainly composed of non-amyloidogenic proteins, salts, and
glucose. Both OPEs displayed fluorescence turn-on in CSF likely caused by their non-selective
interaction to albumin and salt. Despite this fluorescence enhancement, both OPEs show
minimal background fluorescence when used at 100 nM. At such low concentration, OPEs
were still able to detect amyloid aggregates in PB but OPE12- lost sensing activity in CSF while
OPE24+ maintained its sensing properties. These two amyloid sensors were also evaluated in
CSF samples isolated from patients diagnosed with dementia which resulted in the lack of
sensing of pathologically relevant aggregates. The poor performance of OPE is probably due
to the low aggregate concentrations found in CSF in AD patients (picogram range) which are
several orders of magnitude lower than our calculated limits of detection (microgram range),
creating a hurdle for our sensors. To overcome the low oligomer concentration in CSF, we
investigated the protein misfolding cyclic amplification assay by spiking CSF with monomeric
Aβ40 which should undergo fast fibrillation in the presence of oligomeric seed. This assay was
previously described to detect oligomers at concentration as low as 3 fM. Low protein
fibrillation was observed CSF isolated from demented patients resulting in a lack of sensing
by OPE. This slow fibrillation might indicate that the assay needs further optimization to
ensure rapid fibrillation in the presence of low oligomers seed concentration which could be
achieved by changing the incubation conditions. Despite poor performance of OPE in CSF,
this work will guide future research to further evaluate OPE for the detection of amyloid
aggregates in CSF as a diagnostic tool.
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6.5 Experimental Methods
Material
Purified synthetic amyloid β-40 (Aβ40) was acquired from peptide 2.0. Bovine insulin, hen
egg white lysozyme and bovine serum albumin (BSA) were purchased from Sigma-Aldrich
(St. Louis, MO). N-terminus acetylated PHF6 (Ac-PHF6) and non-acetylated PHF6 (NH3+PHF6) were synthetized through a solid-phase synthetic method as previously described,
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and were purified by reverse phase HPLC. Human derived tau (htau) oligomers were
graciously provided by Dr. Kayed Rakez252. Recombinant tau 441 was produced and purified
as previously described252. Human cerebrospinal fluid (CSF) sample pooled from  3 healthy
donors was purchased from Lee Biosolutions (Maryland Heights, MO). CSF sample isolated
from patients diagnosed with dementia, from patients in labor and delivery units (L&D
controls) and from older patients without neuropathology (age-matched controls) were
graciously provided by Dr. Gary Rosenberg. All CSF samples were centrifuged at 8,000 rpm
for 8 minutes and supernatant was stored -20 ˚C until use. Dulbecco’s Modified Eagle’s
Medium (DMEM) F12 media and glucose were purchased from Sigma-Aldrich (St. Louis,
MO). Hydrochloric acid (HCl) was purchased from Merck, (Kenilworth, NJ). Sodium citrate
was acquired from Fisher Scientific, (Hampton, NH). Sodium azide, NaCl and dimethyl
sulfoxide (DMSO) were obtained from EMD Millipore (Burlington, MA). Tris was purchased
from BioRad (Hercules, CA). Phosphate buffer (PB) was prepared with sodium phosphate
monobasic monohydrate and sodium phosphate dibasic anhydrous purchased from Thermo
Fisher Scientific (Waltham, MA). Water was purified by MilliQ purification system (Millipore
Synergy UV) before use. ThT was acquired from ACROS Organics (Belgium). OPEs were
synthesized and purified by previously published procedures181.
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Protein solubilization and preparation of amyloid aggregates
Hen egg-white lysozyme (Sigma-Aldrich, St. Louis, MO) was dissolved at 5 mg/mL in 10 mM
sodium citrate pH 3 with 0.1 M NaCl. Protein concentration was verified by using absorbance
at 280 nm and the coefficient of extinction (2.63 L/(g.cm))253. Lysozyme protein was then
incubated at 70 ˚C for 48 hours under magnetic stirring to form fibrils. Insulin from bovine
pancreas (Sigma-Aldrich, St. Louis, MO) was solubilized in 25 mM HCl at 599 µM and was
incubated at 60 ˚C for 2 days under quiescent conditions. Synthetic Aβ40 (peptide 2.0,
Chantilly, VA) was solubilized in DMSO at 50 mg/mL. After sonicating the peptide for 5
minutes with the 550T Ultrasonic Cleaner (VWR International, Radnor, PA) and removing
any insoluble particle by centrifugation at 14,000 g for 15min, Aβ40 was diluted in 40 mM
Tris pH 8.0 buffer containing 150 mM NaCl and 0.01 % w/v sodium azide. The protein was
then incubated at 37 ˚C for 23 days under quiescent conditions to ensure protein fibrillation.
Two tau hexapeptide
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VQIVYK311 (PHF6) were synthesized by a solid-phase method as

previously described101: N-terminus acetylated PHF6 (Ac-PHF6) which is prone to fibrillation
and non-acetylated PHF6 (NH3+-PHF6) known to remain monomeric during incubation101.
Peptides were purified by reverse phase HPLC (RP-HPLC) using an acetonitrile-water gradient
containing 0.1% TFA. Lyophilized peptides were solubilized in MilliQ water to reach 3
mg/mL. The exact peptide concentration was determined by using absorbance at 280 nm and
the coefficient of extinction (ɛ280nm = 1195.9 cm-1M-1 117 MWAc-PHF6 = 790 g/mol, MWNH3+PHF6

= 748 g/mol). NH3+-PHF6 was stored in -70˚C until use, while Ac-PHF6 was incubated

at 75 ˚C for 5 days to form fibrils.
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Aβ protein misfolding cyclic amplification (Aβ-PMCA) assay
Aβ40 monomers aggregate-free solution was prepared by solubilizing the peptide at 50 mg/mL
in DMSO following by sonication for 1 minutes and centrifugation at 14,000 g for 15 min. The
supernatant was stored at -70˚C until use. Solution of 50 µM Aβ40 monomers was prepared
in 50 mM PB and 100 mM NaCl. Aβ40 monomers were either incubated alone or in the
presence of 2.6 µM Aβ40 protofibrils or in CSF aliquots at 37 ˚C for up to 6 days. Aβ40
protofibrils were prepared through sonication of mature fibrils for 10 minutes with the 550T
Ultrasonic Cleaner (VWR International, Radnor, PA). These mature fibrils were initially
produced after 23 days of incubation of 100 µM Aβ40 monomers at 37 ˚C in 50 mM PB and
100 mM NaCl.
Fluorescence measurement
Thioflavin T (ThT), OPE12- and OPE24+ were solubilized in MilliQ water at concentration
between 100-250 µM. Dyes concentration were determined from their extinction coefficients
(MWThT: 318.85 g/mol and ɛThT412nm in water: 3.6 x 104 M−1cm−1, 43; MWOPE12-: 724.79 g/mol
and ɛ OPE12-370 nm in water (3.92 ± 0.013) x 104 M−1.cm−1 181; MWOPE24+: 1002.64 g/mol and
ɛ OPE24+378nm in water (8.29 ± 0.033) x 104 M−1.cm−1 181). All dyes were sonicated before use
with the 550T Ultrasonic Cleaner (VWR International, Radnor, PA) 4 times for 15 seconds to
breakdown any aggregates. OPE and ThT fluorescence spectra were recorded in a quartz
cuvette (Starna cells Inc., Atascadero, CA) with the PTI QuantaMaster 40 steady state
spectrofluorometer (HORIBA Scientific, Edison, NJ) at concentration between 100 nM and 1
µM for OPE or between 1 to 20 µM for ThT, in the presence of biological samples (amyloid
proteins, bovine serum albumin, glucose, PBS and CSF). After 30 minutes of incubation at
room temperature the emission spectra were recorded at the excitation wavelengths 390, 410
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and 440 nm for OPE12-, OPE24+ and ThT, respectively. The excitation spectra were recorded at
the emission wavelengths of 450, 460 and 480 nm for OPE12-, OPE24+ and ThT, respectively.
Each fluorescence measurement was done in duplicate.
Binding constant
OPE’s dissociation constant (kd) to protein was determined from a constant protein
concentration binding assay211. Briefly, OPE’s fluorescence was recorded at concentration
between 0 - 2 µM in the presence of 21 µg/mL of protein. The integrated emission area of OPE
was calculated and was background subtracted with the corresponding OPE emission spectrum
recorded in 10 mM phosphate buffer (PB). The dissociation constant was determined from the
plot of emission integrated area versus sensor concentration. Kd were extracted from data
fitting to a nonlinear regression curve assuming site specific binding and using a Hill
coefficient (h) to account for any binding cooperativity.
Limit of detection
Limit of detection was defined as being the smallest protein concentration that can be detected
by OPE with high certainty and was calculated as previously described (Equation 3)220. LOD
was determined as being three-time OPE’s background standard deviation. The corresponding
protein concentration was determined using the slope of the fluorescence signal vs.
concentration correlation
𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑳𝑶𝑫 =

𝟑𝝈
𝑺

(3)

where σ is the standard deviation of the dye alone (blank) and S is the slope of the signal vs.
concentration correlation220.
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TEM imaging
Amyloid aggregates were imaged by transmission electron microscopy. The proteins were
diluted at 21 µg/mL in MilliQ water and were loaded onto a glow discharge grid. After letting
the protein adsorb on the grid for 5 minutes, the excess of protein was wicked away and then
the grid was stained using 2% uranyl acetate through four consecutive staining steps. The first
one consisted in applying the stain for 3 min and the three last staining steps consisted in
applying uranyl acetate for 1 min only. Between each staining step, the excess of stain was
wicked away. After the last staining step, the grid was air dried for 30 minutes before imaging
with the HITACHI HT7700 transmission electron microscope (Hitachi High Technologies
Corp., Tokyo, Japan).
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6.8 Supplementary Information

Figure S1: Binding assay profiles of OPE12- (A) and OPE24+ (B) to six proteins present at 21
µg/mL (insulin fibrils, lysozyme fibrils, Aβ40 fibrils, PHF6 fibrils, hTau oligomers and BSA).
These saturation binding assay curves were obtained by fitting the data to a nonlinear
regression assuming site specific binding with binding cooperativity on OriginPro 9.
Experiments were performed in duplicates and error bars represent standard deviations. The
maximum specific binding (Bmax), the Hill coefficient (h), the dissociation constant (Kd) and
the R2 values are summarized in the table (C). OPE has been shown to form superluminescence complexes at concentration above 10 µM leading to fluorescence red-shift and
peak sharpening. To isolate OPE/fibrils binding from OPE complexation, the binding assay
was performed at OPE concentration bellow 2 µM.
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Figure S2: Linear correlations between fluorescence integrated area of OPE12- (A) and OPE24+
(B) (1 µM) versus protein concentration. Seven proteins were tested: insulin fibrils, lysozyme
fibrils, PHF6 fibrils, hTau oligomers, Aβ40 fibrils, Aβ40 monomers, and BSA. Aβ40
monomers was only tested with OPE24+. Data were fitted to a linear fit on OriginPro. The
intercept and slopes values are summarized in the table below.
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Figure S3: ThT fluorescence in the presence of a mixture of fibrils. (A) 21 µg/mL Aβ40 fibrils
and 21 µg/mL PHF6 fibrils. (B.) 21 µg/mL Aβ40 fibrils and 90 µg/mL PHF6 fibrils. (C.) 21
µg/mL Aβ40 fibrils and 21 µg/mL insulin fibrils. ThT fluorescence was analyzed for the sensor
alone (black), in the presence of Aβ40 fibrils (blue), PHF6 fibrils (red), insulin fibrils (orange),
both Aβ40 and PHF6 fibrils (green), both Aβ40 and insulin fibrils (purple). The excitation (dot
line) and emission (solid line) were recorded for both sensors. The additive fluorescence in the
presence of both fibrils was determined by calculating the following ratio (~ 1 meaning perfect
additive fluorescence):
𝐹
+ 𝐹𝑃𝐻𝐹6𝑓:𝑂𝑃𝐸
Condition A: ThT 𝐴𝛽𝑓:𝑂𝑃𝐸
= 0.73
𝐹
(𝐴𝛽𝑓+𝑃𝐻𝐹6𝑓):𝑂𝑃𝐸

Condition B: ThT
Condition C: ThT

𝐹𝐴𝛽𝑓:𝑂𝑃𝐸 + 𝐹𝑃𝐻𝐹6𝑓:𝑂𝑃𝐸

= 1.06

𝐹(𝐴𝛽𝑓+𝑃𝐻𝐹6𝑓):𝑂𝑃𝐸
𝐹𝐴𝛽𝑓:𝑂𝑃𝐸 + 𝐹𝐼𝑛𝑠𝑓:𝑂𝑃𝐸
RP-HPLC:
𝐹(𝐴𝛽𝑓+𝐼𝑛𝑠𝑓):𝑂𝑃𝐸
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Figure S4: Reverse phase chromatogram of healthy CSF. 100 µL CSF were centrifuged (15
min at 14,000 rpm) to remove insoluble species and the supernatant was injected into the
Eclipse XDB C18 column (Agilent Technology, Santa Clara, CA) pre-equilibrated at 40 ˚C
with 95% of mobile phase A (water containing 0.1% TFA) and 5% of mobile phase B
(acetonitrile containing 0.1% TFA). The proteins were eluted using a 5-100% linear gradient
of mobile phase B over 40 min. The absorbance at 215 nm was monitored. The main protein
peak was eluted at around 55% of mobile phase B.
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Figure S5: OPE12- fluorescence (A) and absorbance (B) spectra in the presence of DMEM F12
media and Aβ fibrils. DMEM F12 media is composed of 15 mM HEPES, 0.055 g/L sodium
pyruvate 3.15 g/L glucose, unknown concentration of sodium bicarbonate and phenol red used
as a pH indicator. OPE12- spectroscopic change was analyzed in the presence of DMEM F12
media. (A) OPE12- emission recorded at 1 µM in 100% and 50% media reached an intensity of
around 25x103 counts/sec similarly to the fluorescence generated in the presence of 21 µg/mL
Aβ fibrils (5 µM). OPE1- emission spectrum recorded in the presence of media also present a
new spectral signature with a sharp peak at around 440 nm and a shoulder at around 470 nm.
This spectral signature indicates the formation of stable OPE complexed likely made of Jaggregates. (B) OPE12- absorbance spectrum in the presence of media was characterized by a
drastic right shift and sharpening also supporting the formation of J-aggregates.

Figure S6: OPE12-, OPE24+ and ThT emission integrated area recorded at 100 nM in PB (A)
and CSF (B) spiked with amyloid proteins at 21 µg/mL. Asterisks indicate significant
differences with the sensor alone in buffer (PB or CSF) (t-test with a p-value ≤ 0.01).
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Figure S7: Thioflavin T background fluorescence spectra in PB, CSF, and in the presence of
A40 fibrils. Excitation and emission spectra of a 100 nM, 1 µM, and 20 M Thioflavin T in
PB (A) and CSF (C). (B) and (D)Fluorescence excitation and emission spectra of 100 nM ThT
(blue) in PB and CSF solution compared to fluorescence spectra of spiked solutions with 21
µg/mL of Aβ40 in vitro fibrils. (red lines).
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Figure S8: OPE12-, OPE24+ and ThT emission integrated area and detection factor in the
presence of CSF samples isolated from healthy patients or patients with dementia. Top:
Integrated emission intensity of OPEs and ThT displayed as a bar graphs. Grey bar represents
the dye (100 nM) in phosphate buffer, the black bar is the dye (100 nM) in purchased healthy
CSF. The red, green, and yellow bars are the sensors in CSF from dementia diagnosed patients,
labor and delivery controls, and age matched non-dementia diagnosed patients, respectively.
Bottom: The protein detection factor (PDF) of OPEs and ThT in CSF samples isolated from
healthy or demented patients. The red dashed-line representing the PDF value of 1 used as a
threshold to determine positive detection.

159

Figure S9: OPE12-(A) and OPE24+(B) fluorescence at 100 nM in CSF samples diluted 10-fold
in water. Three CSF samples were tested: CSF from L&D controls, CSF age-matched controls
and CSF from patients diagnosed with dementia. Both the excitation (dashed line) and
emission (solid line) spectra are reported.
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Figure S10: Seeding potency of Aβ40 sonicated fibrils and CSF evaluation through ThT (A),
OPE12- (B) and OPE24+(C) fluorescence recorded at day 0 and after 1 and 6 days of incubation
at 37 ˚C.
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7.1 Abstract
Photodynamic therapy (PDT) is an attractive strategy to clear toxic amyloid aggregates
involved in Alzheimer’s disease. One limitation of such a strategy is off-target oxidation which
can be lethal for the surrounding cells. We have recently shown that a fluorescent oligo-pphenylene ethynylene-based sensor (OPE) selectively detects pre-fibrillar and fibrillar
aggregates made of disease-relevant proteins such as amyloid-β and α-synuclein. We also
demonstrated that the same sensor photosensitizes singlet oxygen species under illumination
once bound to a scaffold through the generation of triplet state. The selective sensing and the
controllable generation of singlet oxygens make OPE a promising photosensitizer for the
selective photo-oxidation of toxic amyloid aggregates. In this paper we characterized OPE’s
selective photosensitizing activity and compared that to the well-known photosensitizer
methylene blue (MB). Results show that while MB non-selectively photo-oxidized both
monomeric and fibrillar conformations of Aβ40, OPE oxidized only Aβ40 fibrils. We further
identified that two histidine residues on the Aβ40 fibril surface and a methionine residue
located in the fibril core are oxidized by the OPE. Aβ40 fibril oxidation caused their
disassembly into shorter β-sheets rich fibrils that display low cell toxicity and could potentially
be cleared by endogenous cellular pathways. The investigation of OPE as a selective Aβ
aggregate photo-oxidizer with minimal off-target oxidation will contribute toward the
development of PDT as a viable strategy to treat neurodegenerative disorders.

Keywords: Alzheimer’s disease, amyloid aggregates, oligo-p-phenylene ethylene, photooxidation, fibrils disassembly
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7.2 Introduction
The deposition of amyloid plaques made of the amyloid-β (Aβ) peptide is one of the hallmarks
of Alzheimer’s disease229, 230. The deposition of Aβ is driven by its abnormal misfolding and
aggregation into small oligomers that subsequently grow into large fibrils6-8, 213. The oligomers,
which are transient and heterogeneous in nature, are known to be more toxic than the mature
fibrils. Mechanism of their toxicity is still unclear but their interactions with cell membrane
that lead to membrane destabilization and pore formation have been proposed to cause cell
apoptosis9, 21, 22. Aβ fibrils also play a role in neurodegeneration through impairment in axonal
transport25, 26 or by inducing the aggregation of tau protein and seeding the formation of
neurofibrillary tangle254. Additionally, amyloid aggregates are also involved in the rapid and
predictable spatiotemporal disease progression through their cell-to-cell transmissibility34, 255,
256

. The role of amyloid aggregates in neurodegenerative impairment make their selective

degradation and clearance an attractive therapeutic approach.
Therapeutic strategies targeting amyloid aggregates are currently being investigated,
including the use of enzymes (neprilysin 257, insulin-degrading enzyme 258, 259 and endothelinconverting enzyme 260, 261) or anti-Aβ immunotherapy that stimulates an immune response to
produce antibodies against Aβ plaques262. These approaches have several limitations including
the non-selective degradation of the native protein which is believed to have important
physiological functions263, 264.
Photodynamic therapy (PDT) is a strategy currently used in oncology76,

265

and

dermatology74 through the oxidation of biological molecules, including proteins, lipids and
amino acids, that subsequently leads to cell death266. In PDT, a photosensitizer is used to
generate

singlet

oxygens

1

O2

(photosensitization

164

type

II)

and/or

free

radicals

(photosensitization type I) upon light exposure through energy transfer from an excited triplet
state267. Several photosensitizers have already been investigated for the photo-oxidation of Aβ
such as riboflavin,67 rose bengal,78 water-soluble porphyrin molecules,79 flavin-based
catalysts67, 68 and methylene blue (MB)69. These studies showed that photo-oxidation of Aβ
monomers inhibits fibrillization67, 78, 79 and that photo-oxidized fibrils disassemble into shorter
structures displaying lower cell toxicity68. MB is one of the main photosensitizers already
approved by the FDA in oncology80, 268 and has been investigated for photo-oxidation of Aβ
plaques both in vitro and in vivo69. However, MB has an important drawback due to its nonselective binding to negatively charged substrates such as proteins, lipids or nucleic acids

80

that could lead to non-selective oxidation of cellular organelles causing cell apoptosis. The risk
of off-target oxidation highlights the need to develop new photosensitizer compounds that are
highly selective toward the aggregated conformation of proteins over their native conformers.
We recently showed that a class of novel oligomeric p-phenylene ethynylene
compounds (OPEs) selectively bind to and detect β-sheet rich amyloid fibrils81, 82, 220. The small
and negatively charged OPE12- (Table 7-1) characterized by one repeat unit with carboxyethyl
ester end groups and sulfonate terminated side chains detects fibrils made of two model
amyloid proteins, insulin and lysozyme,

81, 82

and two disease-relevant proteins, Aβ and α-

synuclein220. More importantly, OPE12- was also capable of selectively detecting the more
toxic, pre-fibrillar aggregates of Aβ42 and α-synuclein220. OPE’s superior sensor performance
compared to that of the commonly used thioflavin T dye could be attributed to its high
sensitivity to fluorescence quenching where the conjugated sensor is quenched in an aqueous
solvent and binding to amyloid aggregates reverses quenching and leads to fluorescence
recovery or turn-on83,

178, 181, 182

. The ability to detect a wilder set of protein aggregate
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conformations stems from the combination of modes that leads to fluorescence turn-on of the
OPEs, including hydrophobic unquenching, backbone planarization, and OPE complexation
upon binding to amyloid aggregates81, 82, 87, 181.
In addition to sensing, we recently showed that fluorescence recovery of OPE12- from
binding to cationic detergent cetyltrimethylammonium bromide (CTAB) is accompanied by
the generation of the triplet state which subsequently photosensitizes singlet oxygens87.
Importantly, as the quenched, or unbound state, of OPE12- does not have photosensitizing
activity, both fluorescence and photosensitizing properties of the compound are controllable,
which makes this probe highly promising as a selective and controllable photosensitizer.
In this study, we evaluated the potential of OPE12- as a controllable photosensitizer for
the selective photo-oxidization of Aβ fibrils over its monomeric counterpart. The well-known,
but non-selective, photosensitizer methylene blue (MB) was also studied and compared to
OPE12-. Oxidation of both Aβ monomers and fibrils with light exposure in the presence of
OPE12- or MB was investigated. Oxidized amino acids on Aβ fibrils were identified, and the
effect of fibril oxidation on fibril morphology, secondary structures, and cell toxicity were
evaluated.
Table 7-1: Structures of OPE12- and methylene blue (MB)
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7.3 Results
Developing a photosensitizer for the selective oxidation of Aβ40 aggregates over the
monomeric conformer is essential to avoid off-target oxidation which could cause side effects
in a biological environment. In this study, we evaluated OPE12- as a selective photo-oxidizer
and compared it the well-known photosensitizer MB.

Spectroscopic features of OPE12- and MB in the presence of Aβ40 monomers
and fibrils
We have previously shown that the photosensitization activity of OPE12- is activated by its
fluorescence turn-on through complexation with oppositely charged detergent molecules87. In
this study, we first evaluated absorbance and fluorescence spectral signatures of both OPE12and MB in the presence of monomeric and fibrillar Aβ40.
Aβ40 fibrils were produced by incubating the monomeric peptide at 150 µM in pH 8.0
Tris buffer at 37 ˚C over 23 days. At pH 8.0, Aβ40 peptide is negatively charged with a net
charge of -4.465. The unincubated Aβ does not present any features on TEM images as shown
Figure 7-2A indicating that the peptide is most likely monomeric, while incubated peptide
formed large cluster of fibrils (Figure 7-2B). These fibrils were previously described to be rich
in β-sheet while the monomeric counterpart is mainly composed of random coil220.

Figure 7-2: TEM images of Aβ monomers (A) and fibrils (B). Freshly solubilized Aβ
monomers do not present any feature on TEM images while after 23 days of incubation Aβ
formed large cluster of fibrils.
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OPE12- and MB absorbance and emission spectra were analyzed in the presence of
different concentrations of Aβ40 monomers and fibrils (Figure 7-3A1-A2 and B1-B2). OPE12absorbance spectrum is characterized by two main peaks at 316 nm and 368 nm. In the presence
of Aβ monomers and fibrils, OPE12- absorbance spectrum was unchanged in terms of peak
position and intensity, as previously described (Figure 7-3A)220. MB absorbance spectrum
characterized by one main peak at 663 nm increased by 14-22% in the presence of both Aβ
monomers and fibrils, but its shape and position stayed unchanged.
OPE12- and MB fluorescence was also characterized (Figure 7-3 A3, A4, B3 and B4).
At 1µM, OPE12- is quenched in water and in the presence of Aβ40 monomers between 1 to 5
µM no significant change in emission intensity was observed (Figure 7-3 A3). In the presence
of fibrillar Aβ40, OPE12- emission increased and blue shifted with fibrils concentration (Figure
7-3 A4) as previously described191, 220. This fluorescence enhancement can be attributed to
hydrophobic unquenching, backbone planarization and/or OPE12- complexation leading to the
formation of J-dimers181,

269-271

. These results indicate that OPE12- display a selective

fluorescence turn-on upon binding to Aβ fibrils which can be used to track the formation of
aggregates. MB is also a fluorescent molecule characterized by an emission peak center at 685
nm. In the presence of both monomeric and fibrillar Aβ, MB emission enhanced by 30-50%
which could be induced by its interaction to the negatively charge Aβ peptide causing MB
planarization and so preventing non-radiative relaxation decay of the photo-excited MB69, 272.
This observation indicates that MB interacts similarly to both Aβ conformations.
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Figure 7-3: Absorbance (1 and 2) and fluorescence emission spectra (2 and 3) of OPE12- (A)
and MB (B) at 1 µM in the presence of varying concentrations of Aβ40 monomers or fibrils
(0, 1, 3 and 5 µM). OPE12- displays a selective fluorescence turn-on in the presence of Aβ40
fibrils which is proportional to the peptide concentration. MB exhibits a weak fluorescence
turn-on for both monomeric and fibrillar Aβ40.
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DNPH dot blot of Aβ40 oxidation
To evaluate the potency of OPE12- to selectively photo-oxidize Aβ40 fibrils over the
monomeric counterpart, the oxidation state of both Aβ40 conformations irradiated in the
presence of OPE12- were characterized and compared to MB. This study consisted in
monitoring the carbonyl content of the protein by DNPH dot blot, which increases as a result
of protein photo-oxidation273. DNPH dot blot was carried out on Aβ40 fibrils and monomers
incubated at 5 µM in the dark and under irradiation between 0 to 6 hours in the absence or
presence of a photosensitizer at 1 µM (Figure 7-4). Aβ40 monomers and fibrils do not display
any change in the carbonyl content after exposition to light in the absence of photosensitizer
(Figure 7-4B, columns 1 and 2). DNPH dot blot of Aβ40 fibrils is slightly darker compare to
Aβ40 monomers (Figure 7-4B, columns 1 and 2, incubation time 0 hour). This difference
could be attributed to a minor oxidation of the fibrils during the 23 days of incubation at 37 ˚C
necessary to produce fibrils, or could be due to non-specific binding of DNPH to the dense and
sticky fibrils. In the presence of both photosensitizers and under light irradiation, Aβ40 fibrils
are characterized by a large increase in the carbonyl content (Figure 7-4B, column 5 and 8).
When Aβ40 fibrils samples were incubated in the dark, no change was observed (Figure 7-4A
column 5 and 8), indicating that both OPE12- and MB are light-controllable photo-oxidizers.
Additionally, when Aβ40 monomers were irradiated in the presence of MB, a slight increase
in carbonyl content were observed (Figure 7-4B, column 7) which might indicate that MB
oxidized both Aβ40 conformations.
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Figure 7-4: Results from DNPH dot blot assay of Aβ40 monomers and fibrils (5 µM) in the
presence of OPE12- or MB (1 µM) at different irradiation times. The presence of a dark dot
indicates higher carbonyl content. At time 0-hour Aβ fibrils incubated with MB (column B8)
present higher carbonyl content than the same protein incubated alone (column B2) which
could be due to short light exposure during membrane preparation causing MB
photosensitizing activity turn-on.

Mass spectrometry characterization of Aβ40 oxidation
To further characterize the oxidation of Aβ40 monomers and fibrils by OPE12- and MB, both
peptide conformations were analyzed by electrospray ionization mass spectrometry (ESI-MS).
Figure 7-5 shows ESI-MS chromatograms of Aβ40 monomer (25 µM) before and after
irradiation in the presence of OPE12- and MB (1 µM). The analysis of Aβ40 monomers before
irradiation (Figure 7-5A) showed the presence of a peptide with a mass to charge ratio (m/z)
of 1082 corresponding to the protonated Aβ40 (+ 4 protons). The ESI-MS analysis of Aβ40
monomer obtained after irradiation in the presence of OPE12- was similar to the one generated
from the native Aβ40 monomer (Figure 7-5C), which indicates that the light treatment in the
presence of OPE12- did not induce any change in the protein. In contrast, in the presence of
MB, m/z peaks were right shifted (Figure 7-5B) showing an increase in the overall mass of
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the monomeric peptide. Several oxidized Aβ40 monomer species were produced after light
treatment with MB which was also confirmed by revers phase HPLC (Figure S1) where the
oxidized peptide was eluted earlier in a broad peak revealing the presence of a mixture of more
hydrophilic peptides. The oxidation of monomeric Aβ by MB is also supported by a previous
study69.

Figure 7-5: Mass spectrometry chromatogram of 25 µM Aβ40 monomers non-irradiated (A)
and 25 µM Aβ40 monomers irradiated for 4 hours in the presence of 1 µM of MB (B) or OPE12(C). Non-irradiated Aβ40 monomer is characterized by a m/z peak at 1082.80 corresponding
to Aβ40 with 4 protonation. Similar profile was observed after irradiation in the presence of
OPE12- indicating that OPE did not oxidize the monomeric peptide. After irradiation of Aβ40
in the presence of MB, a mixture of oxidized monomers appeared.
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The oxidation of Aβ40 fibrils by both photosensitizers was also characterized by ESIMS. Fibrils were digested with the Endoproteinase LysC (Figure 7-6A) and Aβ29-40 fragment
was analyzed. After irradiating 25 µM Aβ40 fibrils in the presence of MB at 1 µM, Aβ29-40
peak shifted by 16 Da (Figure 7-6C) indicating the addition of an oxygen. The only amino
acid that can be photo-oxidized in this fragment is Met35 suggesting that this amino acid was
oxidized into a methionine sulfoxide, as previously described68. After treatment with OPE12-,
similar changes in Aβ29-40 m/z were observed, however the non-oxidized population was still
present in the sample (Figure 7-6D) showing that OPE12- only partially oxidized Met35.
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Figure 7-6: Cleavage sites of Endoproteinase LysC in Aβ40 peptide (A) and ESI mass
spectrometry chromatograms of Aβ29-40 fragment generated after fibrils incubation at 25 µM
in the dark (B) and after 4 hours irradiation in the presence of 1 µM MB (C) or OPE12- (D).

Amino acid analysis of oxidized Aβ40
Amino acid analysis (AAA) was also carried out on both Aβ40 monomers and fibrils after light
exposition in the presence of MB or OPE12- (Figure 7-7). OPE12- was previously shown to not
oxidize Aβ40 monomers by ESI-MS (Figure 7-5), for this reason only Aβ40 monomer
irradiated in the presence of MB was analyzed (Figure 7-7A). Aβ40 fibrils generated before
and after irradiation in the presence of both OPE12- and MB (Figure 7-7B) were also
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characterized. Before AAA, Aβ40 peptides were hydrolyzed with 6 N HCl. This treatment is
known to destroy partially Met which affect the accuracy of this analysis274. For this reason,
no conclusion was made regarding the effect of MB and OPE12- on methionine content.
The amino acid analysis shows that after exposing Aβ40 monomers and fibrils to
irradiation in the presence of MB, the histidine content was reduced from 3 to 1 (Figure 7-7A
and B). Interestingly, Tyrosine content was partially reduced in Aβ40 monomers which is
supported by the ESI-MS analysis (Figure 7-5) but stayed unchanged in Aβ40 fibrils after light
treatment in the presence of MB. Aβ40 fibrils irradiated in the presence of both OPE12- and
MB (Figure 7-7B) were characterized by a reduction in His content and no change in Tyr
content. With support of ESI-MS results previously described, two histidine, one tyrosine and
one methionine were oxidized in Aβ40 monomers by MB and but only two histidine and one
methionine were oxidized in Aβ40 fibrils by both MB and OPE12-.
The different oxidation pattern observed in monomeric and fibrillar Aβ40 after light
treatment with MB might be explained by a difference in the Tyr environment which can be
attributed to the three-dimensional structural conformation of Aβ275. The importance of protein
secondary structure for Tyr oxidation was previously described in the case of insulin in which
Tyr was found non-oxidized in the native form of the protein (hexamer) but was oxidized when
insulin was denatured in 8 M urea276.

175

Figure 7-7: Amino acid analysis of 25 µM Aβ40 monomers (A) and fibrils (B) before and
after 4 hours irradiation in the presence of 5 µM of MB or OPE12-. Amino acid content was
determined by normalizing the raw data with the signal generated for phenylalanine knowing
that 3 phenylalanine are present in the protein. The x axis describes the type and number of
amino acids expected in Aβ40 peptide. Glutamic acid and glutamine could not be differentiated
during this analysis and so they appear as Glx. Similarly, aspartic acid and asparagine appear
as Asx. Ile content appear to be lower than expected (around 1.2 instead of 2), which might be
explained by the poor hydrolysis of the bound Ile-Ile. Red arrows indicate the three amino
acids that can be photo-oxidized (Tyr, Met and His). Methionine is partially destroyed during
hydrolysis which prevented any conclusion on the effect of MB and OPE12- on Met content.

Molecular dynamics analysis of OPE12- binding pockets on Aβ40 protofibrils
The localization of the photo-oxidizable amino acids within the Aβ40 peptide and the position
of OPE12- binding pockets on the Aβ40 protofibrils is essential to understand the photooxidation pattern of this photosensitizer.
Protofibril structure made of 24 Aβ9-40 peptides was obtained from the 2LMN188
protein databank (PDB) file (Figure 7-8A). The first 8 amino acids formed a disordered region,
that is why they are not represented in this structure. The structure of a single Aβ9-40 monomer
hairpin was extracted from the protofibril PDB structure after energy minimization and
equilibration for 100 ns (Figure 7-8B). This screen shot is a representation of the intrinsically
disorder monomers.
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Aβ contains 5 amino acids that can be photo-oxidized: His6, His13, His14, Tyr10 and
Met35 (Figure 7-8). The localization of these amino acids within Aβ monomer and protofibril
are shown Figure 7-8B and Figure 7-8C, respectively. All 5 amino acids are freely exposed
to the solvent when the protein is monomeric. In the protofibril, Met35 is buried inside the βsheet core while His13, His14 and Tyr10 are localized at the surface of the protofibrils and
His6 is in the disordered N-terminal fragment (not represented on this structure).
OPE12- binding pockets on the Aβ40 protofibril were analyzed by molecular dynamics
with 12 OPE molecules. 11 out of 12 OPE molecules bound to the protofibrils either as single
molecule (pocket # 1, 4 and 5) or as a complex (pockets # 2, 3 and 6) (Figure 7-9A). More
specifically six binding pockets were identified, three of them were located on the β-sheet (#2,
3 and 6; Figure 7-9B and C), one was located on the β-turn (#5; Figure 7-9D) and the last
two were at the end of the protofibrils (#1 and 4; Figure 7-9B and E). Tyrosine and histidine
were located within 4 Å of OPE12- in the case of four binding pockets (#2, 3, 5 and 6) which
make them highly susceptible for oxidation by singlet oxygen species which are highly reactive
and can diffuse through 100-200 Å in a biological system75, 76, 277. In contrast, Methionine was
buried inside the core of the fibrils which makes it less accessible to singlet oxygen species as
the environment of the amino acids play an important role in the efficiency of the photooxidation278. OPE12- cluster located in the binding pocket #4 (extremity of the protofibrils) was
the closest to Met35 within a distance of 5.6 Å. The other OPE12- clusters were further away
from Methionine (between 19.8 – 41.6 Å) which might explain the partial oxidation of Met35
by OPE12- previously observed.
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Figure 7-8: Localization of the oxidizable amino acids in Aβ40 sequence (A), and their special
localization within the monomeric (B) and protofibrillar (C) peptide. Methionine is indicated
in yellow, Tyrosine is in green and Histidine is blue.

Figure 7-9: OPE12- binding pocket in Aβ protofibrils (A). B, C, D and E show different
zoom-in of the 6 binding pockets. A binding pocket might correspond to the interaction of a
single OPE or a cluster of OPE. Methionine is indicated in yellow, Tyrosine is in green and
Histidine is blue.

Effect of oxidation on Aβ40 fibril morphology and secondary structure
The effect of fibrils oxidation on their morphology and secondary structure was characterized
by TEM imaging and circular dichroism (CD) spectroscopy, respectively. As showed Figure
7-10A, untreated Aβ40 fibrils were long and formed large clusters. After irradiation in the
absence of photosensitizer, the fibril clusters appeared smaller but were still present (Figure
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7-10B). When the fibrils were irradiated with either MB or OPE12- they broke down into shorter
protofibrils (Figure 7-10C and D).
Fibrils secondary structure was also analyzed. Aβ40 fibrils had a secondary structure
rich in β-sheet with a positive and negative CD peaks at 192 nm and 215 nm, respectively, and
was not affected by irradiation in the absence of sensitizer (Figure 7-10E). After irradiation in
the presence of OPE12- or MB (Figure 7-10G and H), no change in the secondary was
observed. Overall, these results indicate that photo-oxidation promotes fibrils breakdown but
does not alter their secondary structure.

Figure 7-10: TEM images (A-D) and circular dichroism spectroscopy (E-G) of Aβ40 fibrils
irradiated in the absence and presence of a photosensitizer. A-D: TEM images of 5 µM Aβ40
fibrils incubated in the absence or presence of 1 µM MB or OPE12- were taken before (A) after
4 hours of irradiation in the absence and presence of MB or OPE12- (B, C and D). E-G: CD
spectra were recorded from 50 µM Aβ fibrils incubated in the absence or presence of 10 µM
MB or OPE12- overtime during light exposition.
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Cell toxicity of oxidized Aβ40 fibrils
We have shown that both OPE12- and MB oxidize Aβ40 fibrils to produce short oxidized
protofibrils rich in β-sheet. It is essential to investigate OPE12- and MB intrinsic cell toxicity
as well as oxidized fibrils neurotoxicity.
OPE12- and MB cell toxicity was evaluated at different concentrations (between 1-10
µM). SHSY-5Y neuroblastoma cells were exposed to dark or light for 5 min in the presence of
both photosensitizers before being incubated at 37˚C, 5% CO2 for 24 hours. After incubation,
cell viability was monitored by MTS assay. As shown Figure 7-11A, cells alone were not
affected by the light treatment. In the presence of both MB and OPE12- and after dark treatment,
cell viability was close to 100% showing that both compounds are not cytotoxic after 24 hours
of incubation at concentration as high as 10 µM. After exposition to light in the presence of
MB at concentration higher than 5 µM, cell viability was lower than the 70% threshold
generally considered for cytotoxicity111 and the cell viability was significantly different
compared to the dark condition (p-value ≤ 0.01). In contrast, the presence of OPE12- did not
affect cell viability even after light treatment. These results indicate that MB is not toxic when
kept in the dark but become cytotoxic when exposed to light at concentration higher than 5 µM
which can be associated to the generation of singlet oxygen species. OPE12- is a more
controllable photosensitizer as no toxicity was observed when OPE12- was exposed to light in
the presence of neuroblastoma cells.
The effect of photo-oxidation on Aβ40 fibrils cell toxicity was also investigated
(Figure 7-11B). Fibrils were incubated at 50 µM in the dark or under irradiation for 4 hours in
10 mM PB pH 7.4 in the absence and presence of 10 µM OPE12- or MB. After light treatment,
fibrils were added to the cells to reach 20 µM and were incubated for 48 hours at 37 ˚C, 5%
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CO2 before monitoring cell viability by MTS assay. In the presence of 4 µM MB, cell viability
decreased to 20% in both light and dark conditions, which indicates that after a long incubation
of 48 hours MB became cytotoxic which was not observed after 24 hours treatment (Figure
7-11A). MB cell toxicity might be associated to the generation of singlet oxygen species when
the samples were exposed to sun light during cell preparation which might be enough to active
the photosensitizing activity of MB. In contrast, the presence of 4 µM OPE12- (non-irradiated
and irradiated) did not cause any reduction in cell viability which confirms that OPE is not
cytotoxic even after 48 hours treatment. Aβ40 fibrils exposed to dark and light in the absence
of photosensitizer were not cytotoxic, however in the presence of irradiated fibrils the cell
viability standard deviation was larger (between 95-65%). This large variation might be caused
by the formation of cytotoxic protofibrils during the light treatment as the formation of shorter
fibrils were observed after irradiation (Figure 7-10). Cells exposed to oxidized fibrils with
OPE12- displayed similar viability compared to the non-irradiated fibrils indicating that the
shorter oxidized fibrils are not cytotoxic.

181

Figure 7-11: (A) OPE12- and MB cell toxicity after irradiating the cells for 5 min in the
presence of the varying concentration of photosensitizer and after 24 hours of incubation. (B)
Oxidized Aβ40 fibrils cell toxicity after 48 hours treatment. Cell viability was normalized to
the negative control, untreated cells. Error bars represent standard deviations of quintuplet
experiments. Red dashed line represents 70% viability threshold used to define cytotoxicity111.
Blue asterisks indicate significant differences between the dark and irradiated incubations (ttest with a p-value ≤ 0.01).

7.4 Discussion
OPE12- selectively and controllably photo-oxidizes Aβ40 fibrils over monomers
PDT is an attractive method to selectively photo-oxidize amyloid aggregates and promote their
disassembly and clearance to treat neurodegenerative disorders such as Alzheimer’s disease.
Photosensitizers used for such application need to be highly selective toward the amyloid
aggregates to avoid any off-target oxidation. In this study we evaluated the selective photooxidation of Aβ40 fibrils by a novel conjugated polyelectrolyte, OPE12-, and compared it the
well-known photosensitizer MB.
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DNPH dot-blot (Figure 7-4), ESI-MS (Figure 7-5 and Figure 7-6) and amino acid
analysis (Figure 7-7) were used to monitor the oxidation of both Aβ40 monomers and fibrils
when exposed to light in the presence of OPE12- or MB. DNPH dot-blot revealed that OPE12is a light-controllable photosensitizer oxidizing selectively Aβ40 fibrils over the monomeric
counterpart with minimal off-target oxidation. The selective oxidation of the fibrillar
conformation can be explained by the high binding affinity of OPE12- to the fibrils (kd: 0.70 ±
0.1 μM)220, and its low interaction to the monomeric counterpart as shown by no fluorescence
turn-on (Figure 7-3B). ESI-MS and amino acid analysis demonstrated that MB oxidized both
Aβ40 conformations under irradiation (Figure 7-5 and Figure 7-7A) which makes it less
controllable than OPE12-. The non-selective photo-oxidation of both Aβ monomers and fibrils
by MB can be attributed to its interaction to the negatively charged peptides under both
conformations as MB was previously described to interaction with monomeric Aβ42 with a
binding constant of 48.7 ± 3.6 μM69.

OPE12- photo-oxidizes His13, H14 and Met35 in Aβ40 fibrils
In Aβ40, five amino acids can be photo-oxidized: : 3 Histidine (His6, His13, His14), 1 Tyrosine
(Tyr10) and 1 Methionine (Met35)273. Amino acid analysis (Figure 7-7) and mass
spectrometry (Figure 7-6) showed that after light treatment in the presence of OPE12- and MB,
2 His and 1 Met were oxidized in Aβ40 fibrils. OPE12- only partially oxidized Met35 which
might be due to a lower singlet oxygen quantum yield (MB φΔ ~ 0.5) 80 and/or by the position
of Met35 in the core of the fibrils (Figure 7-8 and Figure 7-9) limiting its accessibility by
singlet oxygen species. To better understand the different photosensitizing activity of OPE12and MB, singlet oxygen quantum yield should be characterized by luminescence or
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photochemical methods with both photosentisitizers279. Interestingly, Tyr10 was not oxidized
by either molecule in the fibrils despite its close location to His13 and His14 which were both
oxidized. The low potency of tyrosine to be photo-oxidize can be explained by the lower rate
constant, K, for 1O2 quenching by Tyrosine compared to Histidine and Methionine (KHis = 4.6
x 10-7> KMet =1.3 x 10-7 > KTyr = 0.2-0.5 x 10-7 M-1.s-1)278, 280. The photo-oxidation of 2His and
1Met by OPE12- and MB is supported by previous studies describing Aβ40 fibrils photooxidation by a flavin-based catalyst and Iridium (III) Complex where His13, His 14 and Met35
were oxidized (Figure 7-12)281, 282.

Figure 7-12: Photo-oxidation sites on Aβ40 (A) and plausible products of oxidation (B)

OPE12- photo-sensitization disassembles Aβ fibrils into non-toxic protofibrils
Aβ40 fibrils are thermodynamic stable 283 which makes their degradation challenging. Photooxidation of Aβ40 fibrils reduces their overall hydrophobicity and could promote their
breakdown284. To better understand the effect of oxidation on fibrils morphology and
secondary structure, we analyzed them by TEM imaging and CD spectroscopy (Figure 7-10),
respectively. We showed that after being irradiated with either MB or OPE12-, Aβ40 fibrils
breakdown into short protofibrils rich in β-sheet. Fibrils disassembly might be caused by the
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oxidation of methionine located in the core of the fibrils, which could be involved in the
stabilization of the long fibrils284. As the protofibrils and oligomers are known to be more toxic
than fibrils, 9, 21, 22, 285 we evaluated cell toxicity of the oxidized protofibrils (Figure 7-11). We
observed that oxidized protofibrils do not display higher toxicity compared to untreated fibrils
indicating that using PDT to break down the fibrils will not generate more toxic species.
Overall, the disassembly of long fibrils into shorter oxidized structure by PDT is promising to
assure amyloid aggregates clearance.

7.5 Conclusion
In this study we investigated the selective photo-oxidation of Aβ40 fibrils over monomers by
OPE12- and compared it to MB. We showed that MB oxidizes non-selectively both Aβ
conformations while OPE12- selectively oxidizes Aβ fibrils. OPE12- photo-oxidizes fibrils at
the position His13, His14 and Met35 through the generation of 1O2 which causes fibrils
disassembly into short oxidized protofibrils characterized by low cell toxicity. OPE12- was
previously shown to also selectively interact with oligomeric and fibrillar aggregates made of
various disease-relevant proteins including Aβ and α-synuclein, which makes OPE12- ideal to
target a large range of toxic amyloid aggregates involved in neurodegenerative disorders.
Additionally, the selective interaction to pre-fibrillar aggregates makes OPE12- a potential
candidate for photo-oxidizing the most toxic species, oligomers, which could be used for early
treatment of neurodegenerative diseases before irreversible damages are observed in patients.
Finally, OPE12- selective detection of amyloid aggregates and photodynamic activity could
lead to the development of a novel theranostic agent.
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7.6 Experimental Methods
Material
Synthetic amyloid β-40 (Aβ40) was purchased from Peptide 2.0 (Chantilly, VA). Tris was
obtained from BioRad (Hercules, CA). Sodium chloride (NaCl), dimethyl sulfoxide (DMSO),
sodium azide, acetonitrile, methanol and hydrochloride acid (HCl) were acquired from EMD
Millipore (Burlington, MA). SH-SY5Y neuroblastoma cells, Dulbecco’s Modified Eagle’s
Medium (DMEM) F12 media, fetal bovine serum (FBS), 2,4-dinitrophenylhydrazine (DNPH),
Trifluoroacetic acid (TFA) and Tween® 20 were obtained from Sigma-Aldrich (St. Louis,
MO). Penicillin-streptomycin (PS) at 10,000 U/mL, AP Rabbit anti-Goat IgG (H+L) secondary
antibody and 1-Step NBT-BCIP substrate were purchased from Thermo Fisher (Waltham,
MA). The CellTiter 96® AQueous One Solution Cell Proliferation Assay was purchased form
Promega (Madison, WI). Goat anti-DNP primary antibody was acquired from Bethyl
(Montgomery, TX). OPE12- was synthesized and purified by previously published
procedures181. MB was purchased from Avantor (Radnor, PA). 400 mesh copper grids covered
by a Formvar/Carbon film (5-10 nm) were obtained from Ted Pella (Redding, CA) and 2%
aqueous uranyl acetate was purchased from Electron Microscopy Sciences (Hatfield, PA).
Aβ40 monomers and fibrils preparation
Lyophilized Aβ40 peptide was solubilized in DMSO at 50 mg/mL. After centrifugation at
14,000 rpm for 15 min, the supernatant was removed and stored in a -70 ˚C freezer. Monomeric
Aβ was diluted to 150 µM with a pH 8.0 40 mM Tris buffer containing 150 mM NaCl and
0.01% sodium azide, and incubated at 37 ˚C for 23 days to form fibrils220. Photo-oxidation of
both Aβ40 monomers and fibrils by either OPE12- or MB was performed by incubating the
peptides with the photosensitizer at a molar ratio 5 to 1 or 25 to 1. The mixtures were either
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kept in the dark or exposed to light in a photochamber (Luzchem Research Inc.) using 10 LZC
420 lamps (Osram Sylvania, Wilmington, MA) which emit UV light between 350 and 700 nm
at 8W per bulb.
Absorbance and fluorescence measurements
OPE12- and MB absorbance and emission spectra were recorded at 1 µM in the presence of
varying Aβ concentrations (0, 1, 3 and 5 µM) in pH 7.4 10 mM phosphate buffer (PB) after 30
minutes of incubation in the dark at room temperature. Absorbance spectra were obtained with
a Lambda 35 UV/VIS spectrometer (PerkinElmer, Waltham, MA) in a quartz cuvette
(PerkinElmer, Waltham, MA). Emission scans were obtained at excitation wavelengths of 390
nm and 660 nm for OPE12- and MB, respectively, and were recorded using a PTI QuantaMaster
40 steady state spectrofluorometer (HORIBA Scientific, Edison, NJ) in a quartz cuvette (Starna
cells Inc., Atascadero, CA).
DNPH dot blot
0.2 µm PVDF membrane (ThermoFisher, Waltham, MA) was soaked in 100% methanol for
15 seconds, then in water for 5 minutes, and finally in TPBS for 15 min. After incubating Aβ40
monomers or fibrils with the photosensitizer (5 µM protein with 1 µM photosensitizer) in the
dark or under illumination for up to 6 hours, samples were blotted onto the membrane (four
times 1 µL) and let dry for 15 minutes. DNPH derivatization of protein carbonyl groups was
carried out as previously described286. Briefly, the membrane was equilibrated in 2.5 N HCl
for 5 minutes before transferring to a 20 mM DNPH solution in 2.5 N HCl for 5 minutes.
Excess DNPH was then washed away with three 5 mL aliquots of 2.5 N HCl and then 5 mL
aliquots of 100% methanol. The membrane was then immuno-stained. The membrane was
immerged in the blocking buffer containing 5% nonfat dry milk in pH 7.4 phosphate buffered
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saline (PBS) with 0.1% Tween 20, for 24 hours at room temperature. The membrane was then
washed six times with the washing buffer made of Tween20-PBS buffer (5 min per wash)
before applying the goat anti-DNP primary antibody diluted at 1:10,000 in blocking buffer, for
2 h under agitation in the dark. The membrane was then washed six times with the washing
buffer before applying the rabbit anti-goat IgG secondary antibody, alkaline phosphatase (AP)
conjugate diluted at 1: 10,000 in blocking buffer, for 2 h under agitation in the dark. The
membrane was washed 3 time with the washing buffer and 3 time with PBS before revealing
the dot blot with the 1-Step NBT-BCIP substrate. Once the dots appeared, the membrane was
rinsed twice with distilled water for 2 minutes under agitation and was dried overnight before
imaging the membrane.
Amino acid analysis (AAA)
Samples containing 25 µM Aβ40 and 5 µM photosensitizer were kept in the dark or were
irradiated for 4 hours. After light treatment, samples were sent to the Molecular Structural
Facility at University of California Davis for amino acid analysis (AAA) using a sodium citrate
buffer system. Briefly, this analysis consisted of drying 100 µL of 25 µM peptide samples and
performing a liquid phase hydrolysis using 200 µL 6 N HCl containing 1% phenol for 24 hours
at 110 ˚ C. After hydrolysis, the protein was dried and added to norleucine, an internal standard,
to reach a final volume of 200 µL. The sample was analyzed on a cation-exchange
chromatography column using a L-8800 Hitachi analyzer and a post column ninhydrin reaction
detection system.
Protein desalting
Both monomeric and fibrillar proteins were desalted using the Amicon Centrifugal Filter
(Millipore Sigma, Burlington, MA). 250 µL of peptide at 150 µM was loaded onto the filter to
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which 4 mL of PB was added before centrifuging the filter at 3500 rpm for 20 min. After four
washing steps, the retentate was collected and volume adjusted to 250 µL. The protein
concentration was then determined using the Bradford protein concentration assay (SigmaAldrich, St. Louis, MO).
Electrospray ionization mass spectrometry (ESI-MS)
Desalted Aβ40 monomers and fibrils samples were analyzed by ESI-MS after 4 hours of
irradiation in the absence and presence of MB or OPE12- (25 µM protein with 1 µM
photosensitizer). Before analysis, Aβ40 fibrils were digested using Endoproteinase Lys C
(New England BioLabs, Ipswich, MA) at 1/50 (w/w) enzyme to protein ratio. The digestion
was performed by incubating the sample at 37 ˚C for 16 hours. Aβ40 monomers and
fragmented fibrils were diluted to 5 µg/mL using acetonitrile with 1% TFA and were analyzed
under continuous ESI-MS spray on SYNAPT G2 Mass Spectrometry instrument from Waters
at the Center for Integrated Nanotechnology (CINT) facility in Los Alamos National
Laboratory. This analysis was performed in a positive mode by using the following settings:
Capillary = 3.5 kV, sampling cone = 251, extraction cone = 5, source temperature = 120 °C,
desolvation temperature = 300 °C, and desolvation gas flow = 650 L/h. Data were analyzed
with the software MassLynxV4.1.
Reverse phase high performance liquid chromatography (RP-HPLC)
The monomeric protein was analyzed by RP-HPLC on an Agilent 1100 instrument (Agilent
Technology, Santa Clara, CA) before and after irradiation in the presence of OPE12- and MB
(5 µM protein with 1 µM photosensitizer). 110 µL of 5 µM protein was centrifuged at 14,000
rpm for 15 minutes. The supernatant (100 µL) was loaded onto an Eclipse XDB C18 column
(Agilent Technology, Santa Clara, CA) pre-equilibrated at 40 ˚C with 95% of mobile phase A
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(water containing 0.1% TFA) and 5% of mobile phase B (acetonitrile containing 0.1% TFA).
Aβ40 was eluted using a 5-100% linear gradient of mobile phase B over 40 min. The
absorbance at 215 nm was monitored. Each chromatogram was background subtracted using
the Agilent ChemStation software.
Circular dichroism (CD) spectroscopy
Desalted protein solutions were diluted to 50 µM in 10 mM PB in the absence or presence of
10 µM MB or OPE12-. After exposition to light, the peptide was loaded into a quartz cuvette
with a path length of 1 mm (Starna cells Inc, Atascadero, CA) and analyzed on an AVIV 410
CD Spectrometer (AVIV, Lakewood, NJ) between 190 and 270 nm using an averaging time
of 15 seconds. Three scans were recorded per sample and averaged signal was converted to
molar ellipticity119.
TEM imaging
Aβ40 samples were diluted to 5 µM using MilliQ water. After the grids were glow discharged
(Harrick Plasma Cleaner, Carson City, NV) for 30 seconds, the sample was loaded and let
adsorbed for 5 min. After wicking away excess sample, the grid was stained one time for 3
minutes and three times for 1-minute each using 2% uranyl acetate (Electron Microscopy
Sciences, Hatfield, PA). Excess stain was wicked away in between the steps. The grid was then
air dried for 30 minutes and imaged using a HITACHI HT7700 transmission electron
microscope (Hitachi High Technologies Corp., Tokyo, Japan) with the beam current at 8.0 µA
and the accelerating voltage at 80 keV.
Cell toxicity assay
SHSY-5Y cells were cultivated in DMEM media containing 1% PS and 10% FBS at 37˚C and
5% CO2. When the neuroblastoma cells reached 80% confluency, they were used to set up 96
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well plates with 20,000 cells/100 µL well. After 16 hours of incubation, media was changed
with serum deprived DMEM media and cells were further incubated for 24 hours to ensure cell
synchronization. Cells were then treated with a sample containing appropriate protein and
sensitizer concentrations and were incubated for another 24 or 48 hours after which cell
viability was monitored by MTS assay. The assay involved adding 20 µL MTS reagent in each
well already containing 100 µL media and incubating the plate for 3 hours before measuring
the absorbance at 490 nm with a Spectra Max M2 plate reader (Molecular Devices, Sunnyvale,
CA). The background absorbance of MTS in media alone was subtracted from the absorbance
obtained in the presence of cells. Absorbance obtained for untreated cells were also obtained
and used as 100% viability.
All atom molecular dynamics (MD) simulation
The initial configurations for the Aβ fibril - OPE12- simulations were built with UCSF
Chimera287. The fibril structure, 2LMN188 was obtained from the Protein Databank. In this
work, we prepared an Aβ(9-40) protofibril made of 24 peptides to evaluate OPE12- binding
sites. 12 OPEs were positioned around the protofibril at a distance of 10 Å away from the
protofibril surface. The anionic OPE12- was built using the GaussView 5 package and geometry
optimizations was carried out with Gaussian 09.288 Simulations were prepared using the
AMBERTools suite289. Parameters for simulating the protein structures were obtained from
the AMBER14 force field. OPEs were parameterized using the AMBER generalized force
field (GAFF) and partial charges were generated using the R.E.D. server290, 291. Each system
was solvated in explicit water molecules (using the TIP3 model) and counter ions were added
to neutralize the system (a total of 48 Na+ ions). Molecular dynamics was performed using the
AMBER MD package as previously described224. Coordinates for the single Aβ9-40 monomer
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hairpin were extracted from the protofibril PDB structure following energy minimization and
equilibration of the monomer peptide. Production MD simulations were carried out for 100 ns.
OPE12- binding sites on the protofibril surface were analyzed using Chimera to determine the
proximity of bound OPEs to oxidizable residues on the protofibrils. Residues within 4 Å of
bound OPEs (either single or complexed) were selected and counted. Distances of the
oxidizable methionine residues to bound OPEs, which were larger than the 4 Å cutoff, were
determined as the center-of-mass distances between methionine residues and bound OPEs.
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Supplementary Information

Figure S1: Reverse phase HPLC of Aβ40 monomers before and after irradiation in the
presence of MB and OPE12-. Aβ40 monomers non-irradiated and irradiated in the presence of
OPE12- display a similar elution time corresponding to 44.6-44.4% acetonitrile. When the
peptide is irradiated in the presence of MB, the elution profile of Aβ40 monomers changed.
The main peak is eluted earlier (43.5% acetonitrile) which shows that Aβ40 peptide became
more hydrophilic. Also, the peak presents a should, is not sharp which show the presence of a
several populations of Aβ40… The change in hydrophobicity of Aβ40 monomers after
irradiation by MB can be explained by oxidation of the protein.
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Chapter 8: Summary and Future Directions

8.1 Summary
The research presented in this dissertation contributed to a better understanding of amyloid
membrane-mediated toxicity and helped evaluate a novel fluorescent probe as a selective
amyloid sensor and controllable amyloid photo-oxidizer.
In Chapter 3, we characterized the molecular-level changes associated with PHF6
insertion into a lipid membrane as part of its toxicity pathway. By using two isoforms, the nonprone to fibrillation NH3+-PHF6 and the fibrillation prone Ac-PHF6, the importance of
fibrillation potency on membrane interaction and disruption was evaluated. Interestingly, both
peptides interacted rapidly with the anionic lipid membrane causing membrane destabilization
through lipid extraction and were prone to membrane-mediated fibrillation. The fibrillation
potency of the peptide influenced the structural changes associated with the interaction of
PHF6 to the lipid membrane as well as the rate at which the membrane destabilization took
place. In fact, Ac-PHF6 exhibited a faster membrane disruption which was accompanied by a
rapid formation of β-sheet structure on the lipid membrane and was also characterized by a fast
membrane-mediated fibrillation. Overall, this work contributed to a broader understanding of
tau toxicity mechanism. This characterization could contribute to a significant advancement in
the development of novel therapeutic strategies.
The following chapters were focused on evaluating oligomeric p-phenylene ethynylene
(OPE) as an amyloid sensor and selective photo-oxidizer. In Chapter 4, OPE’s capability to
detect fibrillar and pre-fibrillar aggregates made of three disease-relevant proteins, Aβ40,
Aβ42 and α-synuclein, was characterized. The negatively charged OPE12- and the positively
charged OPE24+ were evaluated and compared to the well-known amyloid sensor ThT, in terms
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of amyloid detection factor (ADF), limit of detection, and affinity. Both OPEs displayed higher
sensing properties for the detection of fibrillar aggregates compared to ThT in terms of binding
affinity and ADF value. Strikingly, OPEs detected pre-fibrillar aggregates made of Aβ42 and
α-synuclein proteins that ThT failed to detect. The superior sensing properties of OPEs make
them ideal to track the formation of early aggregates (oligomers and protofibrils) and to shine
light on the amyloid aggregation mechanism which is still poorly understood.
In Chapter 5, OPE was further characterized as an amyloid probe. Its background
fluorescence was analyzed as well as its effect on amyloid aggregation and cell toxicity. We
found that OPE formed super-luminescent complexes at concentration higher than 10 µM
which limits the selective sensing of amyloid aggregates. When used at the usual 1 µM, OPE
background fluorescence was minimal and OPE conserved its sensing properties. Additionally,
when co-incubated with Aβ40, OPE did not alter neither the aggregation kinetic nor the
aggregates morphology, hydrophobicity and toxicity. Overall, OPE’s high sensitivity,
selectivity and affinity toward amyloid aggregates and its low neurotoxicity make it ideal to
analyze amyloid aggregation kinetic in vitro and in a cell culture environment through
fluorescence-microscopy. This potential application will be discussed in the future directions
section.
In Chapter 6, we investigated OPE sensing properties in a physiological sample,
cerebrospinal fluid (CSF). This investigation consisted in spiking CSF with five amyloid
aggregates: lysozyme fibrils, insulin fibrils, Aβ40 fibrils, PHF6 fibrils and htau oligomers.
Interestingly, OPE12- was superior at detecting amyloid aggregates in phosphate buffer but lost
its sensing properties in CSF, while OPE24+ remained sensitive to amyloid aggregates in such
complex environment. The loss of OPE12- sensing properties might be due to its non-selective
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interaction to albumin present at high concentration in CSF (around 300 µg/mL). The detection
of amyloid aggregates in CSF samples isolated from patient with dementia was also
investigated. OPE24+ did not display selective fluorescence turn-on in dementia CSF compared
to healthy CSF. The lack of detection might be due to the limit of detection of OPE 24+ which
is in the sub-microgram concentration while aggregates concentration in CSF is expected to be
in the picogram range. To overcome the low oligomer concentration in CSF, we investigated
the protein misfolding cyclic amplification (PMCA) assay by spiking CSF with monomeric
Aβ40 which should undergo fast fibrillation in the presence of oligomeric seed. CSF isolated
form patients with dementia did not display large amyloid fibrillation. These results will guide
future research to evaluate OPE for the detection of amyloid aggregates in CSF as a diagnostic
tool through the optimization of the PMCA assay. Additionally, OPE24+’s detection of amyloid
aggregates in CSF could result in new applications such as the detection of amorphous
aggregates in protein-based pharmaceuticals. This last application will be discussed in the
future direction section.
Finally, in Chapter 7 we evaluated OPE12- as a controllable photo-oxidizer of amyloid
fibrils made of Aβ40 peptide and comparing it to the well-known photosensitizer methylene
blue (MB). MB was found to photo-oxidize both monomeric and fibrillar peptides. In contrast,
OPE selectively photo-oxidized Aβ fibrils over the monomeric counterpart. Three amino acids
have been found to be oxidized by OPE12-, His13 and His14 which are located at the surface
of the fibrils and Met 35 which is buried inside the fibrillar structure. As a result of photooxidation, Aβ40 fibrils disassembled into short protofibrils characterized by low cell toxicity.
Taken together, OPEs selective sensing and controllable photo-sensitization activity could lead
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to the development of a novel generation of theranostic molecules for the detection and
treatment of neurodegenerative diseases.

8.2 Future Directions
The research presented here provides a solid understanding of OPE sensing of a large array of
pre-fibrillar and fibrillar amyloid aggregates which open the door to a multitude of
applications.
The robustness of OPE12- sensing properties when co-incubated with Aβ40 described
in Chapter 5 and its binding to early aggregates could be employed to further characterized
amyloid aggregation in vitro and ex vivo. First, OPE could be used in real-time fluorescence
microscopy to determine amyloid aggregation kinetic parameters214. Secondly, OPE low cell
toxicity suggests that this probe could be used to monitor protein aggregation in an ex vivo cell
culture model. Knowing that Aβ aggregation is accelerated when the peptide interacts with cell
membrane, we could also gain a better understanding of this off-pathway aggregation by using
OPE fluorescence in cell culture real-time imaging.
The selective photo-oxidation of Aβ40 fibrils by OPE12- was well characterized in
Chapter 7 in terms of oxidized amino acids and effect on fibrils morphology and cytotoxicity.
However, the effect of oxidation on amyloid fibrillation potency and on toxicity pathway has
not been investigated. As future work, we propose to evaluate the effect of photo-oxidation on
oligomers and protofibrils potency to act as aggregation seeds. Furthermore, one of the main
toxicity mechanisms of amyloid proteins has been shown to rely on their interaction to cell
membrane. This interaction is mainly driven by electrostatic interactions which might be
altered by photo-oxidation. Based on this information, it would be interesting to further
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characterize the effect of oxidation on Aβ40 interaction to the negatively charged lipid
membrane and evaluate the effect on membrane-mediated fibrillation. This additional study
could reveal the potential of photo-oxidation not only to breakdown existing fibrils but also to
inhibit aggregation and decrease amyloid toxicity.
Finally, OPE sensing of amyloid aggregates in a complex environment such as CSF
described in Chapter 6 could lead to other applications such as the detection of amorphous
protein aggregates found in protein-based pharmaceutical preparations. The presence of
amorphous aggregates is currently a challenge as they can cause total or partial loss of the
therapeutic properties or might even be immunogenic292. To evaluate OPE for such application,
first OPE sensing of amorphous aggregates should be characterized. Such aggregates could be
produced from lysozyme or BSA proteins293. OPE interaction to pharmaceutical proteins such
as antibodies should also be investigated. Finally, OPE background fluorescence in the
presence of most commonly used excipients (surfactant, amino acids, sugar, polyols, polymers
and chelating agent) should be evaluated294.
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Chapter 9: Abbreviations

AAA, amino acid analysis; Aβ, amyloid β; Aβ-PMCA, Aβ-protein misfolding cyclic
amplification; Ac-PHF6, N-terminal acetylated PHF6; AD, Alzheimer’s disease; ADF,
amyloid detection factor; BSA, bovine serum albumin; CD, circular dichroism; CSF,
cerebrospinal fluid; CTAB, cetyltrimethylammonium bromide; DLS, dynamic light scattering;
DMEM, Dulbecco’s Modified Eagle’s Medium; DMPC, 1,2-dimyristoyl-sn-glycero-3phosphocholine; DMPG, 1,2-Dimyristoyl-sn-glycero-3-phosphorylglycerol; DMSO, dimethyl
sulfoxide; DNPH, 2,4-Dinitrophenylhydrazine; ESI-MS, electrospray ionization mass
spectrometry; EthD1, ethidium homodimer-1; FBS, fetal bovine serum; FM, Fluorescence
microscopy; GAFF, generalized force field; GIXD, grazing incidence X-ray diffraction; h, Hill
coefficient; HCl, hydrochloride acid; HEWL, hen egg white lysozyme; HAS, human serum
albumin; htau oligomers, human isolated tau oligomers; kd, dissociation constant; LC, liquid
condensed; LE, liquid expanded; L&D, labor and delivery units; LOD, limit of detection; LUV,
large unilamellar vesicles; MB, methylene blue; MD, molecular dynamics; MTB, microtubule
binding; MTS, 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium; NaCl, sodium chloride; ND, neurodegenerative disorders; NFTs, neurofibrillary
tangles; NH3+-PHF6, PHF6 with a standard N-terminus; NR, Nile red; OPE, oligo-p-phenylene
ethynylene; PB, phosphate buffer; PD, Parkinson's disease; PDB, protein databank; PDF,
protein detection factor; PDT, photodynamic therapy; PE, phenylene ethynylenes; PET,
Positron Emission Tomography; PHF, paired helical filaments; PS, penicillin-streptomycin;
POPC, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPG, 1-palmitoyl-2-oleoyl-snglycero-3-phospho-(1'-rac-glycerol); RP-HPLC, reverse phase high performance liquid
chromatography; SEC, Size exclusion chromatography; TEM, transmission electron
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microscopy; TFA, trifluoroacetic acid; ThT, Thioflavin T; TIRFM, internal reflection
fluorescence

microscopy;

TR-DHPE,

Texas

Red

1,2-dihexadecanoyl-sn-glycero-3-

Phosphoethanoloamine triethylammonium salt; XR, X-ray reflectivity
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